Product version Guoqian Jiang Jane Bane Junguk Hur Yu Lin Abra Guo Rebecca Racz Yongqun "Oliver" He (YH) 2016-05-16 ODNAE is an extension of OAE with a focus on drug-associated neuropathy adverse events. OWL-DL An ontology for the annotation of the adverse event domain. ODNAE: Ontology of Drug Neuropathy Adverse Events Vision Release; 1.0.13 Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. Really of interest to developers only BFO OWL specification label BFO OWL specification label Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 Person:Alan Ruttenberg Really of interest to developers only BFO CLIF specification label BFO CLIF specification label editor preferred label editor preferred term The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> editor preferred label editor preferred term editor preferred term example example of usage A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> example of usage example of usage has curation status PERSON:Alan Ruttenberg PERSON:Bill Bug PERSON:Melanie Courtot OBI_0000281 has curation status has curation status definition definition The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition definition textual definition editor note An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. PERSON:Daniel Schober GROUP:OBI:<http://purl.obfoundry.org/obo/obi> IAO:0000116 uberon editor_note 1 editor_note editor note editor note definition editor term editor Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition editor definition editor term editor term editor alternative term An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) PERSON:Daniel Schober GROUP:OBI:<http://purl.obolibrary.org/obo/obi> alternative term alternative term definition source formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 PERSON:Daniel Schober Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w GROUP:OBI:<http://purl.obolibrary.org/obo/obi> definition source definition source curator note An administrative note of use for a curator but of no use for a user PERSON:Alan Ruttenberg IAO:0000232 uberon curator_notes 1 curator_notes curator note curator note curator notes imported from For external terms/classes, the ontology from which the term was imported PERSON:Alan Ruttenberg PERSON:Melanie Courtot GROUP:OBI:<http://purl.obolibrary.org/obo/obi> imported from imported from expand expression to elucidation elucidation has associated axiom(nl) has associated axiom(nl) has associated axiom(fol) has associated axiom(fol) YH, JX a chinese translation represents a chinese translation of the existing term. Chinese translation An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. temporal interpretation https://code.google.com/p/obo-relations/wiki/ROAndTime logical macro assertion on an object property An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. UBPROP:0000001 uberon external_definition 1 external_definition This annotation property may be replaced with an annotation property from an external ontology such as IAO external_definition A textual description of an axiom loss in this ontology compared to an external ontology. UBPROP:0000002 uberon axiom_lost_from_external_ontology 1 axiom_lost_from_external_ontology This annotation property may be replaced with an annotation property from an external ontology such as IAO axiom_lost_from_external_ontology Notes on the homology status of this class. UBPROP:0000003 uberon homology_notes 1 homology_notes This annotation property may be replaced with an annotation property from an external ontology such as IAO homology_notes Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. UBPROP:0000007 uberon has_relational_adjective 1 has_relational_adjective has_relational_adjective Notes on the how instances of this class vary across species. UBPROP:0000008 uberon taxon_notes 1 taxon_notes taxon_notes Notes on the structure, composition or histology of instances of this class. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000010 uberon structure_notes 1 structure_notes structure_notes Notes on how similar or equivalent classes are represented in other ontologies. This annotation property may be replaced with an annotation property from an external ontology such as IAO UBPROP:0000012 uberon external_ontology_notes 1 external_ontology_notes external_ontology_notes has_RxCUI CUMBO A class which has a weakened disjointness axiom, to avoid inconsistency. These are kept separately in the uberon_disjoint_from_strict ontology. A class that represents an early developmental structure, like a blastocyst. This part of the ontology is undergoing review to remove inappropriate grouping classes. EFO slim functional_classification Subset consisting of classes creating for grouping purposes classes that have some inconsistency with FMA somewhat fuzzy grouping for analysis purposes, currently composed of something like: liver, heart, skeletal, kidney, bladder, brain, skin, mouth, esophagus, stomach, small intestine, large intestines, trachea nose, lungs, brain, spinal cord, peripheral nerves, kidneys, ureters, bladder, urethra, gonads organs, excluding individual muscles and skeletal elements Uberon slim - somewhat arbitrary subset that excludes obscure terms and deep compositional terms abstract upper-level terms not directly useful for analysis core classes typically found across vertebrates. one purpose is to create a rough set of terms that could be used to start a new vertebrate AO abstract upper-level terms not directly useful for analysis subset_property has_alternative_id has_broad_synonym database_cross_reference has_exact_synonym has_narrow_synonym has_obo_namespace has_related_synonym in_subset shorthand label uberon foaf-depicted_by 1 foaf-depicted_by depicted_by BFO:0000050 uberon part_of part_of part of part_of BFO:0000067 uberon contains_process contains_process contains process contains process has-s-dep_st [copied from inverse property 'specifically depends on at some time'] A pain s-depends_on the organism that is experiencing the pain [copied from inverse property 'specifically depends on at some time'] a gait s-depends_on the walking object. (All at some specific time.) [copied from inverse property 'specifically depends on at some time'] a shape s-depends_on the shaped object [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of headache s-depends_on some head [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a dependent continuant on an independent continuant: an instance of temperature s-depends_on some organism [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: a process of cell death s-depends_on a cell [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of a process on something: an instance of seeing (a relational process) s-depends_on some organism and on some seen entity, which may be an occurrent or a continuant [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of answering a question is dependent on a prior process of asking a question [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on another: a process of obeying a command is dependent on a prior process of issuing a command [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of hitting a ball with a cricket bat [copied from inverse property 'specifically depends on at some time'] one-sided s-dependence of one occurrent on multiple independent continuants: a relational process of paying cash to a merchant in exchange for a bag of figs [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of buying and the associated process of selling [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: a process of increasing the volume of a portion of gas while temperature remains constant and the associated process of decreasing the pressure exerted by the gas [copied from inverse property 'specifically depends on at some time'] reciprocal s-dependence between occurrents: in a game of chess the process of playing with the white pieces is mutually dependent on the process of playing with the black pieces [copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: football match on the players, the ground, the ball [copied from inverse property 'specifically depends on at some time'] the one-sided dependence of an occurrent on an independent continuant: handwave on a hand [copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the hue, saturation and brightness of a color [45 [copied from inverse property 'specifically depends on at some time'] the three-sided reciprocal s-dependence of the pitch, timbre and volume of a tone [45 [copied from inverse property 'specifically depends on at some time'] the two-sided reciprocal s-dependence of the roles of husband and wife [20 [copied from inverse property 'specifically depends on at some time'] Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'specifically depends on at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'specifically depends on@en'(x,y,t) [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: An entity – for example an act of communication or a game of football – can s-depends_on more than one entity. Complex phenomena for example in the psychological and social realms (such as inferring, commanding and requesting) or in the realm of multi-organismal biological processes (such as infection and resistance), will involve multiple families of dependence relations, involving both continuants and occurrents [1, 4, 28 [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: S-dependence is just one type of dependence among many; it is what, in the literature, is referred to as ‘existential dependence’ [87, 46, 65, 20 [copied from inverse property 'specifically depends on at some time'] BFO 2 Reference: the relation of s-depends_on does not in every case require simultaneous existence of its relata. Note the difference between such cases and the cases of continuant universals defined historically: the act of answering depends existentially on the prior act of questioning; the human being who was baptized or who answered a question does not himself depend existentially on the prior act of baptism or answering. He would still exist even if these acts had never taken place. [copied from inverse property 'specifically depends on at some time'] BFO2 Reference: specifically dependent continuant\; process; process boundary [copied from inverse property 'specifically depends on at some time'] To say that b s-depends_on a at t is to say that b and c do not share common parts & b is of its nature such that it cannot exist unless c exists & b is not a boundary of c and b is not a site of which c is the host [64 has specific dependent at some time has_specified_input see is_input_of example_of_usage A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. 8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Coutot has_specified_input has_specified_output A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. PERSON: Alan Ruttenberg PERSON: Bjoern Peters PERSON: Larry Hunter PERSON: Melanie Courtot has_specified_output RO:0000052 inheres_in inheres in bearer of this apple is bearer of this red color this vase is bearer of this fragility a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. bearer_of is bearer of RO:0000053 uberon bearer_of bearer_of bearer of bearer of role of RO:0001015 uberon location_of location_of location of location_of RO:0001025 uberon located_in located_in located in located_in The relationships between a boundary (a 2D immaterial entity) and the material entity that it delimits. RO:0002000 boundary_of boundary of FMA:85999 dbprop:nerve RO:0002005 nerve supply uberon innervated_by innervated_by http://code.google.com/p/obo-relations/issues/detail?id=6 innervated_by innervated_by RO:0002081 before_or_simultaneous_with before_or_simultaneous_with RO:0002086 ends_after ends_after RO:0002090 immediately_precedes immediately_precedes starts_during happens_during A overlaps B if they share some part in common. x overlaps y if and only if there exists some z such that x has part z and z part of y x overlaps y iff they have some part in common. BFO_0000051 some (BFO_0000050 some ?Y) RO:0002131 uberon overlaps overlaps overlaps overlaps RO:0002134 uberon innervates innervates http://code.google.com/p/obo-relations/issues/detail?id=6 innervates innervates X continuous_with Y if and only if X and Y share a fiat boundary. RO:0002150 uberon continuous_with continuous_with continuous with continuous_with Binary relationship: x connected_to y if and only if there exists some z such that z connects x and y in a ternary connected_to(x,y,z) relationship. RO:0002170 uberon connected_to connected_to Connection does not imply overlaps. connected to connected to Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) RO:0002176 uberon connects connects connects connects a is attached to part of b if a is attached to b, or a is attached to some p, where p is part of b. RO:0002177 uberon attaches_to_part_of attached_to_part_of attaches_to_part_of attached to part of attaches_to_part_of Relation between an arterial structure and another structure, where the arterial structure acts as a conduit channeling fluid, substance or energy. relation between an artery and the structure is supplies with blood. FMA:86003 RO:0002178 arterial supply of uberon supplies supplies source: FMA supplies supplies x develops from y if and only if either (a) x directly develops from y or (b) there exists some z such that x directly develops from z and z develops from y RO:0002202 uberon develops_from develops_from develops from develops_from Candidate definition: x directly_develops from y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p, and a substantial portion of the matter of y comes from x, and the start of x is coincident with or after the end of y RO:0002207 uberon directly_develops_from directly_develops_from directly develops from directly_develops_from RO:0002222 temporally_related_to temporally related to x ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) ∧ ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. RO:0002230 ends_with ends with x has developmental contribution from y iff x has some part z such that z develops from y RO:0002254 uberon has_developmental_contribution_from has_developmental_contribution_from has developmental contribution from has developmental contribution from t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. t1 induced_by t2 if there is a process of developmental induction (GO:0031128) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor anatomical structure type T to T', where T' develops_from T RO:0002256 uberon developmentally_induced_by developmentally_induced_by sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) developmentally induced by developmentally_induced_by Candidate definition: x developmentally related to y if and only if there exists some developmental process (GO:0032502) p such that x and y both participates in p, and x is the output of p and y is the input of p RO:0002258 uberon developmentally_preceded_by developmentally_preceded_by developmentally preceded by developmentally preceded by q inheres in part of w if and only if there exists some p such that q inheres in p and p part of w. RO:0002314 inheres_in_part_of inheres in part of A relationship that holds via some environmental process RO:0002320 evolutionarily_related_to evolutionarily related to A mereological relationship or a topological relationship RO:0002323 mereotopologically_related_to mereotopologically related to A relationship that holds via some developmental process (GO:0032502) RO:0002324 developmentally_related_to developmentally related to RO:0002328 uberon functionally_related_to functionally_related_to functionally related to functionally related to FMA:85990 RO:0002371 uberon attaches_to attached_to attaches_to attached to attaches_to RO:0002375 in_branching_relationship_with in branching relationship with x is a branching part of y if and only if x is part of y and x is a branch_of the main stem of y we need to check if FMA branch_of implies part_of. the relation we intend to use here should - for example, see vestibulocochlear nerve FMA:85994 RO:0002380 uberon branching_part_of branching_part_of branching part of branching_part_of x has developmental potential involving y iff x is capable of a developmental process with output y. y may be the successor of x, or may be a different structure in the vicinity (as for example in the case of developmental induction). RO:0002384 has_developmental_potential_involving has developmental potential involving RO:0002487 relation_between_structure_and_stage relation between structure and stage Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. c existence starts during s iff start_of(c) part_of s BFO:0000068 RO:0002488 begins_to_exist_during uberon existence_starts_during existence_starts_during existence starts during RO:0002490 existence_overlaps existence overlaps x transformation of y if x is the immediate transformation of y, or is linked to y through a chain of transformation relationships RO:0002494 transforms from uberon transformation_of transformation_of transformation of RO:0002502 depends_on depends on RO:0002507 uberon has_material_contribution_from has_material_contribution_from has material contribution from a produces b if some process that occurs_in a has_output b, where a and b are material entities. Examples: hybridoma cell line produces monoclonal antibody reagent; chondroblast produces avascular GAG-rich matrix. RO:0003000 uberon produces produces produces produces RO:0003001 uberon produced_by produced_by produced by produced_by uberon transitively_connected_to transitively_connected to NDF-RT:N0000000065 Physiochemical Activity N0000000065 989958 C1372991 C308 Physiochemical Activity [MoA] NDF-RT:N0000000066 Small Ion Transport Pump Interactions N0000000066 986087 C1373107 C310 Small Ion Transport Pump Interactions [MoA] NDF-RT:N0000000067 HER Receptor Family Interactions N0000000067 986672 EGFR Family Interactions Epidermal Growth Factor Receptor Family Interactions HER Family Interactions Human Epidermal Growth Factor Receptor Family Interactions C2916814 C312 HER Receptor Family Interactions [MoA] NDF-RT:N0000000069 Calcium Channel Antagonists D002121 Calcium Channel Blockers N0000000069 986242 Calcium Channel Blocker C2757014 C316 Calcium Channel Antagonists [MoA] NDF-RT:N0000000070 Angiotensin 2 Receptor Antagonists N0000000070 984935 Angiotensin II Receptor Antagonists Angiotensin II Receptor Blockers C2757003 C318 Angiotensin 2 Receptor Antagonists [MoA] NDF-RT:N0000000072 Active Transporter Interactions N0000000072 1031287 C1373104 C322 Active Transporter Interactions [MoA] NDF-RT:N0000000076 Protease Inhibitors D011480 Protease Inhibitors N0000000076 992709 C2756997 C330 Protease Inhibitors [MoA] NDF-RT:N0000000082 Immunologic Factors D007155 Immunologic Factors N0000000082 993127 C2757006 C342 Immunologic Factors [MoA] NDF-RT:N0000000083 Leukotriene Receptor Antagonists N0000000083 992724 C2757015 C344 Leukotriene Receptor Antagonists [MoA] NDF-RT:N0000000084 Sex Hormone Receptor Antagonists N0000000084 985639 C1373000 C346 Sex Hormone Receptor Antagonists [MoA] NDF-RT:N0000000085 Receptor Interactions N0000000085 988560 C1372999 C348 Receptor Interactions [MoA] NDF-RT:N0000000087 Chelating Activity D002614 Chelating Activity N0000000087 1025213 C1527256 C352 Chelating Activity [MoA] NDF-RT:N0000000092 Adrenergic Antagonists D018674 Adrenergic Antagonists N0000000092 993129 C2757018 C362 Adrenergic Antagonists [MoA] NDF-RT:N0000000097 Cholinergic Muscarinic Receptor Interactions N0000000097 986244 C1373009 C372 Cholinergic Muscarinic Receptor Interactions [MoA] NDF-RT:N0000000098 Thymidylate Synthetase Inhibitors N0000000098 993154 C2756988 C374 Thymidylate Synthetase Inhibitors [MoA] NDF-RT:N0000000099 Adrenergic alpha-Antagonists D000317 Adrenergic alpha-Antagonists N0000000099 1023426 Alpha-adrenergic Blocker alpha-Adrenergic Antagonists C2756989 C376 Adrenergic alpha-Antagonists [MoA] NDF-RT:N0000000102 Norepinephrine Uptake Inhibitors D018759 Adrenergic Uptake Inhibitors N0000000102 989028 C2757023 C382 Norepinephrine Uptake Inhibitors [MoA] NDF-RT:N0000000103 Reverse Transcriptase Inhibitors D018894 Reverse Transcriptase Inhibitors N0000000103 993157 C2757067 C384 Reverse Transcriptase Inhibitors [MoA] NDF-RT:N0000000104 Cholinergic Muscarinic Agonists N0000000104 990721 C2757026 C386 Cholinergic Muscarinic Agonists [MoA] NDF-RT:N0000000105 Neurotransmitter Transporter Interactions N0000000105 985066 C1373006 C388 Neurotransmitter Transporter Interactions [MoA] NDF-RT:N0000000109 Serotonin Uptake Inhibitors D017367 Serotonin Uptake Inhibitors N0000000109 992711 C2757053 C396 Serotonin Uptake Inhibitors [MoA] NDF-RT:N0000000111 Folic Acid Metabolism Inhibitors D005493 Folic Acid Antagonists N0000000111 1029786 Folic Acid Antagonists Folic Acid Metabolic Inhibitors C2916820 C400 Folic Acid Metabolism Inhibitors [MoA] NDF-RT:N0000000114 Dopamine Uptake Inhibitors D018765 Dopamine Uptake Inhibitors N0000000114 1028789 C2757017 C406 Dopamine Uptake Inhibitors [MoA] NDF-RT:N0000000117 Dopamine Agonists D018491 Dopamine Agonists N0000000117 992714 Dopaminergic Agonist C2757007 C412 Dopamine Agonists [MoA] NDF-RT:N0000000118 GABA A Modulators N0000000118 990722 GABA A Receptor Modulators C1373017 C414 GABA A Modulators [MoA] NDF-RT:N0000000121 Hydroxymethylglutaryl-CoA Reductase Inhibitors D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors N0000000121 993150 HMG-CoA Reductase Inhibitor HMG-CoA Reductase Inhibitors C2756999 C420 Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] NDF-RT:N0000000122 Adrenergic Agonists D000322 Adrenergic Agonists N0000000122 1029285 C2757025 C422 Adrenergic Agonists [MoA] NDF-RT:N0000000124 Leukotriene Receptor Interactions N0000000124 987670 C1373014 C426 Leukotriene Receptor Interactions [MoA] NDF-RT:N0000000128 Phosphodiesterase Inhibitors D010726 Phosphodiesterase Inhibitors N0000000128 993167 C1656262 C434 Phosphodiesterase Inhibitors [MoA] NDF-RT:N0000000130 Serotonin Antagonists D012702 Serotonin Antagonists N0000000130 993156 C2757052 C438 Serotonin Antagonists [MoA] NDF-RT:N0000000132 Organic Anion Transporter Interactions N0000000132 987411 C1373100 C442 Organic Anion Transporter Interactions [MoA] NDF-RT:N0000000133 Enzyme Inhibitors D004791 Enzyme Inhibitors N0000000133 1032544 C2756995 C444 Enzyme Inhibitors [MoA] NDF-RT:N0000000134 Lipoxygenase Inhibitors D016859 Lipoxygenase Inhibitors N0000000134 1031400 C2757064 C446 Lipoxygenase Inhibitors [MoA] NDF-RT:N0000000135 Immunologic Adjuvants D000276 Adjuvants, Immunologic N0000000135 989878 Adjuvants, Immunologic C1383096 C448 Immunologic Adjuvants [MoA] NDF-RT:N0000000138 GABA A Receptor Interactions N0000000138 988922 C1373022 C454 GABA A Receptor Interactions [MoA] NDF-RT:N0000000140 Calcium Channel Interactions N0000000140 990245 C1373020 C458 Calcium Channel Interactions [MoA] NDF-RT:N0000000144 Iron Chelating Activity D007502 Iron Chelating Activity N0000000144 985781 C2757050 C466 Iron Chelating Activity [MoA] NDF-RT:N0000000145 Estrogen Receptor Antagonists N0000000145 984514 Estrogen Receptor Inhibitor C1373098 C468 Estrogen Receptor Antagonists [MoA] NDF-RT:N0000000147 Proton Pump Inhibitors N0000000147 986356 C1384478 C472 Proton Pump Inhibitors [MoA] NDF-RT:N0000000149 Hormone Receptor Agonists N0000000149 985200 C1373095 C476 Hormone Receptor Agonists [MoA] NDF-RT:N0000000150 Protein Synthesis Inhibitors D011500 Protein Synthesis Inhibitors N0000000150 993158 C2757051 C478 Protein Synthesis Inhibitors [MoA] NDF-RT:N0000000152 G-Protein-linked Receptor Interactions N0000000152 984725 G-Protein-linked Receptor-Effector Interactions C2916797 C482 G-Protein-linked Receptor Interactions [MoA] NDF-RT:N0000000153 Adrenergic Receptor Interactions N0000000153 987972 C1373072 C484 Adrenergic Receptor Interactions [MoA] NDF-RT:N0000000155 Uncouplers N0000000155 986674 C1373071 C488 Uncouplers [MoA] NDF-RT:N0000000156 Chloride Channel Interactions N0000000156 987326 C1373070 C490 Chloride Channel Interactions [MoA] NDF-RT:N0000000159 Glucocorticoid Receptor Agonists N0000000159 989879 C1373068 C496 Glucocorticoid Receptor Agonists [MoA] NDF-RT:N0000000160 Cyclooxygenase Inhibitors D016861 Cyclooxygenase Inhibitors N0000000160 992710 C2756982 C498 Cyclooxygenase Inhibitors [MoA] NDF-RT:N0000000161 Adrenergic beta-Antagonists D000319 Adrenergic beta-Antagonists N0000000161 993131 Beta-adrenergic Blocker Beta-adrenergic Receptor Inhibitor beta-Adrenergic Antagonists beta-Adrenergic Blocker beta-Adrenergic Receptor Inhibitor C2757061 C500 Adrenergic beta-Antagonists [MoA] NDF-RT:N0000000162 Steroid Receptor Antagonists N0000000162 987973 C1373067 C502 Steroid Receptor Antagonists [MoA] NDF-RT:N0000000167 Serotonin Transporter Interactions N0000000167 987204 C1373063 C512 Serotonin Transporter Interactions [MoA] NDF-RT:N0000000168 Selective Estrogen Receptor Modulators D020845 Selective Estrogen Receptor Modulators N0000000168 993164 C2757056 C514 Selective Estrogen Receptor Modulators [MoA] NDF-RT:N0000000172 Steroid Receptor Modulators N0000000172 987671 C1373061 C522 Steroid Receptor Modulators [MoA] NDF-RT:N0000000174 Opioid Agonists N0000000174 985466 C1373059 C526 Opioid Agonists [MoA] NDF-RT:N0000000175 Cytokine Receptor Superfamily Interactions N0000000175 984937 C1373058 C528 Cytokine Receptor Superfamily Interactions [MoA] NDF-RT:N0000000176 Topoisomerase Inhibitors N0000000176 989757 DNA Gyrase Inhibitors Topoisomerase Inhibitor C1384454 C530 Topoisomerase Inhibitors [MoA] NDF-RT:N0000000177 Cholinesterase Inhibitors D002800 Cholinesterase Inhibitors N0000000177 992680 C2757012 C532 Cholinesterase Inhibitors [MoA] NDF-RT:N0000000180 Sodium Channel Interactions N0000000180 987802 C1373055 C538 Sodium Channel Interactions [MoA] NDF-RT:N0000000181 Angiotensin-converting Enzyme Inhibitors D000806 Angiotensin-Converting Enzyme Inhibitors N0000000181 992731 Angiotensin Converting Enzyme Inhibitor C2757044 C540 Angiotensin-converting Enzyme Inhibitors [MoA] NDF-RT:N0000000182 Steroid Hormone Receptor Agonists N0000000182 990907 C1373054 C542 Steroid Hormone Receptor Agonists [MoA] NDF-RT:N0000000183 Acetyl Aldehyde Dehydrogenase Inhibitors N0000000183 986817 C1373053 C544 Acetyl Aldehyde Dehydrogenase Inhibitors [MoA] NDF-RT:N0000000184 Monoamine Oxidase Inhibitors D008996 Monoamine Oxidase Inhibitors N0000000184 992698 MAOI C2756978 C546 Monoamine Oxidase Inhibitors [MoA] NDF-RT:N0000000185 Progestational Hormone Receptor Agonists N0000000185 986818 C1373052 C548 Progestational Hormone Receptor Agonists [MoA] NDF-RT:N0000000190 Histamine H1 Receptor Antagonists D006634 Histamine H1 Antagonists N0000000190 992695 H1 Receptor Antagonists H1 Receptor Blockers Histamine H1 Antagonists Histamine H1 Blockers C2757048 C558 Histamine H1 Receptor Antagonists [MoA] NDF-RT:N0000000191 Dihydrofolate Reductase Inhibitors N0000000191 441741 C1373048 C560 Dihydrofolate Reductase Inhibitors [MoA] NDF-RT:N0000000193 Ion Channel Interactions N0000000193 988382 C1373047 C564 Ion Channel Interactions [MoA] NDF-RT:N0000000198 Serotonin Receptor Interactions N0000000198 988082 C1373043 C574 Serotonin Receptor Interactions [MoA] NDF-RT:N0000000200 Opioid Receptor Interactions N0000000200 989758 C1373041 C578 Opioid Receptor Interactions [MoA] NDF-RT:N0000000203 Dopamine Receptor Interactions N0000000203 985948 C1373039 C584 Dopamine Receptor Interactions [MoA] NDF-RT:N0000000205 Radiopharmaceutical Activity D019275 Radiopharmaceuticals N0000000205 987975 C2757000 C588 Radiopharmaceutical Activity [MoA] NDF-RT:N0000000206 Xanthine Oxidase Inhibitors N0000000206 984728 C1384464 C590 Xanthine Oxidase Inhibitors [MoA] NDF-RT:N0000000207 Histamine Receptor Antagonists D006633 Histamine Antagonists N0000000207 989667 Histamine Antagonists C1383092 C592 Histamine Receptor Antagonists [MoA] NDF-RT:N0000000209 Adrenergic alpha-Agonists D000316 Adrenergic alpha-Agonists N0000000209 1029039 alpha-Adrenergic Agonists C2757042 C596 Adrenergic alpha-Agonists [MoA] NDF-RT:N0000000211 Potassium Channel Interactions N0000000211 989960 C1373036 C600 Potassium Channel Interactions [MoA] NDF-RT:N0000000212 Ribonucleotide Reductase Inhibitors N0000000212 441728 C1373035 C602 Ribonucleotide Reductase Inhibitors [MoA] NDF-RT:N0000000213 Receptor Protein Kinase Interactions N0000000213 986538 C1373034 C604 Receptor Protein Kinase Interactions [MoA] NDF-RT:N0000000214 Sex Hormone Receptor Agonists N0000000214 990080 C1373033 C606 Sex Hormone Receptor Agonists [MoA] NDF-RT:N0000000216 Histamine Receptor Interactions N0000000216 989394 C1373031 C610 Histamine Receptor Interactions [MoA] NDF-RT:N0000000219 Dopamine Transporter Interactions N0000000219 984515 C1373028 C616 Dopamine Transporter Interactions [MoA] NDF-RT:N0000000221 Hormone Receptor Antagonists N0000000221 990790 C1373026 C620 Hormone Receptor Antagonists [MoA] NDF-RT:N0000000225 Insulin Receptor Agonists N0000000225 986676 C1373092 C628 Insulin Receptor Agonists [MoA] NDF-RT:N0000000230 Dopamine Antagonists D018492 Dopamine Antagonists N0000000230 1032050 C2757008 C638 Dopamine Antagonists [MoA] NDF-RT:N0000000233 Nucleic Acid Synthesis Inhibitors D019384 Nucleic Acid Synthesis Inhibitors N0000000233 993166 C2757009 C644 Nucleic Acid Synthesis Inhibitors [MoA] NDF-RT:N0000000234 Norepinephrine Transporter Interactions N0000000234 988817 C2267223 C646 Norepinephrine Transporter Interactions [MoA] NDF-RT:N0000000236 Alkylating Activity D000477 Alkylating Activity N0000000236 1031878 C2756975 C650 Alkylating Activity [MoA] NDF-RT:N0000000240 Insulin Receptor Interactions N0000000240 987414 C1373083 C658 Insulin Receptor Interactions [MoA] NDF-RT:N0000000242 Transcription Factor Activity N0000000242 1028825 C1148759 C662 Transcription Factor Activity [MoA] NDF-RT:N0000000243 Androgen Receptor Antagonists N0000000243 989356 Androgen Receptor Inhibitor C1373082 C664 Androgen Receptor Antagonists [MoA] NDF-RT:N0000000246 HIV Protease Inhibitors D017320 HIV Protease Inhibitors N0000000246 993149 Human Immunodeficiency Virus Protease Inhibitors C2756991 C670 HIV Protease Inhibitors [MoA] NDF-RT:N0000000247 Biological Response Modifiers D015545 Biological Response Modifiers N0000000247 993132 C2757019 C672 Biological Response Modifiers [MoA] NDF-RT:N0000000254 Immunologic and Biological Factors D007151 Immunologic and Biological Factors N0000000254 1032698 C0021048 C686 Immunologic and Biological Factors [MoA] NDF-RT:N0000000255 Hormone Receptor Modulators N0000000255 989214 C1373075 C688 Hormone Receptor Modulators [MoA] NDF-RT:N0000000256 Serotonin Agonists D017366 Serotonin Agonists N0000000256 1022850 C2756998 C690 Serotonin Agonists [MoA] NDF-RT:N0000000257 Hormone Receptor Interactions N0000000257 986361 C1373074 C692 Hormone Receptor Interactions [MoA] NDF-RT:N0000008288 Cyclooxygenase 2 Inhibitors N0000008288 993136 COX-2 Inhibitors Cyclooxygenase II Inhibitors C2757001 C26942 Cyclooxygenase 2 Inhibitors [MoA] NDF-RT:N0000009918 Adrenergic alpha2-Agonists N0000009918 1035126 Adrenergic alpha-2 Agonists alpha-2 Adrenergic Agonists C1373110 C30202 Adrenergic alpha2-Agonists [MoA] NDF-RT:N0000009923 Adrenergic beta1-Antagonists N0000009923 986189 Adrenergic beta-1 Antagonists beta-1 Adrenergic Antagonists C1373134 C30212 Adrenergic beta1-Antagonists [MoA] NDF-RT:N0000009924 Adrenergic beta2-Antagonists N0000009924 987660 Adrenergic beta-2 Antagonists beta-2 Adrenergic Antagonists C1373133 C30214 Adrenergic beta2-Antagonists [MoA] NDF-RT:N0000009946 Para-Aminobenzoic Acid Inhibitors N0000009946 984916 PABA Inhibitor C2916799 C30260 Para-Aminobenzoic Acid Inhibitors [MoA] NDF-RT:N0000009948 Non-Nucleoside Reverse Transcriptase Inhibitors N0000009948 989597 C1373120 C30264 Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] NDF-RT:N0000009949 Antibody-Receptor Interactions N0000009949 985716 C2267208 C30266 Antibody-Receptor Interactions [MoA] NDF-RT:N0000009950 Tumor Necrosis Factor Receptor Interactions N0000009950 984657 TNF Receptor Interactions C1373118 C30268 Tumor Necrosis Factor Receptor Interactions [MoA] NDF-RT:N0000009956 Sterol Synthesis Inhibitors N0000009956 988794 C1373112 C30280 Sterol Synthesis Inhibitors [MoA] NDF-RT:N0000009958 Bone Surface Interactions N0000009958 985507 C1373129 C30284 Bone Surface Interactions [MoA] NDF-RT:N0000010215 Transpeptidase Inhibitors N0000010215 984931 PBP inhibitors Transpepsidase Inhibitors penicillin binding protein Inhibitors C1373138 C31788 Transpeptidase Inhibitors [MoA] NDF-RT:N0000010226 Antibody Interactions N0000010226 987958 C2916825 C31810 Antibody Interactions [MoA] NDF-RT:N0000010255 Cellular Structure Molecule Interactions N0000010255 989808 C1373148 C31868 Cellular Structure Molecule Interactions [MoA] NDF-RT:N0000010256 Tubulin Interactions N0000010256 1023254 C1373147 C31870 Tubulin Interactions [MoA] NDF-RT:N0000010260 beta Tubulin Interactions N0000010260 986466 C1373143 C31878 beta Tubulin Interactions [MoA] NDF-RT:N0000010261 Neurokinin 1 Receptor Interactions N0000010261 984193 NK 1 Receptor Interactions Substance P Receptor Interactions C1373142 C31880 Neurokinin 1 Receptor Interactions [MoA] NDF-RT:N0000010262 Neurokinin 1 Antagonists N0000010262 988216 NK 1 Receptor Antagonists Substance P Receptor Antagonists C2916827 C31882 Neurokinin 1 Antagonists [MoA] NDF-RT:N0000010278 Interleukin 2 Receptor Interactions N0000010278 984934 IL2 Receptor Interactions C1373153 C31914 Interleukin 2 Receptor Interactions [MoA] NDF-RT:N0000010279 Interleukin 2 Receptor Antagonists N0000010279 986467 IL2 Receptor Antagonists IL2 Receptor Blockers IL2 Receptor Inhibitors Interleukin 2 Receptor Blockers Interleukin 2 Receptor Inhibitors C1373152 C31916 Interleukin 2 Receptor Antagonists [MoA] NDF-RT:N0000019992 Hypothalmic Hormone Interactions N0000019992 985094 C2267109 C300377 Hypothalmic Hormone Interactions [MoA] NDF-RT:N0000019993 Hypothalamic Hormone Receptor Agonists N0000019993 989569 C2916835 C300378 Hypothalamic Hormone Receptor Agonists [MoA] NDF-RT:N0000020000 Receptor Tyrosine Kinase Inhibitors N0000020000 987029 C2267115 C300385 Receptor Tyrosine Kinase Inhibitors [MoA] NDF-RT:N0000020001 Tyrosine Kinase Inhibitors N0000020001 1028392 C2757011 C300386 Tyrosine Kinase Inhibitors [MoA] NDF-RT:N0000020006 HER Receptor Family Antagonists N0000020006 990667 EGFR Family Antagonists EGFR Family Inhibitors Epidermal Growth Factor Receptor Family Antagonists Epidermal Growth Factor Receptor Family Inhibitors HER Antagonists HER Family Antagonists HER Family Inhibitors HER Inhibitors HER Receptor Family Inhibitors Human Epidermal Growth Factor Receptor Family Antagonists Human Epidermal Growth Factor Receptor Family Inhibitors C2916840 C300391 HER Receptor Family Antagonists [MoA] NDF-RT:N0000020008 HER2/Neu/cerbB2 Antagonists N0000020008 984590 HER-2 Antagonists HER-2 Inhibitors HER-2/Neu/cerbB2 Antagonists HER-2/Neu/cerbB2 Inhibitors HER2 Antagonists HER2 Inhibitors HER2/Neu/cerbB2 Inhibitors C2916795 C300393 HER2/Neu/cerbB2 Antagonists [MoA] NDF-RT:N0000020009 Bcr-Abl Tyrosine Kinase Inhibitors N0000020009 984994 Bcr-Abl Tyrosine Kinase Inhibitor C2267122 C300394 Bcr-Abl Tyrosine Kinase Inhibitors [MoA] NDF-RT:N0000020010 HER1 Antagonists N0000020010 989266 EGFR Antagonists EGFR Inhibitors Epidermal Growth Factor Receptor Antagonists Epidermal Growth Factor Receptor Inhibitors HER-1 Antagonists HER-1 Inhibitors HER1 Inhibitors C2916831 C300395 HER1 Antagonists [MoA] NDF-RT:N0000020018 Glucosyl Transferase Inhibitors N0000020018 988136 C2267130 C300403 Glucosyl Transferase Inhibitors [MoA] NDF-RT:N0000020019 Glucosylceramide Synthase Inhibitors N0000020019 989376 C2267131 C300404 Glucosylceramide Synthase Inhibitors [MoA] NDF-RT:N0000020025 14-alpha Demethylase Inhibitors N0000020025 989952 C2267137 C300411 14-alpha Demethylase Inhibitors [MoA] NDF-RT:N0000020026 Phosphodiesterase 5 Inhibitors N0000020026 985515 Phosphodiesterase V Inhibitor Phosphodiesterase V Inhibitors C2267138 C300412 Phosphodiesterase 5 Inhibitors [MoA] NDF-RT:N0000020065 L-Calcium Channel Receptor Antagonists N0000020065 989377 C2916833 C300455 L-Calcium Channel Receptor Antagonists [MoA] NDF-RT:N0000020084 Ubiquitin Ligase Inhibitors N0000020084 986156 C1661195 C300474 Ubiquitin Ligase Inhibitors [MoA] NDF-RT:N0000020089 Viral Envelope Interactions N0000020089 989812 C2267190 C300479 Viral Envelope Interactions [MoA] NDF-RT:N0000175074 Nucleoside Synthesis Inhibitors N0000175074 987332 C2266855 C634436 Nucleoside Synthesis Inhibitors [MoA] NDF-RT:N0000175075 Proteasome Inhibitors N0000175075 988088 Proteasome Inhibitor Proteosome Inhibitors C2266856 C634437 Proteasome Inhibitors [MoA] NDF-RT:N0000175076 Protein Kinase Inhibitors N0000175076 993161 C2757016 C634438 Protein Kinase Inhibitors [MoA] NDF-RT:N0000175082 Kinase Inhibitors N0000175082 1025684 C1152564 C634444 Kinase Inhibitors [MoA] NDF-RT:N0000175355 Binding Activity N0000175355 990338 C2266866 C634738 Binding Activity [MoA] NDF-RT:N0000175368 Cholinergic Interactions N0000175368 987379 C2266879 C634751 Cholinergic Interactions [MoA] NDF-RT:N0000175369 Cholinergic Agonists N0000175369 1033063 C2757066 C634752 Cholinergic Agonists [MoA] NDF-RT:N0000175446 Tumor Necrosis Factor alpha Receptor Blocking Activity N0000175446 988325 TNF-a Receptor Blocking Activity TNF-alpha Receptor Blocking Activity C2267209 C30270 Tumor Necrosis Factor alpha Receptor Blocking Activity [MoA] NDF-RT:N0000175450 Corticosteroid Hormone Receptor Agonists N0000175450 988660 C2266939 C634830 Corticosteroid Hormone Receptor Agonists [MoA] NDF-RT:N0000175451 Tumor Necrosis Factor Receptor Blocking Activity N0000175451 984952 TNF Blocker TNF Receptor Blocking Activity C2266940 C634831 Tumor Necrosis Factor Receptor Blocking Activity [MoA] NDF-RT:N0000175472 Metal Chelating Activity N0000175472 986481 C1154714 C634853 Metal Chelating Activity [MoA] NDF-RT:N0000175919 Cholesterol Synthesis Inhibitors N0000175919 991925 C2917205 C635357 Cholesterol Synthesis Inhibitors [MoA] BFO:0000001 entity Entity Julius Caesar Verdi’s Requiem the Second World War your body mass index BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) entity BFO:0000002 continuant Continuant BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] continuant BFO:0000003 occurrent Occurrent BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] occurrent BFO:0000004 ic IndependentContinuant a chair a heart a leg a molecule a spatial region an atom an orchestra. an organism the bottom right portion of a human torso the interior of your mouth b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] independent continuant BFO:0000015 process Process a process of cell-division, \ a beating of the heart a process of meiosis a process of sleeping the course of a disease the flight of a bird the life of an organism your process of aging. p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] process BFO:0000016 disposition Disposition an atom of element X has the disposition to decay to an atom of element Y certain people have a predisposition to colon cancer children are innately disposed to categorize objects in certain ways. the cell wall is disposed to filter chemicals in endocytosis and exocytosis BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] disposition BFO:0000017 realizable RealizableEntity the disposition of this piece of metal to conduct electricity. the disposition of your blood to coagulate the function of your reproductive organs the role of being a doctor the role of this boundary to delineate where Utah and Colorado meet To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] realizable entity BFO:0000019 quality Quality the ambient temperature of this portion of air the color of a tomato the length of the circumference of your waist the mass of this piece of gold. the shape of your nose the shape of your nostril a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] quality BFO:0000020 sdc SpecificallyDependentContinuant Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key of one-sided specifically dependent continuants: the mass of this tomato of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. the disposition of this fish to decay the function of this heart: to pump blood the mutual dependence of proton donors and acceptors in chemical reactions [79 the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction the pink color of a medium rare piece of grilled filet mignon at its center the role of being a doctor the shape of this hole. the smell of this portion of mozzarella b is a relational specifically dependent continuant = Def. b is a specifically dependent continuant and there are n &gt; 1 independent continuants c1, … cn which are not spatial regions are such that for all 1 i &lt; j n, ci and cj share no common parts, are such that for each 1 i n, b s-depends_on ci at every time t during the course of b’s existence (axiom label in BFO2 Reference: [131-004]) b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. (iff (RelationalSpecificallyDependentContinuant a) (and (SpecificallyDependentContinuant a) (forall (t) (exists (b c) (and (not (SpatialRegion b)) (not (SpatialRegion c)) (not (= b c)) (not (exists (d) (and (continuantPartOfAt d b t) (continuantPartOfAt d c t)))) (specificallyDependsOnAt a b t) (specificallyDependsOnAt a c t)))))) // axiom label in BFO2 CLIF: [131-004] (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] specifically dependent continuant BFO:0000023 role Role John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. the priest role the role of a boundary to demarcate two neighboring administrative territories the role of a building in serving as a military target the role of a stone in marking a property boundary the role of subject in a clinical trial the student role BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] role BFO:0000030 object Object atom cell cells and organisms engineered artifacts grain of sand molecule organelle organism planet solid portions of matter star BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 BFO 2 Reference: an object is a maximal causally unified material entity BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) object object BFO:0000031 gdc GenericallyDependentContinuant The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. the pdf file on your laptop, the pdf file that is a copy thereof on my laptop the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] generically dependent continuant BFO:0000040 material MaterialEntity a flame a forest fire a human being a hurricane a photon a puff of smoke a sea wave a tornado an aggregate of human beings. an energy wave an epidemic the undetached arm of a human being BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] material entity material entity A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. 121243 CHEBI:127308 Beilstein:7694998 ChEMBL:127308 ChemIDplus:137234-62-9 DrugBank:137234-62-9 DrugBank:DB00582 KEGG COMPOUND:137234-62-9 KEGG COMPOUND:C07622 KEGG DRUG:137234-62-9 KEGG DRUG:D00578 Patent:EP440372 Patent:US5278175 Wikipedia:Voriconazole (2R,3S)-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol (R-(R*,S*))-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha-(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol (alphaR,betaS)-alpha-(2,4-difluorophenyl)-5-fluoro-beta-methyl-alpha(1H-1,2,4-triazol-1-ylmethyl)-4-pyrimidineethanol C16H14F3N5O C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F InChI=1S/C16H14F3N5O/c1-10(15-14(19)5-20-7-22-15)16(25,6-24-9-21-8-23-24)12-3-2-11(17)4-13(12)18/h2-5,7-10,25H,6H2,1H3/t10-,16+/m0/s1 InChIKey=BCEHBSKCWLPMDN-MGPLVRAMSA-N VCZ Vfend voriconazole CHEBI:10023 voriconazole CHEBI:10023 Quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively. 2551 CHEBI:102718 CHEBI:3717 CHEBI:41638 Beilstein:3568352 ChEMBL:100241 ChEMBL:102718 ChEMBL:10397494 ChEMBL:10737746 ChemIDplus:85721-33-1 DrugBank:DB00537 KEGG COMPOUND:85721-33-1 KEGG DRUG:D00186 Patent:DE3142854 Patent:US4670444 Wikipedia:Ciprofloxacin 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid Ciprofloxacin ciprofloxacin 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID 1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid 1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid 1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid C17H18FN3O3 InChI=1S/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24) InChIKey=MYSWGUAQZAJSOK-UHFFFAOYSA-N OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O ciprofloxacin ciprofloxacine ciprofloxacino ciprofloxacinum CHEBI:100241 Ciprofloxacin ciprofloxacin CHEBI:100241 A synthetic fluoroquinolone with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase. 7517 CHEBI:7629 Beilstein:567897 ChEMBL:100246 ChemIDplus:70458-96-7 CiteXplore:3317294 CiteXplore:3908074 CiteXplore:6211142 CiteXplore:6224685 CiteXplore:6234465 CiteXplore:6454381 CiteXplore:6461606 DrugBank:DB01059 Gmelin:1576626 KEGG COMPOUND:70458-96-7 KEGG COMPOUND:C06687 KEGG DRUG:D00210 Patent:BE863429 Patent:DE2840910 Patent:US4146719 Patent:US4292317 Wikipedia:Norfloxacin 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid 1,4-Dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid 1-Ethyl-6-fluor-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-chinolincarbonsaeure 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid C16H18FN3O3 CCn1cc(C(O)=O)c(=O)c2cc(F)c(cc12)N1CCNCC1 InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23) InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N NFLX norfloxacin norfloxacine norfloxacino norfloxacinum CHEBI:100246 Norfloxacin norfloxacin CHEBI:100246 An indole that has formula C31H33N3O6S. 114970 Beilstein:3641829 ChemIDplus:107753-78-6 DrugBank:DB00549 KEGG COMPOUND:107753-78-6 KEGG COMPOUND:C07206 KEGG DRUG:D00411 Wikipedia:Zafirlukast cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate 4-(5-cyclopentyloxycarbonylamino-1-methyl-1H-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide Accolate C31H33N3O6S COc1cc(ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12)C(=O)NS(=O)(=O)c1ccccc1C InChI=1S/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35) InChIKey=YEEZWCHGZNKEEK-UHFFFAOYSA-N cyclopentyl 3-(2-methoxy-4-((o-tolylsulfonyl)carbamoyl)benzyl)-1-methylindole-5-carbamate zafirlukast CHEBI:10100 zafirlukast CHEBI:10100 A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position. 74667 Beilstein:8153844 ChemIDplus:151319-34-5 DrugBank:151319-34-5 DrugBank:DB00962 KEGG COMPOUND:151319-34-5 KEGG COMPOUND:C07484 KEGG DRUG:151319-34-5 KEGG DRUG:D00530 NIST Chemistry WebBook:151319-34-5 Patent:US4626538 Wikipedia:Zaleplon N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide 3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide C17H15N5O CCN(C(C)=O)c1cccc(c1)-c1ccnc2c(cnn12)C#N InChI=1S/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3 InChIKey=HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon CHEBI:10102 zaleplon CHEBI:10102 A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. 11413 CHEBI:619601 Beilstein:763034 ChEMBL:19112024 ChEMBL:619601 ChemIDplus:30516-87-1 DrugBank:30516-87-1 DrugBank:DB00495 KEGG COMPOUND:30516-87-1 KEGG COMPOUND:C07210 KEGG DRUG:30516-87-1 KEGG DRUG:D00413 Patent:US4724232 Wikipedia:Zidovudine 3'-azido-3'-deoxythymidine AZT Azidothymidine C10H13N5O4 Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 InChIKey=HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudin Zidovudinum zidovudine CHEBI:10110 Zidovudine zidovudine CHEBI:10110 A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms. 115698 Beilstein:6669199 ChemIDplus:146939-27-7 DrugBank:146939-27-7 DrugBank:DB00246 KEGG COMPOUND:C07568 KEGG DRUG:146939-27-7 KEGG DRUG:D08687 Patent:EP281309 Patent:US4831031 Wikipedia:Ziprasidone 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one Ziprasidone C21H21ClN4OS Clc1cc2NC(=O)Cc2cc1CCN1CCN(CC1)c1nsc2ccccc12 InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) InChIKey=MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidona ziprasidone ziprasidonum CHEBI:10119 ziprasidone CHEBI:10119 An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position. 39993 Beilstein:4355785 ChemIDplus:82626-48-0 DrugBank:82626-48-0 DrugBank:DB00425 KEGG COMPOUND:82626-48-0 KEGG COMPOUND:C07219 KEGG DRUG:82626-48-0 KEGG DRUG:D08690 NIST Chemistry WebBook:82626-48-0 Patent:EP50563 Patent:US4382938 Wikipedia:Zolpidem N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide C19H21N3O CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1 InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3 InChIKey=ZAFYATHCZYHLPB-UHFFFAOYSA-N N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide zolpidem zolpidemum CHEBI:10125 zolpidem CHEBI:10125 A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position. 39998 CHEBI:139857 Beilstein:1077076 ChEMBL:139857 ChemIDplus:68291-97-4 DrugBank:68291-97-4 DrugBank:DB00909 KEGG COMPOUND:68291-97-4 KEGG COMPOUND:C07504 KEGG DRUG:68291-97-4 KEGG DRUG:D00538 Patent:JP7877057 Patent:US4172896 Wikipedia:Zonisamide 1-(1,2-benzisoxazol-3-yl)methanesulfonamide 1,2-Benzisoxazole-3-methanesulfonamide 3-(Sulfamoylmethyl)-1,2-benzisoxazole Benzo[d]isoxazol-3-yl-methanesulfonamide C8H8N2O3S InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) InChIKey=UBQNRHZMVUUOMG-UHFFFAOYSA-N NS(=O)(=O)Cc1noc2ccccc12 zonisamida zonisamide zonisamidum CHEBI:10127 zonisamide CHEBI:10127 The (S,S)-diastereoisomer of 2,3-dihydro-1,5-benzothiazepin-4(5H)-one in which positions 2 and 3 are substituted by 4-methoxyphenyl and acetoxy, respectively, while the hydrogen attached to the nitrogen is substituted by a 2-(dimethylamino)ethyl group. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension. 3443 CHEBI:4602 Beilstein:3573079 ChEMBL:101278 ChemIDplus:42399-41-7 DrugBank:DB00343 KEGG COMPOUND:42399-41-7 KEGG COMPOUND:C06958 KEGG DRUG:D07845 NIST Chemistry WebBook:42399-41-7 Patent:DE1805714 Patent:DE3415035 Patent:US3562257 Patent:US4552695 Wikipedia:Diltiazem (2S,3S)-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate DILTIAZEM Diltiazem (+)-cis-5-[2-(dimethylamino)ethyl]-2,3-dihydro-3-hydroxy-2-(p-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one acetate ester (2S,3S)-5-(2-(dimethylamino)ethyl)-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-3-yl acetate (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one Acetic acid (2S,3S)-5-(2-dimethylamino-ethyl)-2-(4-methoxy-phenyl)-4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]thiazepin-3-yl ester C22H26N2O4S COc1ccc(cc1)[C@@H]1Sc2ccccc2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O InChI=1S/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1 InChIKey=HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem diltiazemum CHEBI:101278 Diltiazem diltiazem CHEBI:101278 Barbituric acid in which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. Frequently combined with other medicines, such as aspirin, paracetamol and codeine, it is used for treatment of pain and headache. 19860 Beilstein:202119 ChEMBL:102524 ChEMBL:6864729 ChemIDplus:77-26-9 DrugBank:DB00241 KEGG DRUG:D03182 NIST Chemistry WebBook:77-26-9 Wikipedia:Butalbital 5-(2-methylpropyl)-5-(prop-2-en-1-yl)pyrimidine-2,4,6(1H,3H,5H)-trione 5-(2-methylpropyl)-5-prop-2-enyl-1,3-diazinane-2,4,6-trione 5-Allyl-5-isobutyl-pyrimidine-2,4,6-trione 5-allyl-5-(2'-methyl-n-propyl) barbituric acid 5-allyl-5-(2-methylpropyl)barbituric acid 5-allyl-5-isobutyl-2,4,6(1H,3H,5H)-pyrimidinetrione 5-allyl-5-isobutylbarbituric acid 5-isobutyl-5-allylbarbituric acid C11H16N2O3 CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O InChI=1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16) InChIKey=UZVHFVZFNXBMQJ-UHFFFAOYSA-N allylbarbital allylbarbitone allylbarbituric acid butalbarbital butalbital butalbitalum iso-butylallylbarbituric acid itobarbital tetrallobarbital CHEBI:102524 butalbital CHEBI:102524 A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). 37418 Beilstein:5346011 ChemIDplus:103628-46-2 CiteXplore:11045888 CiteXplore:11401410 CiteXplore:12172708 CiteXplore:12856385 CiteXplore:12917936 CiteXplore:15652399 CiteXplore:16120224 CiteXplore:16142613 CiteXplore:17557349 CiteXplore:18442019 CiteXplore:19619527 CiteXplore:19825906 CiteXplore:22106962 CiteXplore:22150557 CiteXplore:22272067 CiteXplore:22302025 CiteXplore:22336849 CiteXplore:22336867 CiteXplore:22336868 CiteXplore:22435741 DrugBank:DB00669 HMDB:HMDB05037 KEGG COMPOUND:103628-46-2 KEGG COMPOUND:C07319 KEGG DRUG:D00451 NIST Chemistry WebBook:103628-46-2 Reaxys:5346011 Wikipedia:Sumatriptan 1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide (3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide 3-[2-(dimethylamino)ethyl]-N-methylindole-5-methanesulfonamide C14H21N3O2S CNS(=O)(=O)Cc1ccc2[nH]cc(CCN(C)C)c2c1 Imigran Imitrex InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3 InChIKey=KQKPFRSPSRPDEB-UHFFFAOYSA-N Sumatran Sumax sumatriptan sumatriptanum CHEBI:10650 Sumatriptan sumatriptan CHEBI:10650 The carboxamide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid. 4337 CHEBI:310077 CHEBI:5012 ChEMBL:10669565 ChEMBL:10987438 ChEMBL:11585443 ChEMBL:119915 ChEMBL:14698188 ChEMBL:310077 ChemIDplus:437-38-7 CiteXplore:16621415 DrugBank:DB00813 KEGG DRUG:437-38-7 KEGG DRUG:D00320 Patent:FR1344366 Patent:US3164600 Reaxys:494484 Wikipedia:Fentanyl FENTANYL N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide 1-phenethyl-4-(N-phenylpropionamido)piperidine 1-phenethyl-4-N-propionylanilinopiperidine C22H28N2O CCC(=O)N(C1CCN(CC1)CCc1ccccc1)c1ccccc1 InChI=1S/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3 InChIKey=PJMPHNIQZUBGLI-UHFFFAOYSA-N N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-phenethyl-4-piperidyl)propionanilide N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide N-phenethyl-4-(N-propionylanilino)piperidine N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide fentanila fentanyl fentanylum CHEBI:119915 Fentanyl fentanyl CHEBI:119915 Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity. 33562 CHEBI:45085 CHEBI:8158 ChEMBL:127780 ChemIDplus:4428-95-9 CiteXplore:11576919 CiteXplore:15182735 CiteXplore:16858125 CiteXplore:19213941 CiteXplore:19288498 CiteXplore:21056575 CiteXplore:21566148 DrugBank:DB00529 KEGG COMPOUND:4428-95-9 KEGG COMPOUND:C06456 PDBeChem:PPF Reaxys:1756501 Wikipedia:Foscarnet PHOSPHONOFORMIC ACID dihydroxyphosphanecarboxylic acid oxide CH3O5P FOSCARNET Foscarmet InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6) InChIKey=ZJAOAACCNHFJAH-UHFFFAOYSA-N OC(=O)P(O)(O)=O carboxyphosphonic acid foscarnet phosphonomethanoic acid CHEBI:127780 Foscarnet phosphonoformic acid CHEBI:127780 Any amide of aniline. CiteXplore:6205897 KEGG COMPOUND:C01402 anilide C7H6NOR N-phenyl amide N-phenyl amides [*]C(=O)Nc1ccccc1 CHEBI:13248 anilide CHEBI:13248 Benzoic acid carrying an acetoxy group at the 2-position. 1191 CHEBI:22188 CHEBI:22203 CHEBI:2890 CHEBI:40705 Beilstein:779271 ChemIDplus:50-78-2 CiteXplore:11402787 CiteXplore:11597554 CiteXplore:11733186 CiteXplore:12852484 CiteXplore:14753751 CiteXplore:15542410 CiteXplore:15590729 CiteXplore:1650428 CiteXplore:18226435 CiteXplore:18335236 CiteXplore:19386367 CiteXplore:19706045 CiteXplore:21699808 CiteXplore:445303 DrugBank:DB00945 Gmelin:218864 KEGG COMPOUND:50-78-2 KEGG COMPOUND:C01405 KEGG DRUG:D00109 NIST Chemistry WebBook:50-78-2 PDBeChem:AIN Reaxys:779271 Wikipedia:Aspirin 2-(acetyloxy)benzoic acid Acetylsalicylic acid 2-(ACETYLOXY)BENZOIC ACID 2-Acetoxybenzenecarboxylic acid 2-acetoxybenzoic acid ASA Acetylsalicylate Acetylsalicylsaeure Aspirin Azetylsalizylsaeure C9H8O4 CC(=O)Oc1ccccc1C(O)=O Easprin InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12) InChIKey=BSYNRYMUTXBXSQ-UHFFFAOYSA-N O-acetylsalicylic acid acide 2-(acetyloxy)benzoique acide acetylsalicylique acido acetilsalicilico acidum acetylsalicylicum o-acetoxybenzoic acid o-carboxyphenyl acetate salicylic acid acetate CHEBI:15365 Aspirin acetylsalicylic acid CHEBI:15365 An optically active form of dopa having L-configuration. 6375 CHEBI:11693 CHEBI:13098 CHEBI:1377 CHEBI:19825 CHEBI:41871 CHEBI:49933 Beilstein:2215169 Beilstein:6060047 COMe:MOL000169 ChemIDplus:59-92-7 CiteXplore:8301021 DrugBank:DB01235 Gmelin:365846 KEGG COMPOUND:59-92-7 KEGG COMPOUND:C00355 KEGG DRUG:D00059 NIST Chemistry WebBook:59-92-7 PDBeChem:DAH_LFOH Reaxys:2215169 Wikipedia:Levodopa (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid L-DOPA L-Dopa L-dopa (-)-3-(3,4-dihydroxyphenyl)-L-alanine (-)-dopa 3,4-DIHYDROXYPHENYLALANINE 3,4-Dihydroxy-L-phenylalanine 3-Hydroxy-L-tyrosine C9H11NO4 Dihydroxy-L-phenylalanine Dopar InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1 InChIKey=WTDRDQBEARUVNC-LURJTMIESA-N L-beta-(3,4-Dihydroxyphenyl)alanine N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O beta-(3,4-dihydroxyphenyl)-L-alanine beta-(3,4-dihydroxyphenyl)alanine levodopa levodopum CHEBI:15765 L-dopa Levodopa CHEBI:15765 Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers. CHEBI:13694 CHEBI:26960 CHEBI:9340 KEGG COMPOUND:C00297 sulfides RSR SR2 Sulfide Thioether organic sulfides thioether thioethers CHEBI:16385 organic sulfide CHEBI:16385 Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. CHEBI:14753 CHEBI:25906 CHEBI:7990 KEGG COMPOUND:C00012 Peptide peptides C2H4NO2R(C2H2NOR)n Peptid peptido peptidos CHEBI:16670 peptide CHEBI:16670 Codeine is an alkaloid found in the opium poppy, Papaver somniferum var. album; has analgesic, anti-tussive and anti-diarrhoeal properties. 2670 CHEBI:14006 CHEBI:23348 CHEBI:3803 Beilstein:5303198 Beilstein:5768734 Beilstein:94996 ChemIDplus:76-57-3 CiteXplore:2215478 DrugBank:DB00318 Gmelin:232454 KEGG COMPOUND:76-57-3 KEGG COMPOUND:C06174 NIST Chemistry WebBook:76-57-3 Wikipedia:Codeine 3-methoxy-17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-6alpha-ol Codeine (5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-3-methoxy-17-methylmorphinan-6-ol 7,8-didehydro-4,5alpha-epoxy-3-methoxy-17-methylmorphinan-6alpha-ol C18H21NO3 Codein Codicept Coducept InChI=1S/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1 InChIKey=OROGSEYTTFOCAN-DNJOTXNNSA-N O(3)-methylmorphine [H][C@]12C=C[C@H](O)[C@@H]3Oc4c(OC)ccc5C[C@H]1N(C)CC[C@@]23c45 codeina codeine codeine anhydrous l-codeine methylmorphine morphine 3-methyl ether morphine monomethyl ether morphine-3-methyl ether CHEBI:16714 Codeine codeine CHEBI:16714 CHEBI:13431 CHEBI:8749 KEGG COMPOUND:C00375 CH4NR NC[*] RCH2NH2 primary aliphatic amines CHEBI:17062 primary aliphatic amine CHEBI:17062 A amino cyclitol glycoside that consists of streptidine having a disaccharyl moiety attached at the 4-position. The parent of the streptomycin class 10109 CHEBI:15119 CHEBI:26784 CHEBI:45745 CHEBI:9284 Beilstein:74498 ChemIDplus:57-92-1 CiteXplore:11228320 CiteXplore:11905029 CiteXplore:12118520 CiteXplore:13030054 CiteXplore:13116094 CiteXplore:13136149 CiteXplore:13596285 CiteXplore:13691614 CiteXplore:13985260 CiteXplore:13990247 CiteXplore:14623118 CiteXplore:14828344 CiteXplore:14852338 CiteXplore:14939639 CiteXplore:15081082 CiteXplore:15137533 CiteXplore:15207172 CiteXplore:15686853 CiteXplore:15736038 CiteXplore:16904706 CiteXplore:17105735 CiteXplore:17238915 CiteXplore:17429930 CiteXplore:18173084 CiteXplore:18916143 CiteXplore:19052412 CiteXplore:19335957 CiteXplore:21350946 CiteXplore:21362244 CiteXplore:21593257 CiteXplore:21937264 DrugBank:DB01082 KEGG COMPOUND:57-92-1 KEGG COMPOUND:C00413 KEGG DRUG:D08531 PDBeChem:SRY Reaxys:74498 Wikipedia:Streptomycin N,N'''-[(1R,2R,3S,4R,5R,6S)-4-{5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyloxy}-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine STREPTOMYCIN 2,4-Diguanidino-3,5,6-trihydroxycyclohexyl 5-deoxy-2-O-(2-deoxy-2-methylamino-alpha-L-glucopyranosyl)-3-C-formyl-beta-L-lyxopentanofuranoside C21H39N7O12 CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]1[C@@H](O[C@@H](C)[C@]1(O)C=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]1NC(N)=N InChI=1S/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1 InChIKey=UCSJYZPVAKXKNQ-HZYVHMACSA-N Kantrex SM [2-deoxy-2-(dimethylamino)-alpha-L-glucopyranosyl]-(1->2)-[5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]-(1->4)-{N',N'''-[(1,3,5/2,4,6)-2,4,5,6-tetrahydroxycyclohexane-1,3-diyl]diguanidine} streptomycin CHEBI:17076 Streptomycin streptomycin CHEBI:17076 A compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H). CHEBI:13427 CHEBI:24974 CHEBI:6127 CHEBI:8742 KEGG COMPOUND:C00709 KEGG COMPOUND:C01450 Ketone ketones COR2 Keton R-CO-R' [*]C([*])=O cetone ketones CHEBI:17087 ketone CHEBI:17087 Any member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6. CHEBI:14742 CHEBI:25869 CHEBI:7961 CiteXplore:12833570 CiteXplore:1502708 CiteXplore:16033609 CiteXplore:7798534 KEGG COMPOUND:C00395 Penicillin penicillin penicillins C9H11N2O4SR [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC([*])=O)C(O)=O penicillins CHEBI:17334 penicillin CHEBI:17334 A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. Gemcitabine is used in various carcinomas: non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. 12574 CHEBI:42752 CHEBI:5295 Beilstein:5382060 ChEMBL:11356111 ChEMBL:17101674 ChEMBL:175901 ChEMBL:17602464 ChEMBL:17887663 ChEMBL:17939651 ChEMBL:18186604 ChEMBL:18257544 ChemIDplus:95058-81-4 CiteXplore:11034044 CiteXplore:11061612 CiteXplore:11088063 CiteXplore:11122828 CiteXplore:11132538 CiteXplore:11142482 CiteXplore:11221019 CiteXplore:11374818 CiteXplore:11489002 CiteXplore:11504793 CiteXplore:11510027 CiteXplore:11585734 CiteXplore:11595724 CiteXplore:11807603 CiteXplore:11859947 CiteXplore:11901308 CiteXplore:12057041 CiteXplore:12057046 CiteXplore:12057157 CiteXplore:12115355 CiteXplore:12142097 CiteXplore:12571808 CiteXplore:12722678 CiteXplore:12722691 CiteXplore:12743987 CiteXplore:12761494 CiteXplore:12798170 CiteXplore:12917815 CiteXplore:12954073 CiteXplore:14606642 CiteXplore:14653877 CiteXplore:14720338 CiteXplore:15131028 CiteXplore:15160243 CiteXplore:15221904 CiteXplore:15282439 CiteXplore:15297392 CiteXplore:15542781 CiteXplore:15637766 CiteXplore:15744590 CiteXplore:16001951 CiteXplore:16041610 CiteXplore:16080557 CiteXplore:16143373 CiteXplore:16149285 CiteXplore:16317298 CiteXplore:16500746 CiteXplore:16555971 CiteXplore:16584929 CiteXplore:16807461 CiteXplore:16807463 CiteXplore:16894289 CiteXplore:16905983 CiteXplore:17296311 CiteXplore:17296587 CiteXplore:17347561 CiteXplore:17429628 CiteXplore:17460420 CiteXplore:17639396 CiteXplore:17941128 CiteXplore:17987263 CiteXplore:18035967 CiteXplore:18050344 CiteXplore:18086345 CiteXplore:18166944 CiteXplore:18348652 CiteXplore:18773046 CiteXplore:18789834 CiteXplore:18819792 CiteXplore:18981552 CiteXplore:19034448 CiteXplore:19177022 CiteXplore:19399788 CiteXplore:19839926 CiteXplore:19879060 DrugBank:95058-81-4 DrugBank:DB00441 KEGG COMPOUND:95058-81-4 KEGG COMPOUND:C07650 KEGG DRUG:95058-81-4 KEGG DRUG:D02368 PDBeChem:GEO Patent:EP1939198 Patent:EP2108368 Patent:EP2275135 Patent:GB2136425 Patent:US2009124797 Patent:US2010111852 Patent:US4808614 Reaxys:5382060 Wikipedia:Gemcitabine 2'-deoxy-2',2'-difluorocytidine 2',2'-Difluorodeoxycytidine 2'-Deoxy-2',2'-difluorocytidine 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one C9H11F2N3O4 InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 InChIKey=SDUQYLNIPVEERB-QPPQHZFASA-N Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 gemcitabina gemcitabine gemcitabinum CHEBI:175901 gemcitabine CHEBI:175901 Cortisol is a corticosteroid hormone or glucocorticoid produced by zona fasciculata of the adrenal cortex, which is a part of the adrenal gland. It is usually referred to as the "stress hormone" as it is involved in response to stress and anxiety, controlled by corticotropin-releasing hormone (CRH). It increases blood pressure and blood sugar, and reduces immune responses 5492 CHEBI:14023 CHEBI:24633 CHEBI:3893 CHEBI:58221 Beilstein:1354819 ChemIDplus:50-23-7 CiteXplore:10438974 DrugBank:DB00741 KEGG COMPOUND:50-23-7 KEGG COMPOUND:C00735 KEGG DRUG:D00088 LIPID MAPS:LMST02030001 NIST Chemistry WebBook:50-23-7 Patent:US2602769 Wikipedia:Hydrocortisone 11beta,17,21-trihydroxypregn-4-ene-3,20-dione Cortisol cortisol (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione 11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione 11beta-hydrocortisone 17-hydroxycorticosterone 4-pregnen-11beta,17alpha,21-triol-3,20-dione C21H30O5 Hydrocortisone InChI=1S/C21H30O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-16,18,22,24,26H,3-8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 InChIKey=JYGXADMDTFJGBT-VWUMJDOOSA-N Kendall's compound F Reichstein's substance M [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO hidrocortisona hydrocortisone hydrocortisonum CHEBI:17650 Hydrocortisone cortisol CHEBI:17650 Any of a group of aminoglycoside antibiotics produced by fermentation of some Micromonospora spp. 142438 CHEBI:14293 CHEBI:24206 CHEBI:24212 CHEBI:5306 KEGG COMPOUND:1403-66-3 KEGG COMPOUND:C00505 4,6-diamino-3-[3-deoxy-4-C-methyl-3-(methylamino)pentopyranosyloxy]-2-hydroxycyclohexyl 2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)heptopyranoside Gentamicin gentamicin gentamycins CHEBI:17833 Gentamicin Sulfate (USP) gentamycin CHEBI:17833 'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids. CHEBI:14517 CHEBI:25054 CHEBI:6486 KEGG COMPOUND:C01356 Lipid lipid lipids CHEBI:18059 lipid CHEBI:18059 A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group. 7980 CHEBI:14743 CHEBI:25866 CHEBI:45073 CHEBI:7962 Beilstein:44740 ChemIDplus:61-33-6 CiteXplore:10930630 CiteXplore:11431418 CiteXplore:11906332 CiteXplore:12569987 CiteXplore:12850488 CiteXplore:1384868 CiteXplore:16033609 CiteXplore:1709917 CiteXplore:2083978 CiteXplore:6161899 CiteXplore:7602118 CiteXplore:7716788 DrugBank:DB01053 Gmelin:781913 KEGG COMPOUND:61-33-6 KEGG COMPOUND:C05551 KEGG DRUG:D02336 PDBeChem:PNN Patent:US3024169 Reaxys:44740 Wikipedia:Penicillin_G 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid Benzylpenicillin (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 6-(2-phenylacetamido)penicillanic acid C16H18N2O4S InChI=1S/C16H18N2O4S/c1-16(2)12(15(21)22)18-13(20)11(14(18)23-16)17-10(19)8-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 InChIKey=JGSARLDLIJGVTE-MBNYWOFBSA-N PENICILLIN G PG Penicillin G [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)Cc1ccccc1)C(O)=O bencilpenicilina benzylpenicillin benzylpenicilline benzylpenicillinic acid benzylpenicillinum free penicillin II CHEBI:18208 Penicillin G benzylpenicillin CHEBI:18208 CHEBI:1083 CHEBI:11394 CHEBI:11567 CHEBI:11568 CHEBI:19259 CHEBI:19560 CHEBI:4421 KEGG COMPOUND:C02269 KEGG COMPOUND:C03216 2'-Deoxynucleoside 2'-deoxynucleoside 2'-deoxyribonucleosides 2-Deoxy-D-ribosyl-base Deoxynucleoside CHEBI:18274 2'-deoxyribonucleoside CHEBI:18274 A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. CHEBI:13212 CHEBI:13426 CHEBI:13660 CHEBI:25547 CHEBI:7584 KEGG COMPOUND:C00726 Nitrile nitrile nitriles CNR Nitril R-CN [*]C#N nitrilos CHEBI:18379 nitrile CHEBI:18379 delta-lactone 1,5-lactone 1,5-lactones delta-lactona delta-lactonas delta-lactones CHEBI:18946 delta-lactone CHEBI:18946 17-keto steroids 17-ketosteroids 17-oxo steroids CHEBI:19168 17-oxo steroid CHEBI:19168 purine 2'-deoxyribonucleosides CHEBI:19254 purine 2'-deoxyribonucleoside CHEBI:19254 pyrimidine 2'-deoxyribonucleosides CHEBI:19255 pyrimidine 2'-deoxyribonucleoside CHEBI:19255 Any aminopurine having the amino substituent at the 2-position. 2-aminopurines CHEBI:20702 2-aminopurines CHEBI:20702 A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond. glycosylamine N-glycoside N-glycosides N-glycosyl compounds glycosylamines CHEBI:21731 N-glycosyl compound CHEBI:21731 Any of basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom (but not excluding those of animal origin). Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. By extension, certain neutral compounds biogenetically related to basic alkaloids are included. Alkaloid alkaloids Alkaloide alcaloide alcaloides CHEBI:22315 alkaloid CHEBI:22315 CHEBI:22327 alkyl sulfide CHEBI:22327 An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group. amino alcohols aminoalcohol aminoalcohols CHEBI:22478 amino alcohol CHEBI:22478 amino cyclitol glycoside amino cyclitol glycosides CHEBI:22479 amino cyclitol glycoside CHEBI:22479 aminoglycoside antibiotics CHEBI:22507 aminoglycoside antibiotic CHEBI:22507 Any purine having at least one amino substituent. aminopurines CHEBI:22527 aminopurine CHEBI:22527 anthracenequinones anthraquinones CHEBI:22580 anthraquinone CHEBI:22580 Compounds containing the group -N3, and salts of hydrazoic acid, HN3. azides CHEBI:22680 azides CHEBI:22680 Any member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings. azobenzenes CHEBI:22682 azobenzenes CHEBI:22682 Pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure. barbiturates barbituric acids CHEBI:22693 barbiturates CHEBI:22693 CHEBI:22712 benzenes CHEBI:22712 An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. CHEBI:22715 benzimidazoles CHEBI:22715 CHEBI:22723 benzoic acids CHEBI:22723 benzopyrroles CHEBI:22728 benzopyrrole CHEBI:22728 beta-D-glucoside beta-D-glucosides CHEBI:22798 beta-D-glucoside CHEBI:22798 Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond. CHEBI:22888 biphenyls CHEBI:22888 An ester of carbamic acid. carbamate esters carbamates CHEBI:23003 carbamate ester CHEBI:23003 CHEBI:23007 carbohydrate-containing antibiotic CHEBI:23007 A class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. CHEBI:3538 CiteXplore:12833570 CiteXplore:6762896 KEGG COMPOUND:C00875 Cephalosporin C7H5NO3SR2 [H][C@]12SCC([*])=C(N1C(=O)[C@H]2[*])C(O)=O cephalosporins CHEBI:23066 cephalosporin CHEBI:23066 CHEBI:23117 chlorine molecular entity CHEBI:23117 A carbotricyclic compound comprising 5,6,7,9-tetrahydrobenzo[a]heptalene having four methoxy substituents at the 1-, 2-, 3- and 10-positions as well as an oxo group at the 9-position and an acetamido group at the 7-position. 2683 Beilstein:2228812 CiteXplore:9819133 NIST Chemistry WebBook:54192-66-4 Reaxys:2228812 N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide C22H25NO6 COc1cc2CCC(NC(C)=O)c3cc(=O)c(OC)ccc3-c2c(OC)c1OC InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24) InChIKey=IAKHMKGGTNLKSZ-UHFFFAOYSA-N CHEBI:23359 Colchicine colchicine CHEBI:23359 Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. molecular entity entidad molecular entidades moleculares entite moleculaire molecular entities molekulare Entitaet CHEBI:23367 molecular entity CHEBI:23367 Salts and C-organyl derivatives of hydrogen cyanide, HC#N. cyanides CHEBI:23424 cyanides CHEBI:23424 cyclic amide cyclic amides CHEBI:23443 cyclic amide CHEBI:23443 Cyclopeptid Zyklopeptid cyclic peptides peptide cyclique peptido ciclico CHEBI:23449 cyclic peptide CHEBI:23449 A polyol consisting of a cycloalkane containing at least three hydroxy groups, each attached to a different ring carbon atom. cyclitols CHEBI:23451 cyclitol CHEBI:23451 CHEBI:23480 cyclohexanols CHEBI:23480 deoxyribonucleosides CHEBI:23636 deoxyribonucleoside CHEBI:23636 diamines CHEBI:23666 diamine CHEBI:23666 Either one of a pair of heterocyclic organic compounds comprising three carbon atoms and two nitrogen atoms arranged in a ring. diazoles CHEBI:23677 diazole CHEBI:23677 quinolones CHEBI:23765 quinolone CHEBI:23765 Any terpenoid having a C20 skeleton, derived from geranylgeranyl phosphate. LIPID MAPS:LMPR0104 diterpenoids C20 isoprenoids diterpenoides CHEBI:23849 diterpenoid CHEBI:23849 ethanolamine CHEBI:23981 ethanolamines CHEBI:23981 fluorine molecular entity fluorine compounds fluorine molecular entities CHEBI:24062 fluorine molecular entity CHEBI:24062 Compounds containing at least one furan ring. oxacyclopenta-2,4-dienes CHEBI:24129 furans CHEBI:24129 Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood. glucocorticoids CHEBI:24261 glucocorticoid CHEBI:24261 glucosides CHEBI:24278 glucoside CHEBI:24278 A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, which itself may be derived from a saccharide and chalcogen replacements thereof (RS-, RSe-). The bond between the glycosyl group and the OR group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. glycosides O-glycoside O-glycosides glycosides CHEBI:24400 glycoside CHEBI:24400 A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. CHEBI:24431 chemical entity CHEBI:24431 CHEBI:24436 guanidines CHEBI:24436 halogen molecular entity halogen compounds halogen molecular entities CHEBI:24471 halogen molecular entity CHEBI:24471 CHEBI:24531 heterocyclic antibiotic CHEBI:24531 A cyclic compound having as ring members atoms of carbon and at least of one other element. organic heterocycle organic heterocyclic compounds CHEBI:24532 organic heterocyclic compound CHEBI:24532 A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages. homodetic cyclic peptide homodetic cyclic peptides peptide cyclique homodetique peptido ciclico homodetico CHEBI:24613 homodetic cyclic peptide CHEBI:24613 CHEBI:24628 imidazolidine-2,4-dione CHEBI:24628 Hydroxides are chemical compounds containing a hydroxy group or salts containing hydroxide (OH(-)). CHEBI:24651 hydroxides CHEBI:24651 CHEBI:24662 hydroxy-amino acid CHEBI:24662 hydroxy carboxylic acids CHEBI:24669 hydroxy carboxylic acid CHEBI:24669 CHEBI:24734 hydroxyphenylalanine CHEBI:24734 A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. CHEBI:24780 imidazoles CHEBI:24780 CHEBI:24803 indole-3-acetic acids CHEBI:24803 indol-3-yl carboxylic acids CHEBI:24810 indol-3-yl carboxylic acid CHEBI:24810 Any compound containing an indole skeleton. CHEBI:24828 indoles CHEBI:24828 CHEBI:24829 indolones CHEBI:24829 A compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons). oxoacid oxoacids oxacids oxiacids oxo acid oxy-acids oxyacids CHEBI:24833 oxoacid CHEBI:24833 iodine molecular entity iodine compounds iodine molecular entities CHEBI:24860 iodine molecular entity CHEBI:24860 Any lipid formally derived from isoprene (2-methylbuta-1,3-diene), the skeleton of which can generally be discerned in repeated occurrence in the molecule. The skeleton of isoprenoids may differ from strict additivity of isoprene units by loss or shift of a fragment, commonly a methyl group. The class includes both hydrocarbons and oxygenated derivatives. CiteXplore:12769708 CiteXplore:19219049 LIPID MAPS:LMPR01 isoprenoid isoprenoids isoprenoids CHEBI:24913 isoprenoid CHEBI:24913 isoquinoline alkaloids CHEBI:24921 isoquinoline alkaloid CHEBI:24921 A benzopyridine with the nitrogen of the pyridine moiety in position 2. CHEBI:24922 isoquinolines CHEBI:24922 Cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. lactam lactams Laktam Laktame lactams CHEBI:24995 lactam CHEBI:24995 Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. lactone lactones Lacton Lakton Laktone lactona lactonas CHEBI:25000 lactone CHEBI:25000 methylxanthines CHEBI:25348 methylxanthine CHEBI:25348 CHEBI:25359 modified amino acid CHEBI:25359 An oxoacid containing a single carboxy group. monocarboxylic acid monocarboxylic acids CHEBI:25384 monocarboxylic acid CHEBI:25384 CHEBI:25418 morphinane alkaloid CHEBI:25418 organonitrogen heterocyclic antibiotics CHEBI:25558 organonitrogen heterocyclic antibiotic CHEBI:25558 Any molecule that contains a small number (usually 2 to 10) amino-acid residues connected by peptide linkages. oligopeptides Oligopeptid oligopeptido CHEBI:25676 oligopeptide CHEBI:25676 organic heteromonocyclic compounds CHEBI:25693 organic heteromonocyclic compound CHEBI:25693 A compound ROR (where R is not H). ether ethers OR2 [*]O[*] ethers CHEBI:25698 ether CHEBI:25698 Any compound that has an aldehydic or ketonic group as well as a carboxylic acid group in the same molecule. oxo carboxylic acids oxo acids oxo carboxylic acids CHEBI:25754 oxo carboxylic acid CHEBI:25754 oxygen molecular entity oxygen molecular entities CHEBI:25806 oxygen molecular entity CHEBI:25806 oxopurines CHEBI:25810 oxopurine CHEBI:25810 CHEBI:25865 penicillanic acids CHEBI:25865 CHEBI:25985 phenylalanine derivative CHEBI:25985 HP(=O)(OH)2 (phosphonic acid) and its P-substituted derivatives. phosphonic acids CHEBI:26069 phosphonic acids CHEBI:26069 phosphorus molecular entities CHEBI:26082 phosphorus molecular entity CHEBI:26082 CHEBI:26144 piperazines CHEBI:26144 CHEBI:26151 piperidines CHEBI:26151 An adamantane that has formula C10H17N. 620 Beilstein:2204333 ChemIDplus:768-94-5 DrugBank:DB00915 Gmelin:27066 KEGG COMPOUND:768-94-5 KEGG COMPOUND:C06818 KEGG DRUG:D07441 NIST Chemistry WebBook:768-94-5 Wikipedia:Amantadine Amantadine adamantan-1-ylamine 1-adamantanamine 1-adamantylamine 1-aminoadamantane Amantidine Aminoadamantane C10H17N InChI=1S/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2 InChIKey=DKNWSYNQZKUICI-UHFFFAOYSA-N NC12CC3CC(CC(C3)C1)C2 Viregyt Virosol amantadina amantadine amantadinum tricyclo[3.3.1.1(3,7)]decan-1-amine tricyclo[3.3.1.1(3,7)]decan-1-ylamine tricyclo[3.3.1.1(3,7)]decane-1-amine CHEBI:2618 Amantadine amantadine CHEBI:2618 A compound that contains three or more hydroxyl groups. polyols CHEBI:26191 polyol CHEBI:26191 CHEBI:26292 propanone CHEBI:26292 Derivatives of oxoacids RnE(=O)OH in which the hydroxy group is replaced by an amino group and the oxo group is replaced by =NR. In organic chemistry an unspecified amidine is commonly a carboxamidine. amidine amidines Amidines amidines CHEBI:2634 amidine CHEBI:2634 CHEBI:26373 pteridines CHEBI:26373 purine alkaloids CHEBI:26385 purine alkaloid CHEBI:26385 purine nucleoside purine nucleosides CHEBI:26394 purine nucleoside CHEBI:26394 Any compound containing purine as part of its structure. CHEBI:13678 CHEBI:26401 purines CHEBI:26401 pyridinemonocarboxylic acids CHEBI:26420 pyridinemonocarboxylic acid CHEBI:26420 CHEBI:26421 pyridines CHEBI:26421 pyrimidine nucleosides CHEBI:26440 pyrimidine nucleoside CHEBI:26440 CHEBI:26455 pyrroles CHEBI:26455 quinolinemonocarboxylic acids CHEBI:26512 quinolinemonocarboxylic acid CHEBI:26512 A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. CHEBI:26513 quinolines CHEBI:26513 A 1-benzofuran that has formula C25H29I2NO3. 703 Beilstein:1271711 ChemIDplus:1951-25-3 KEGG COMPOUND:1951-25-3 KEGG COMPOUND:C06823 Wikipedia:Amiodarone (2-butyl-1-benzofuran-3-yl){4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl}methanone Amiodarone 2-Butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran 2-Butyl-3-benzofuranyl 4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone 2-n-Butyl-3',5'-diiodo-4'-N-diethylaminoethoxy-3-benzoylbenzofuran C25H29I2NO3 CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1 InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3 InChIKey=IYIKLHRQXLHMJQ-UHFFFAOYSA-N CHEBI:2663 Amiodarone amiodarone CHEBI:2663 A tricyclic antidepressant that has formula C20H23N. 704 Beilstein:2217885 ChemIDplus:50-48-6 KEGG COMPOUND:50-48-6 KEGG COMPOUND:C06824 NIST Chemistry WebBook:50-48-6 Wikipedia:Amitriptyline 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine Amitriptyline 10,11-dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene 10,11-dihydro-N,N-dimethyl-5H-dibenzo(a,d)heptalene-Delta(5),gamma-propylamine 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptatriene 5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene 5-(gamma-dimethylaminopropylidene)-5H-dibenzo[a,d][1,4]cycloheptadiene Amitriptylin C20H23N CN(C)CCC=C1c2ccccc2CCc2ccccc12 InChI=1S/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3 InChIKey=KRMDCWKBEZIMAB-UHFFFAOYSA-N CHEBI:2666 Amitriptyline amitriptyline CHEBI:2666 A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina. 17767 Beilstein:3570229 ChemIDplus:88150-42-9 DrugBank:88150-42-9 DrugBank:DB00381 KEGG COMPOUND:88150-42-9 KEGG COMPOUND:C06825 KEGG DRUG:88150-42-9 KEGG DRUG:D07450 Patent:EP89167 Patent:US4572909 Wikipedia:Amlodipine 3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate 3-Ethyl-5-methyl (+-)-2-(2-aminoethoxymethyl)-4-(o-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate Amlodipine Free Base C20H25ClN2O5 CCOC(=O)C1=C(COCCN)NC(C)=C(C1c1ccccc1Cl)C(=O)OC InChI=1S/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3 InChIKey=HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine amlodipino amlodipinum CHEBI:2668 Amlodipine amlodipine CHEBI:2668 Any steroid that act as hormone. Steroidhormon Steroidhormone hormona esteroide hormonas esteroideas hormone steroide hormones steroides steroid hormones CHEBI:26764 steroid hormone CHEBI:26764 CHEBI:26788 streptomycins CHEBI:26788 CHEBI:26822 sulfide CHEBI:26822 sulfur molecular entity sulfur molecular entities CHEBI:26835 sulfur molecular entity CHEBI:26835 Any natural product or related compound formally derived from isoprene units. Terpenoids may contain oxygen in various functional groups. This class is subdivided according to the number of carbon atoms in the same manner as are terpenes. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group. Terpenoid terpenoids terpenoide terpenoides CHEBI:26873 terpenoid CHEBI:26873 A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. tertiary alcohol C4H7OR3 OC(C[*])(C[*])C[*] tertiary alcohols CHEBI:26878 tertiary alcohol CHEBI:26878 Any oxacycle having an oxolane (tetrahydrofuran) skeleton. CHEBI:26912 oxolanes CHEBI:26912 heterotricyclic compounds organic heterotricyclic compounds CHEBI:26979 organic heterotricyclic compound CHEBI:26979 A 1,2,4-triazole compound having a 3,5-bis(2-cyano-2-propyl)benzyl group at the 1-position. 84857 Beilstein:8005958 ChemIDplus:120511-73-1 DrugBank:120511-73-1 DrugBank:DB01217 KEGG COMPOUND:120511-73-1 KEGG COMPOUND:C08159 KEGG DRUG:120511-73-1 KEGG DRUG:D00960 Patent:EP296749 Patent:US4935437 Wikipedia:Anastrozole 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile) Anastrozol C17H19N5 CC(C)(C#N)c1cc(Cn2cncn2)cc(c1)C(C)(C)C#N InChI=1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3 InChIKey=YBBLVLTVTVSKRW-UHFFFAOYSA-N alpha,alpha,alpha',alpha'-Tetramethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-m-benzenediacetonitrile anastrozole CHEBI:2704 anastrozole CHEBI:2704 trimethylxanthines CHEBI:27134 trimethylxanthine CHEBI:27134 Tryptamine and its substitution derivatives. CHEBI:27162 tryptamines CHEBI:27162 heterobicyclic compounds organic heterobicyclic compounds CHEBI:27171 organic heterobicyclic compound CHEBI:27171 CHEBI:27267 valine derivative CHEBI:27267 A group of indole-indoline dimers which are alkaloids obtained from the Vinca genus of plants. vinca alkaloid vinca alkaloids vincaleukoblastines CHEBI:27288 vinca alkaloid CHEBI:27288 A penicillin compound having a 6beta-(phenoxyacetyl)amino side chain. 7984 CHEBI:25868 CHEBI:44947 CHEBI:7966 Beilstein:96259 ChemIDplus:87-08-1 CiteXplore:10930630 CiteXplore:12569987 CiteXplore:14687482 CiteXplore:16033609 CiteXplore:8566082 KEGG COMPOUND:87-08-1 KEGG COMPOUND:C08126 KEGG DRUG:D05411 PDBeChem:PNV Reaxys:96259 Wikipedia:Phenoxymethylpenicillin 2,2-dimethyl-6beta-[(phenoxyacetyl)amino]penam-3alpha-carboxylic acid 3,3-dimethyl-6beta-[(phenoxyacetyl)amino]penam-2alpha-carboxylic acid (PIN) (2S,5R,6R)-3,3-DIMETHYL-7-OXO-6-(2-PHENOXYACETAMIDO)-4-THIA-1- AZABICYCLO(3.2.0)HEPTANE-2-CARBOXYLIC ACID (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 6-phenoxyacetamidopenicillanic acid C16H18N2O5S Fenospen InChI=1S/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1 InChIKey=BPLBGHOLXOTWMN-MBNYWOFBSA-N Oracillin PV Penicillin V V-Cillin [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)COc1ccccc1)C(O)=O fenoximetilpenicilina penicillin phenoxymethyl phenoxomethylpenicillin phenoxymethylenepenicillinic acid phenoxymethylpenicillin phenoxymethylpenicilline phenoxymethylpenicillinum CHEBI:27446 Penicillin V phenoxymethylpenicillin CHEBI:27446 A trimethylxanthine that has formula C8H10N4O2. 1886 CHEBI:22982 CHEBI:3295 CHEBI:41472 Beilstein:17705 ChemIDplus:58-08-2 DrugBank:DB00201 Gmelin:103040 KEGG COMPOUND:58-08-2 KEGG COMPOUND:C07481 KEGG DRUG:D00528 NIST Chemistry WebBook:58-08-2 PDBeChem:CFF Wikipedia:Caffeine 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione CAFFEINE Caffeine 1,3,7-trimethyl-2,6-dioxopurine 1,3,7-trimethylpurine-2,6-dione 1,3,7-trimethylxanthine 1-methyltheobromine 3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion 7-methyltheophylline C8H10N4O2 Cn1cnc2n(C)c(=O)n(C)c(=O)c12 Coffein InChI=1S/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3 InChIKey=RYYVLZVUVIJVGH-UHFFFAOYSA-N Koffein Thein anhydrous caffeine cafeina cafeine guaranine mateina methyltheobromine teina theine CHEBI:27732 Caffeine caffeine CHEBI:27732 A platinum-containing anticancer drug that interacts with, and forms cross-links between, DNA and proteins. It is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. 2555 CHEBI:23314 CHEBI:3722 ChemIDplus:15663-27-1 DrugBank:DB00515 Gmelin:2519 KEGG COMPOUND:15663-27-1 KEGG COMPOUND:C06911 KEGG DRUG:D00275 MolBase:25 Patent:DE2318020 Patent:DE2329485 (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Cisplatin cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) Briplatin Cismaplat Cl2H6N2Pt H6Cl2N2Pt InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2 InChIKey=LXZZYRPGZAFOLE-UHFFFAOYSA-L Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Platamine Platinex Platinol Randa [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] cis-DDP cis-[PtCl2(NH3)2] cis-diamminedichloroplatinum cis-diammineplatinum(II) dichloride cis-dichlorodiammineplatinum(II) cisplatin cisplatine cisplatino cisplatinum CHEBI:27899 Cisplatin cisplatin CHEBI:27899 CHEBI:10427 CHEBI:22844 CHEBI:27933 beta-lactam antibiotic CHEBI:27933 A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring. 10627 CHEBI:19849 CHEBI:45933 CHEBI:9610 ChemIDplus:32986-56-4 CiteXplore:11000679 CiteXplore:11072877 CiteXplore:11459219 CiteXplore:11478352 CiteXplore:14961139 CiteXplore:15813341 CiteXplore:16205136 CiteXplore:16239129 CiteXplore:16478137 CiteXplore:16650821 CiteXplore:17150225 CiteXplore:18331849 CiteXplore:19072156 CiteXplore:19220547 CiteXplore:19340717 CiteXplore:19465435 CiteXplore:20000576 CiteXplore:20884302 CiteXplore:20938669 CiteXplore:21275493 CiteXplore:21343445 CiteXplore:21357290 CiteXplore:21396748 CiteXplore:21414310 CiteXplore:21429824 CiteXplore:21438171 CiteXplore:21530479 CiteXplore:21592592 CiteXplore:21726492 CiteXplore:21756818 CiteXplore:21796931 CiteXplore:21815282 KEGG COMPOUND:32986-56-4 KEGG COMPOUND:C00397 KEGG DRUG:D00063 PDBeChem:TOY Reaxys:1357507 Wikipedia:Tobramycin (1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside Tobramycin 3'-Deoxykanamycin B C18H37N5O9 InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1 InChIKey=NLVFBUXFDBBNBW-PBSUHMDJSA-N NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O Nebramycin 6 Nebramycin factir 6 O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine Tobracin (TN) Tobrex (TN) CHEBI:28864 Tobramycin tobramycin CHEBI:28864 CHEBI:13211 CHEBI:22207 CHEBI:25383 CHEBI:6977 monocarboxylic acid amide monocarboxylic acid amides CHEBI:29347 monocarboxylic acid amide CHEBI:29347 A monocarboxylic acid amide derived from a fatty acid. CHEBI:13247 CHEBI:22310 CHEBI:22330 CHEBI:2572 CHEBI:35749 CHEBI:38838 KEGG COMPOUND:C02244 LIPID MAPS:LMFA08 fatty amide Aliphatic amide CHNOR2 an aliphatic amide fatty amides CHEBI:29348 fatty amide CHEBI:29348 3-Aminopropane-1,2-diol in which the hydrogen of the primary hydoxy is substituted by a 4-[2-(cyclopropylmethoxy)ethyl]phenyl group and one of the hydrogens attached to the amino group is substituted by isopropyl. It is a selective beta1-receptor blocker and is used in the treatment of glaucoma as well as hypertension, arrhythmias, and coronary heart disease. It is also used to reduce non-fatal cardiac events in patients with heart failure. 1520 CHEBI:101354 Beilstein:1991268 ChEMBL:101354 ChEMBL:10891117 ChEMBL:1361581 ChEMBL:14971904 ChEMBL:15993593 ChemIDplus:63659-18-7 DrugBank:DB00195 KEGG COMPOUND:63659-18-7 KEGG COMPOUND:C06849 KEGG DRUG:D07526 Patent:DE2649605 Patent:US4252984 Wikipedia:Betaxolol 1-{4-[2-(cyclopropylmethoxy)ethyl]phenoxy}-3-(propan-2-ylamino)propan-2-ol 1-(4-(2-(cyclopropylmethoxy)ethyl)phenoxy)-3-((1-methylethyl)amino)-2-propanol 1-(isopropylamino)-3-[p-(cyclopropylmethoxyethyl)phenoxy]-2-propanol C18H29NO3 CC(C)NCC(O)COc1ccc(CCOCC2CC2)cc1 InChI=1S/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3 InChIKey=NWIUTZDMDHAVTP-UHFFFAOYSA-N betaxolol betaxololum CHEBI:3082 Betaxolol betaxolol CHEBI:3082 A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. CHEBI:13804 CHEBI:22288 CHEBI:2553 KEGG COMPOUND:C00069 Alcohol alcohols CHOR3 HOR OC([*])([*])[*] CHEBI:30879 alcohol CHEBI:30879 A carboxamide that has formula C18H14F4N2O4S. 83008 Beilstein:5364666 ChemIDplus:90357-06-5 DrugBank:DB01128 KEGG COMPOUND:C08160 KEGG DRUG:D00961 Patent:EP100172 Patent:US4636505 Wikipedia:Bicalutamide (2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide C18H14F4N2O4S C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F Casodex InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1 InChIKey=LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamida bicalutamide bicalutamidum CHEBI:3090 bicalutamide CHEBI:3090 A platinum coordination entity that has formula C6H12N2O4Pt. 40048 ChemIDplus:41575-94-4 Gmelin:1044703 Gmelin:51428 KEGG DRUG:41575-94-4 KEGG DRUG:D01363 (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum Carboplatin C6H12N2O4Pt C6H6O4Pt.2H3N InChI=1S/C6H8O4.2H3N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H3;/q;;;+2/p-2 InChIKey=OLESAACUTLOWQZ-UHFFFAOYSA-L Paraplatin [H][N]([H])([H])[Pt]1(OC(=O)C2(CCC2)C(=O)O1)[N]([H])([H])[H] cbdca cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II) cis-diammine(1,1-cyclobutanedicarboxylato)platinum cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) CHEBI:31355 Carboplatin carboplatin CHEBI:31355 CHEBI:31577 ethylenediamine derivatives CHEBI:31577 An indole alkaloid that has formula C32H40BrN5O5. 1760 Beilstein:741357 ChemIDplus:25614-03-3 DrugBank:DB01200 KEGG COMPOUND:25614-03-3 KEGG COMPOUND:C06856 KEGG DRUG:D03165 Patent:DE1926045 Patent:US3752814 Wikipedia:Bromocriptine (5'alpha)-2-bromo-12'-hydroxy-5'-(2-methylpropyl)-2'-(propan-2-yl)-3',6',18-trioxoergotaman Bromocriptine (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman 2-bromo-alpha-ergocryptine 2-bromo-alpha-ergokryptin 2-bromo-alpha-ergokryptine C32H40BrN5O5 InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N [H][C@@]12Cc3c(Br)[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N[C@@]1(O[C@]2(O)N([C@@H](CC(C)C)C(=O)N5CCC[C@@]25[H])C1=O)C(C)C)c34 bromocriptine bromocriptinum bromocryptine bromoergocriptine CHEBI:3181 Bromocriptine bromocriptine CHEBI:3181 A platinum coordination entity that has formula C6H14N2.C2O4.Pt. 32592 ChemIDplus:63121-00-6 DrugBank:DB00526 Gmelin:1046012 Gmelin:28892 KEGG COMPOUND:61825-94-3 KEGG COMPOUND:C13258 KEGG DRUG:D01790 (SP-4-2)[(1R,2R)-cyclohexane-1,2-diamine-kappa(2)N,N'][ethanedioato(2-)-kappa(2)O(1),O(2)]platinum Oxaliplatin (SP-4-2-(1R-trans))-(1,2-cyclohexanediamine-N,N')(ethanedioato(2-)-O,O')platinum C6H14N2.C2O4.Pt C8H14N2O4Pt Eloxatin InChI=1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1 InChIKey=ZROHGHOFXNOHSO-BNTLRKBRSA-L [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1 oxalato(1,2-diaminocyclohexane)platinum(II) oxaliplatin oxaliplatine oxaliplatino oxaliplatinum CHEBI:31941 oxaliplatin CHEBI:31941 A propanone that has formula C13H18ClNO. 42347 ChemIDplus:2101062 ChemIDplus:34911-55-2 KEGG COMPOUND:34841-39-9 KEGG COMPOUND:C06860 Wikipedia:Bupropion 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one Bupropion C13H18ClNO CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1 InChI=1S/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3 InChIKey=SNPPWIUOZRMYNY-UHFFFAOYSA-N CHEBI:3219 Bupropion bupropion CHEBI:3219 An azaspiro compound that has formula C21H31N5O2. 1827 Beilstein:964904 ChemIDplus:36505-84-7 DrugBank:DB00490 KEGG COMPOUND:36505-84-7 KEGG COMPOUND:C06861 KEGG DRUG:D07593 Patent:DE2057845 Patent:US3717634 Wikipedia:Buspirone 8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione Buspirone 8-(4-(4-(2-Pyrimidinyl)-1-piperizinyl)butyl)-8-azaspiro(4,5)decane-7,9-dione C21H31N5O2 InChI=1S/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2 InChIKey=QWCRAEMEVRGPNT-UHFFFAOYSA-N O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(CC1)c1ncccn1 buspirona buspirone buspironum CHEBI:3223 Buspirone buspirone CHEBI:3223 A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. CHEBI:26879 CHEBI:9458 KEGG COMPOUND:C02196 Tertiary amine tertiary amines NR3 R3N [*]N([*])[*] tertiaeres Amin CHEBI:32876 tertiary amine CHEBI:32876 A compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group. CHEBI:26263 CHEBI:26265 CHEBI:8407 CHEBI:8409 KEGG COMPOUND:C00893 KEGG COMPOUND:C02580 Primary amine primary amines H2NR N[*] Primary monoamine R-NH2 primaeres Amin CHEBI:32877 primary amine CHEBI:32877 A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups. CHEBI:13814 CHEBI:22474 CHEBI:2641 KEGG COMPOUND:C00706 Amine amines Amin an amine CHEBI:32952 amine CHEBI:32952 An amide is a derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. CHEBI:22473 CHEBI:2633 KEGG COMPOUND:C00241 Amide amides CHEBI:32988 amide CHEBI:32988 An assembly consisting of a central atom (usually metallic) to which is attached a surrounding array of other groups of atoms (ligands). coordination entities coordination entity coordination compounds CHEBI:33240 coordination entity CHEBI:33240 oxoacid derivatives CHEBI:33241 oxoacid derivative CHEBI:33241 A derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. primary amide primary amides CHEBI:33256 primary amide CHEBI:33256 An organosulfur compound is a compound containing at least one carbon-sulfur bond. CHEBI:23010 CHEBI:25714 Wikipedia:Organosulfur_compounds organosulfur compound organosulfur compounds CHEBI:33261 organosulfur compound CHEBI:33261 A heteroorganic entity is an organic molecular entity in which carbon atoms or organic groups are bonded directly to one or more heteroatoms. heteroorganic entities organoelement compounds CHEBI:33285 heteroorganic entity CHEBI:33285 pnictogen molecular entity pnictogen molecular entities CHEBI:33302 pnictogen molecular entity CHEBI:33302 Any p-block molecular entity containing a chalcogen. chalcogen molecular entity chalcogen compounds chalcogen molecular entities CHEBI:33304 chalcogen molecular entity CHEBI:33304 An ester of a carboxylic acid. CHEBI:13204 CHEBI:23028 CHEBI:3408 KEGG COMPOUND:C02391 Carboxylic ester carboxylic ester carboxylic esters CO2R2 carboxylic acid esters CHEBI:33308 carboxylic ester CHEBI:33308 sulfur oxoacid derivative sulfur oxoacid derivatives CHEBI:33424 sulfur oxoacid derivative CHEBI:33424 A molecular entity containing one or more atoms of a transition element. transition element molecular entities transition metal molecular entity CHEBI:33497 transition element molecular entity CHEBI:33497 sulfonic acid derivative derivatives of sulfonic acid sulfonic acid derivatives CHEBI:33552 sulfonic acid derivative CHEBI:33552 An oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. CHEBI:13428 CHEBI:13627 CHEBI:23027 CiteXplore:17147560 CiteXplore:18433345 carboxylic acid carboxylic acids CHO2R Carbonsaeure Carbonsaeuren Karbonsaeure OC([*])=O RC(=O)OH acide carboxylique acides carboxyliques acido carboxilico acidos carboxilicos CHEBI:33575 carboxylic acid CHEBI:33575 A molecular entity containing one or more atoms from any of groups 1, 2, 13, 14, 15, 16, 17, and 18 of the periodic table. main group compounds main group molecular entities CHEBI:33579 main group molecular entity CHEBI:33579 carbon group molecular entity carbon group molecular entities CHEBI:33582 carbon group molecular entity CHEBI:33582 cyclic compounds CHEBI:33595 cyclic compound CHEBI:33595 A cyclic compound having as ring members atoms of the same element only. homocyclic compound homocyclic compounds isocyclic compounds CHEBI:33597 homocyclic compound CHEBI:33597 A cyclic compound in which all of the ring members are carbon atoms. carbocyclic compound carbocyclic compounds carbocycle CHEBI:33598 carbocyclic compound CHEBI:33598 A compound having one atom as the only common member of two rings. spiro compound spiro compounds spiro-fused compounds spirofused compounds CHEBI:33599 spiro compound CHEBI:33599 hydrogen compounds hydrogen molecular entities CHEBI:33608 hydrogen molecular entity CHEBI:33608 polycyclic compounds CHEBI:33635 polycyclic compound CHEBI:33635 A molecule that features two fused rings. bicyclic compounds CHEBI:33636 bicyclic compound CHEBI:33636 Any acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds. aliphatic compounds CHEBI:33653 aliphatic compound CHEBI:33653 An aliphatic compound having a carbocyclic ring structure which may be saturated or unsaturated, but may not be a benzenoid or other aromatic system. alicyclic compounds CHEBI:33654 alicyclic compound CHEBI:33654 A cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character. aromatic compounds aromatic molecular entity aromatics aromatische Verbindungen CHEBI:33655 aromatic compound CHEBI:33655 organic aromatic compounds CHEBI:33659 organic aromatic compound CHEBI:33659 monocyclic compounds CHEBI:33661 monocyclic compound CHEBI:33661 heteromonocyclic compound heteromonocyclic compounds CHEBI:33670 heteromonocyclic compound CHEBI:33670 heteropolycyclic compounds polyheterocyclic compounds CHEBI:33671 heteropolycyclic compound CHEBI:33671 A bicyclic compound in which at least one of the rings contains at least one skeletal heteroatom. heterobicyclic compounds CHEBI:33672 heterobicyclic compound CHEBI:33672 An s-block molecular entity is a molecular entity containing one or more atoms of an s-block element. s-block molecular entity s-block compounds s-block molecular entities CHEBI:33674 s-block molecular entity CHEBI:33674 A p-block molecular entity is a molecular entity containing one or more atoms of a p-block element. p-block compounds p-block molecular entities p-block molecular entitiy CHEBI:33675 p-block molecular entity CHEBI:33675 A d-block molecular entity is a molecular entity containing one or more atoms of a d-block element. d-block molecular entity d-block compounds d-block molecular entities CHEBI:33676 d-block molecular entity CHEBI:33676 A carboxylic acid containing one or more amino groups. CHEBI:13815 CHEBI:22477 Aminocarbonsaeure Aminokarbonsaeure Aminosaeure amino acids CHEBI:33709 amino acid CHEBI:33709 A capsaicinoid that has formula C18H27NO3. 1992 Beilstein:2816484 ChemIDplus:404-86-4 KEGG COMPOUND:404-86-4 KEGG COMPOUND:C06866 KEGG DRUG:D00250 Wikipedia:Capsaicin (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide Capsaicin (E)-8-Methyl-N-vanillyl-6-nonenamide C18H27NO3 COc1cc(CNC(=O)CCCC\C=C\C(C)C)ccc1O InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+ InChIKey=YKPUWZUDDOIDPM-SOFGYWHQSA-N Isodecenoic acid vanillylamide Zostrix trans-8-Methyl-N-vanillyl-6-nonenamide CHEBI:3374 Capsaicin capsaicin CHEBI:3374 copper group molecular entity copper group molecular entities CHEBI:33745 copper group molecular entity CHEBI:33745 nickel group molecular entity nickel group molecular entities CHEBI:33747 nickel group molecular entity CHEBI:33747 platinum molecular entity platinum compounds platinum molecular entities CHEBI:33749 platinum molecular entity CHEBI:33749 An organic compound having at least one hydroxy group attached to a carbon atom. hydroxy compounds organic hydroxy compounds CHEBI:33822 organic hydroxy compound CHEBI:33822 organic cyclic compounds CHEBI:33832 organic cyclic compound CHEBI:33832 A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2). heteroarenes hetarenes CHEBI:33833 heteroarene CHEBI:33833 benzenoid aromatic compounds benzenoid compound CHEBI:33836 benzenoid aromatic compound CHEBI:33836 Nucleosides are ribosyl or deoxyribosyl derivatives of the pyrimidine or purine bases adenine, guanine, xanthine, thymine, cytosine, and uracil. CHEBI:13661 CHEBI:25611 CHEBI:7647 KEGG COMPOUND:C00801 Nucleoside nucleoside nucleosides C5H9O4R nucleosides CHEBI:33838 nucleoside CHEBI:33838 Compounds having one or more hydroxy groups attached to a benzene or other arene ring. CHEBI:13664 CHEBI:13825 CHEBI:25969 CHEBI:2857 KEGG COMPOUND:C15584 MetaCyc:Aryl-Alcohol phenols Aryl alcohol arenols aryl alcohol CHEBI:33853 phenols CHEBI:33853 An amine in which the amino group is linked directly to an aromatic system. CHEBI:22622 CHEBI:2834 aromatic amines CHEBI:33860 aromatic amine CHEBI:33860 transition element coordination entities transition metal coordination compounds transition metal coordination entities CHEBI:33861 transition element coordination entity CHEBI:33861 platinum coordination entity platinum coordination compounds platinum coordination entities CHEBI:33862 platinum coordination entity CHEBI:33862 gold molecular entity gold compounds gold molecular entities CHEBI:33969 gold molecular entity CHEBI:33969 gold coordination compounds gold coordination entities CHEBI:33971 gold coordination entity CHEBI:33971 CHEBI:22721 CHEBI:35259 benzofurans CHEBI:35259 A polyclic compound in which all of the ring members are carbon atoms. carbopolycyclic compounds CHEBI:35294 carbopolycyclic compound CHEBI:35294 homopolycyclic compounds CHEBI:35295 homopolycyclic compound CHEBI:35295 hexoside hexosides CHEBI:35313 hexoside CHEBI:35313 Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from triterpenoids. CHEBI:13687 CHEBI:26768 CHEBI:9263 KEGG COMPOUND:C00377 Steroid steroids a steroid CHEBI:35341 steroid CHEBI:35341 CHEBI:13585 CHEBI:19174 CHEBI:782 KEGG COMPOUND:C03336 17-alpha-Hydroxysteroid 17alpha-hydroxy steroids a 17alpha-hydroxysteroid CHEBI:35342 17alpha-hydroxy steroid CHEBI:35342 CHEBI:1300 CHEBI:13596 CHEBI:19803 KEGG COMPOUND:C02506 21-Hydroxysteroid 21-hydroxy steroids 21-hydroxysteroids a 21-hydroxysteroid CHEBI:35344 21-hydroxy steroid CHEBI:35344 CHEBI:13774 CHEBI:19134 CHEBI:738 KEGG COMPOUND:C01058 11beta-Hydroxysteroid 11beta-hydroxy steroids 11beta-hydroxysteroids an 11beta-hydroxysteroid CHEBI:35346 11beta-hydroxy steroid CHEBI:35346 CHEBI:24748 CHEBI:5814 KEGG COMPOUND:C02159 Hydroxysteroid hydroxy steroids hydroxysteroids CHEBI:35350 hydroxy steroid CHEBI:35350 Any heteroorganic entity containing at least one carbon-nitrogen bond. organonitrogen compounds organonitrogens CHEBI:35352 organonitrogen compound CHEBI:35352 An amide of a sulfonic acid RS(=O)2NR'2. CiteXplore:2434548 sulfonamides NO2SR3 [*]S(=O)(=O)N([*])[*] sulfonamides CHEBI:35358 sulfonamide CHEBI:35358 Compounds having the structure RC(=NR)NR2. The term is used as a suffix in systematic nomenclature to denote the -C(=NH)NH2 group including its carbon atom. KEGG COMPOUND:C06060 carboxamidines Amidines carboxamidines CHEBI:35359 carboxamidine CHEBI:35359 Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC). hydrazides hydrazides CHEBI:35362 hydrazide CHEBI:35362 A hydrazide consisting of hydrazine carrying one or more carboacyl groups. carbohydrazides carbohydrazides CHEBI:35363 carbohydrazide CHEBI:35363 CHEBI:21009 CHEBI:4173 KEGG COMPOUND:C01798 D-Glucoside C6H11O6R D-glucosides CHEBI:35436 D-glucoside CHEBI:35436 Compounds of structure RSSR in which R and R' are organic groups. disulfides S2R2 [*]SS[*] organic disulfides CHEBI:35489 organic disulfide CHEBI:35489 An addition compound contains two or more simpler compounds that can be packed in a definite ratio into a crystal. The term covers donor-acceptor complexes (adducts) and a variety of lattice compounds. addition compounds CHEBI:35504 addition compound CHEBI:35504 An addition compound that contains water in weak chemical combination with another compound. Hydrat hidrato hidratos hydrates CHEBI:35505 hydrate CHEBI:35505 propanolamine propanolamines CHEBI:35533 propanolamine CHEBI:35533 CHEBI:35618 aromatic ether CHEBI:35618 An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. azaspiro compound azaspiro compounds CHEBI:35624 azaspiro compound CHEBI:35624 A beta-lactam is a lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon. CHEBI:10426 CHEBI:22845 KEGG COMPOUND:C01866 beta-Lactam beta-lactam beta-lactams CHEBI:35627 beta-lactam CHEBI:35627 A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. CHEBI:13425 CHEBI:13686 CHEBI:26617 CHEBI:58662 CHEBI:8741 CHEBI:9077 KEGG COMPOUND:C00432 KEGG COMPOUND:C01612 Secondary alcohol secondary alcohol C3H6OR2 R-CHOH-R' [H]C(O)(C[*])C[*] secondary alcohols CHEBI:35681 secondary alcohol CHEBI:35681 CHEBI:35689 tetrazoles CHEBI:35689 An oxoacid containing two carboxy groups. CHEBI:23692 CHEBI:4501 KEGG COMPOUND:C02028 Dicarboxylic acid C2H2O4R dicarboxylic acids CHEBI:35692 dicarboxylic acid CHEBI:35692 A compound formally derived from an oxoacid RkE(=O)l(OH)m (l > 0) and an alcohol, phenol, heteroarenol, or enol by linking with formal loss of water from an acidic hydroxy group of the former and a hydroxy group of the latter. CHEBI:23960 CHEBI:4859 KEGG COMPOUND:C00287 Ester esters CHEBI:35701 ester CHEBI:35701 A compound having the nitro group, -NO2 (free valence on nitrogen), which may be attached to carbon, nitrogen (as in nitramines), or oxygen (as in nitrates), among other elements (in the absence of specification, C-nitro compounds are usually implied). nitro compounds CHEBI:35715 nitro compound CHEBI:35715 A compound having the nitro group (-NO2) attached to carbon atom. C-nitro compounds CHEBI:35716 C-nitro compound CHEBI:35716 triazole compounds CHEBI:35727 triazoles CHEBI:35727 CHEBI:27315 CHEBI:35747 fatty acid esters CHEBI:35748 fatty acid ester CHEBI:35748 CHEBI:24979 CHEBI:25804 keto steroids ketosteroids oxo steroids oxosteroids CHEBI:35789 oxo steroid CHEBI:35789 A compound based on a five-membered heterocyclic aromatic skeleton containing one N and one O atom. oxazole oxazoles CHEBI:35790 oxazole CHEBI:35790 Compounds having the structure R2S=O (R =/= H). sulfoxide sulfoxides CHEBI:35813 sulfoxide CHEBI:35813 Compounds having the structure RS(=O)2R (R =/= H). sulfone sulfones CHEBI:35850 sulfone CHEBI:35850 hydroxy acid hydroxy monocarboxylic acids CHEBI:35868 hydroxy monocarboxylic acid CHEBI:35868 Any monocarboxylic acid having at least one additional oxo functional group. oxo monocarboxylic acids CHEBI:35871 oxo monocarboxylic acid CHEBI:35871 imidazopyrimidines CHEBI:35875 imidazopyrimidine CHEBI:35875 dihydroxy monocarboxylic acids CHEBI:35972 dihydroxy monocarboxylic acid CHEBI:35972 Natural and synthetic antibiotics containing the 4-thia-1-azabicyclo[3.2.0]heptan-7-one structure, generally assumed to have the 5R configuration unless otherwise specified. penams CHEBI:35992 penams CHEBI:35992 Compounds having a fully conjugated cyclic dione structure, such as that of benzoquinones, derived from aromatic compounds by conversion of an even number of -CH= groups into -C(=O)- groups with any necessary rearrangement of double bonds (polycyclic and heterocyclic analogues are included). CHEBI:13684 CHEBI:26517 Wikipedia:Quinone quinone quinones Chinon a quinone quinones CHEBI:36141 quinone CHEBI:36141 A monoester of a dicarboxylic acid. dicarboxylic acid monoesters CHEBI:36244 dicarboxylic acid monoester CHEBI:36244 Any molecular entity consisting of more than one atom. polyatomic entities CHEBI:36357 polyatomic entity CHEBI:36357 CHEBI:36360 phosphorus oxoacids and derivatives CHEBI:36360 pseudoketone pseudoketones pseudoketones CHEBI:36585 pseudoketone CHEBI:36585 Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. carbonyl compounds CHEBI:36586 carbonyl compound CHEBI:36586 Organic compounds containing an oxygen atom, =O, doubly bonded to carbon or another element. oxo compounds organic oxo compounds CHEBI:36587 organic oxo compound CHEBI:36587 A cyclic compound in which a carbonyl group in a ring is bonded to one or two skeletal heteroatoms. cyclic pseudoketones CHEBI:36588 cyclic pseudoketone CHEBI:36588 Compounds in which an acyclic carbonyl group is bonded to one or two acyclic skeletal heteroatoms, except nitrogen, halogen, or halogenoid atoms, or to a heteroatom of a ring or ring system. acyclic pseudoketone acyclic pseudoketones acyclic pseudoketones CHEBI:36589 acyclic pseudoketone CHEBI:36589 An organochlorine compound is a compound containing at least one carbon-chlorine bond. organochlorine compound chloroorganic compounds chlororganische Verbindungen organochlorine compounds CHEBI:36683 organochlorine compound CHEBI:36683 A compound containing at least one carbon-halogen bond. organohalogen compounds CHEBI:36684 organohalogen compound CHEBI:36684 heterotricyclic compound heterotricyclic compounds heterotricyclic compounds CHEBI:36688 heterotricyclic compound CHEBI:36688 Any of a class of steroid hormones that are produced in the adrenal cortex. adrenal cortex hormones corticosteroid hormones CHEBI:36699 corticosteroid hormone CHEBI:36699 aminoquinoline aminoquinolines CHEBI:36709 aminoquinoline CHEBI:36709 A bicyclic compound in which all the ring atoms are carbon. carbobicyclic compounds CHEBI:36785 carbobicyclic compound CHEBI:36785 antidepresivo triciclico antidepresivos triciclicos tricyclic antidepressant drugs tricyclic antidepressants tricyclic antidepressive agents CHEBI:36809 tricyclic antidepressant CHEBI:36809 CHEBI:36815 5-methoxyvalerophenone O-(2-aminoethyl)oxime CHEBI:36815 O-organyl oximes R2C=NOR' (R' =/= H). oxime O-ether oxime O-ethers CNOR3 O-substituted oximes [*]O\N=C(/[*])[*] oxime O-ethers CHEBI:36816 oxime O-ether CHEBI:36816 Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. ring assemblies ring assembly CHEBI:36820 ring assembly CHEBI:36820 17-hydroxy steroids CHEBI:36838 17-hydroxy steroid CHEBI:36838 11-hydroxy steroids CHEBI:36841 11-hydroxy steroid CHEBI:36841 20-oxo steroids CHEBI:36885 20-oxo steroid CHEBI:36885 An organochalcogen compound is a compound containing at least one carbon-chalcogen bond. organochalcogen compound organochalcogen compounds CHEBI:36962 organochalcogen compound CHEBI:36962 An organochalcogen compound containing at least one carbon-oxygen bond. CiteXplore:17586126 organooxygen compound organooxygen compounds CHEBI:36963 organooxygen compound CHEBI:36963 An organoiodine compound is a compound containing at least one carbon-iodine bond. organoiodine compound organoiodine compounds CHEBI:37142 organoiodine compound CHEBI:37142 An organofluorine compound is a compound containing at least one carbon-fluorine bond. organofluorine compound fluoroorganic compound fluoroorganic compounds fluoroorganics fluororganische Verbindungen organofluorine compounds CHEBI:37143 organofluorine compound CHEBI:37143 An anthraquinone substituted with one or more hydroxy groups. CHEBI:13829 CHEBI:24672 an hydroxyanthraquinone CHEBI:37485 hydroxyanthraquinones CHEBI:37485 Derivatives of diazene with the general structure R-N=N-R'. azo compounds azo compounds CHEBI:37533 azo compound CHEBI:37533 A molecular entity consisting of two or more chemical elements. chemical compound heteroatomic molecular entities CHEBI:37577 heteroatomic molecular entity CHEBI:37577 CHEBI:37578 halide CHEBI:37578 Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-C2H2-C2H2)2NR. nitrogen mustards nitrogen mustards CHEBI:37598 nitrogen mustard CHEBI:37598 An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. CHEBI:35354 CHEBI:35355 carboxamides CNOR3 [*]C(=O)N([*])[*] carboxamides primary carboxamide CHEBI:37622 carboxamide CHEBI:37622 A thienopyridine that has formula C16H16ClNO2S. 32968 Beilstein:8151914 ChemIDplus:113665-84-2 DrugBank:DB00758 Patent:EP281459 Patent:EP99802 Patent:US4529596 Patent:US4847265 Wikipedia:Clopidogrel methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate (+)-Clopidogrel C16H16ClNO2S COC(=O)[C@@H](N1CCc2sccc2C1)c1ccccc1Cl InChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1 InChIKey=GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel clopidogrelum CHEBI:37941 clopidogrel CHEBI:37941 thienopyridines CHEBI:37942 thienopyridine CHEBI:37942 CHEBI:37947 benzothiazoles CHEBI:37947 carbotricyclic compounds CHEBI:38032 carbotricyclic compound CHEBI:38032 Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. heterocyclic organonitrogen compounds organonitrogen heterocyclic compounds CHEBI:38101 organonitrogen heterocyclic compound CHEBI:38101 Any organic heterocyclic compound containing at least one ring oxygen atom. CiteXplore:17134300 heterocyclic organooxygen compounds organooxygen heterocyclic compounds oxacycles CHEBI:38104 oxacycle CHEBI:38104 heterocyclic organosulfur compounds organosulfur heterocyclic compounds CHEBI:38106 organosulfur heterocyclic compound CHEBI:38106 organic heteropentacyclic compounds CHEBI:38164 organic heteropentacyclic compound CHEBI:38164 CHEBI:25429 CHEBI:38075 organic heteropolycyclic compounds CHEBI:38166 organic heteropolycyclic compound CHEBI:38166 monocyclic heteroarenes CHEBI:38179 monocyclic heteroarene CHEBI:38179 polycyclic heteroarenes CHEBI:38180 polycyclic heteroarene CHEBI:38180 CHEBI:38261 imidazolidines CHEBI:38261 azabicycloalkanes CHEBI:38295 azabicycloalkane CHEBI:38295 cyclopentapyrroles CHEBI:38296 cyclopentapyrrole CHEBI:38296 CHEBI:38298 benzodioxoles CHEBI:38298 diazolidines CHEBI:38304 diazolidine CHEBI:38304 cephems CHEBI:38311 cephem CHEBI:38311 Any organic heterocyclic compound containing a benzene ring in which two of the C-H fragments have been replaced by isolobal nitrogens (the diazine parent structure). CHEBI:38313 diazines CHEBI:38313 pyrimidones CHEBI:38337 pyrimidone CHEBI:38337 CHEBI:26949 CHEBI:38417 1,3-thiazoles CHEBI:38418 1,3-thiazole CHEBI:38418 phenethylamine alkaloids CHEBI:38605 phenethylamine alkaloid CHEBI:38605 pyrazolopyrimidines CHEBI:38669 pyrazolopyrimidine CHEBI:38669 A gold coordination entity that has formula C4H5AuO4S. 42547 Beilstein:4030297 ChemIDplus:4846-27-9 Gmelin:1043252 Gmelin:1288314 1,2-dicarboxyethanethiolatogold(I) 1,2-dicarboxyethylsulfanylgold gold(1+) 1,2-dicarboxyethanethiolate (1,2-dicarboxyethylthio)gold C4H5AuO4S InChI=1S/C4H6O4S.Au/c5-3(6)1-2(9)4(7)8;/h2,9H,1H2,(H,5,6)(H,7,8);/q;+1/p-1 InChIKey=XJHSMFDIQHVMCY-UHFFFAOYSA-M OC(=O)CC(S[Au])C(O)=O aurothiomalate mercaptobutanedioic acid, monogold(1+) salt CHEBI:38722 Aurothiomalate aurothiomalic acid CHEBI:38722 CHEBI:38830 1-benzofurans CHEBI:38830 An alkaloid containing an indole skeleton. CHEBI:24795 CHEBI:5901 KEGG COMPOUND:C06073 Indole alkaloid indole alkaloids CHEBI:38958 indole alkaloid CHEBI:38958 dioxolanes CHEBI:39430 dioxolane CHEBI:39430 Any compound having a pyrimidine as part of its structure. CHEBI:13681 CHEBI:26448 CHEBI:39447 pyrimidines CHEBI:39447 A dihydroxy monocarboxylic acid that has formula C33H35FN2O5. 83367 CHEBI:2910 CHEBI:39538 Beilstein:8373630 ChemIDplus:134523-00-5 DrugBank:DB01076 KEGG COMPOUND:134523-00-5 KEGG COMPOUND:C06834 KEGG DRUG:D07474 PDBeChem:117 Patent:EP409281 Patent:US5273995 Wikipedia:Atorvastatin (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid Atorvastatin (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID Atorlip C33H35FN2O5 CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1 InChIKey=XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin atorvastatina atorvastatine atorvastatinum CHEBI:39548 atorvastatin CHEBI:39548 KEGG COMPOUND:C02019 Cyclic ketone cyclic ketones CHEBI:3992 cyclic ketone CHEBI:3992 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm. 21949 CHEBI:128119 Beilstein:2126383 ChEMBL:128119 ChEMBL:17725338 ChEMBL:18027916 DrugBank:DB00924 KEGG COMPOUND:303-53-7 KEGG COMPOUND:C06931 KEGG DRUG:D07758 NIST Chemistry WebBook:303-53-7 Patent:GB858187 Wikipedia:Cyclobenzaprine 3-(5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine 3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethylpropan-1-amine Cyclobenzaprine (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine C20H21N CN(C)CCC=C1c2ccccc2C=Cc2ccccc12 InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3 InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Delta(5,gamma)-propylamine ciclobenzaprina cyclobenzaprine cyclobenzaprinum CHEBI:3996 cyclobenzaprine CHEBI:3996 A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring. 519 CHEBI:2601 CHEBI:40276 Beilstein:608611 ChemIDplus:315-30-0 CiteXplore:7602118 DrugBank:DB00437 KEGG DRUG:315-30-0 KEGG DRUG:D00224 NIST Chemistry WebBook:315-30-0 Wikipedia:Allopurinol 1H-pyrazolo[3,4-d]pyrimidin-4-ol Allopurinol 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one 1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one 1H-Pyrazolo(3,4-d)pyrimidin-4-ol 4'-Hydroxypyrazolol(3,4-d)pyrimidine 4-HPP 4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine 4-Hydroxy-3,4-pyrazolopyrimidine 4-Hydroxypyrazolo(3,4-d)pyrimidine 4-Hydroxypyrazolopyrimidine 4-Hydroxypyrazolyl(3,4-d)pyrimidine 4H-Pyrazolo(3,4-d)pyrimidin-4-one AL-100 Allopurinolum Alopurinol C5H4N4O InChI=1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10) InChIKey=OFCNXPDARWKPPY-UHFFFAOYSA-N Oc1ncnc2[nH]ncc12 Zyloprim (TN) CHEBI:40279 Allopurinol allopurinol CHEBI:40279 A delta-lactone that has formula C24H36O5. 6472 CHEBI:40299 CHEBI:6544 ChemIDplus:3631989 ChemIDplus:75330-75-5 KEGG COMPOUND:C07074 KEGG DRUG:75330-75-5 KEGG DRUG:D00359 PDBeChem:803 Wikipedia:Lovastatin (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate LOVASTATIN Lovastatin (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl (S)-2-methyl-butyrate 2beta,6alpha-dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone 6alpha-methylcompactin C24H36O5 InChI=1S/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1 InChIKey=PCZOHLXUXFIOCF-BXMDZJJMSA-N MK-803 ML-530B Mevacor Mevinolin [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)[C@@H](C)CC CHEBI:40303 Lovastatin lovastatin CHEBI:40303 A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. 3008 CHEBI:63586 Beilstein:3647785 ChemIDplus:59865-13-3 CiteXplore:11058832 CiteXplore:11069928 CiteXplore:11079273 CiteXplore:11080188 CiteXplore:11238591 CiteXplore:11256490 CiteXplore:11278005 CiteXplore:11315347 CiteXplore:11370709 CiteXplore:11406057 CiteXplore:11426833 CiteXplore:11442023 CiteXplore:11481617 CiteXplore:11493684 CiteXplore:11529914 CiteXplore:11557554 CiteXplore:11564166 CiteXplore:11676831 CiteXplore:11870366 CiteXplore:12021257 CiteXplore:12050171 CiteXplore:12603598 CiteXplore:12761440 CiteXplore:12929192 CiteXplore:12950728 CiteXplore:14521916 CiteXplore:14621732 CiteXplore:14638917 CiteXplore:14672695 CiteXplore:14682659 CiteXplore:14743390 CiteXplore:15030555 CiteXplore:15175101 CiteXplore:15210365 CiteXplore:15306697 CiteXplore:15383526 CiteXplore:15541012 CiteXplore:15613074 CiteXplore:15626898 CiteXplore:15657176 CiteXplore:1566062 CiteXplore:15711594 CiteXplore:15811524 CiteXplore:15962181 CiteXplore:16372476 CiteXplore:16404634 CiteXplore:16724420 CiteXplore:16801218 CiteXplore:16898534 CiteXplore:17032751 CiteXplore:17083576 CiteXplore:17117422 CiteXplore:17192032 CiteXplore:17220244 CiteXplore:17229932 CiteXplore:17265451 CiteXplore:17446460 CiteXplore:17603747 CiteXplore:18076075 CiteXplore:18171316 CiteXplore:18191430 CiteXplore:18217899 CiteXplore:18259730 CiteXplore:18299432 CiteXplore:18359899 CiteXplore:18583716 CiteXplore:18597363 CiteXplore:18790203 CiteXplore:18818682 CiteXplore:18931077 CiteXplore:18975184 CiteXplore:19282398 CiteXplore:19589783 DrugBank:DB00091 KEGG COMPOUND:59865-13-3 KEGG COMPOUND:C05086 KEGG DRUG:D00184 Patent:US4117118 Reaxys:3647785 Wikipedia:Ciclosporin 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Cyclosporin A (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine] 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Antibiotic S 7481F1 C62H111N11O12 CC[C@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C Ciclosporin Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl) Cyclosporine Gengraf InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1 InChIKey=PMATZTZNYRCHOR-VJRYSDSKSA-N Neoral Sandimmune ciclosporin ciclosporina ciclosporine ciclosporinum CHEBI:4031 Cyclosporine cyclosporin A CHEBI:4031 A tertiary amino compound that has formula C26H29NO. 10324 CHEBI:41767 CHEBI:9396 Beilstein:2062020 ChemIDplus:10540-29-1 DrugBank:DB00675 KEGG COMPOUND:10540-29-1 KEGG COMPOUND:C07108 Patent:BE637389 Patent:BE678807 Patent:US4536516 Wikipedia:Tamoxifen 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine Tamoxifen (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene Apo-Tamox C26H29NO CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1 Crisafeno Diemon InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- InChIKey=NKANXQFJJICGDU-QPLCGJKRSA-N tamoxifen tamoxifene tamoxifeno tamoxifenum trans-Tamoxifen CHEBI:41774 Tamoxifen tamoxifen CHEBI:41774 A fluorinated steroid that has formula C22H29FO5. 3264 CHEBI:41873 CHEBI:4461 Beilstein:2066652 ChemIDplus:50-02-2 DrugBank:DB01234 KEGG DRUG:D00292 Patent:DE1113690 Patent:GB869511 Patent:US3007923 Wikipedia:Dexamethasone 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione Dexamethasone 1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone 16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol 9alpha-Fluoro-16alpha-methylprednisolone C22H29FO5 Decadron InChI=1S/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1 InChIKey=UREBDLICKHMUKA-CXSFZGCWSA-N [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C dexametasona dexamethasone dexamethasonum CHEBI:41879 Dexamethasone dexamethasone CHEBI:41879 Diphenylsulfone in which the hydrogen atom at the 4 position of each of the phenyl groups is substituted by an amino group. It is active against a wide range of bacteria, but is mainly employed for its actions against Mycobacterium leprae, being used as part of multidrug regimens in the treatment of all forms of leprosy. 3108 CHEBI:226356 Beilstein:788055 ChEMBL:226356 ChemIDplus:80-08-0 DrugBank:DB00250 KEGG COMPOUND:80-08-0 KEGG COMPOUND:C07666 KEGG DRUG:D00592 NIST Chemistry WebBook:80-08-0 Patent:FR829926 Wikipedia:Dapsone 4,4'-sulfonyldianiline DAPSONE Dapsone 1,1'-sulfonylbis(4-aminobenzene) 4,4'-Sulfonylbisbenzenamine 4,4'-dapsone 4,4'-diaminodiphenyl sulfone 4,4'-sulfonylbisaniline 4-(4-amino-benzenesulfonyl)-phenylamine 4-(4-aminophenylsulfonyl)aniline 4-(4-aminophenylsulfonyl)benzenamine 4-aminophenyl sulfone Bis(p-aminophenyl) sulfone C12H12N2O2S DADPS DDS DIAPHENYLSULFONE Diaphenylsulfone InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2 InChIKey=MQJKPEGWNLWLTK-UHFFFAOYSA-N Nc1ccc(cc1)S(=O)(=O)c1ccc(N)cc1 bis(4-aminophenyl)sulfone dapsona dapsone dapsonum p,p'-diaminodiphenyl sulfone p,p-sulphonylbisbenzamine p,p-sulphonylbisbenzenamine p-aminophenyl sulfone CHEBI:4325 Dapsone dapsone CHEBI:4325 An acyclic desferrioxamine that has formula C25H48N6O8. 3131 Beilstein:2514118 ChemIDplus:70-51-9 DrugBank:DB00746 KEGG COMPOUND:C06940 KEGG DRUG:D03670 Patent:BE609053 Wikipedia:Deferoxamine N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide C25H48N6O8 CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN DFO Deferoxamin Deferrioxamine Desferrioxamine InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34) InChIKey=UBQYURCVBFRUQT-UHFFFAOYSA-N deferoxamina deferoxamine deferoxaminum deferrioxamine B CHEBI:4356 Deferoxamine desferrioxamine B CHEBI:4356 A dipeptide that has formula C21H31N3O5. 29046 CHEBI:43750 Beilstein:4276619 ChemIDplus:76547-98-3 PDBeChem:LPR Wikipedia:Lisinopril N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (S)-1-(N(2)-(1-carboxy-3-phenylpropyl)-L-lysyl)-L-proline C21H31N3O5 InChI=1S/C21H31N3O5/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29)/t16-,17-,18-/m0/s1 InChIKey=RLAWWYSOJDYHDC-BZSNNMDCSA-N NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N1CCC[C@H]1C(O)=O [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE lisinopril anhydrous CHEBI:43755 Lisinopril lisinopril CHEBI:43755 A pteridine that has formula C20H22N8O5. 6851 CHEBI:44183 CHEBI:6837 Beilstein:70669 ChemIDplus:59-05-2 DrugBank:DB00563 KEGG COMPOUND:59-05-2 KEGG COMPOUND:C01937 KEGG DRUG:D00142 NIST Chemistry WebBook:59-05-2 PDBeChem:MTX Patent:US2512572 Wikipedia:Methotrexate METHOTREXATE Methotrexate N-(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)-L-glutamic acid 4-amino-10-methylfolic acid 4-amino-N(10)-methylpteroylglutamic acid C20H22N8O5 CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(cc1)C(=O)N[C@@H](CCC(O)=O)C(O)=O Emtexate InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1 InChIKey=FBOZXECLQNJBKD-ZDUSSCGKSA-N Ledertrexate MTX N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid Rheumatrex Trexall methotrexate methotrexatum metotrexato CHEBI:44185 Methotrexate methotrexate CHEBI:44185 An urea that has formula CH4N2O2. 5552 CHEBI:44420 CHEBI:5816 ChemIDplus:127-07-1 ChemIDplus:1741548 Gmelin:130423 KEGG COMPOUND:127-07-1 KEGG COMPOUND:C07044 PDBeChem:NHY Wikipedia:Hydroxyurea Hydroxyurea N-hydroxyurea CH4N2O2 Hydroxycarbamid Hydroxycarbamide Hydroxyharnstoff InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4) InChIKey=VSNHCAURESNICA-UHFFFAOYSA-N N-HYDROXYUREA N-carbamoylhydroxylamine NC(=O)NO carbamohydroxamic acid carbamohydroximic acid carbamoyl oxime carbamyl hydroxamate hydrea hydroxycarbamide oxyurea CHEBI:44423 hydroxyurea CHEBI:44423 A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group. 8782 CHEBI:44914 CHEBI:8495 ChemIDplus:1866484 ChemIDplus:2078-54-8 DrugBank:DB00818 KEGG COMPOUND:2078-54-8 KEGG COMPOUND:C07523 KEGG DRUG:D00549 NIST Chemistry WebBook:2078-54-8 PDBeChem:PFL Wikipedia:Propofol 2,6-bis(propan-2-yl)phenol Propofol 2,6-BIS(1-METHYLETHYL)PHENOL 2,6-Diisopropylphenol 2,6-bis(1-methylethyl)phenol C12H18O CC(C)c1cccc(C(C)C)c1O Diprivan Disoprivan Disoprofol InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3 InChIKey=OLBCVFGFOZPWHH-UHFFFAOYSA-N Rapinovet propofol propofolum CHEBI:44915 Propofol propofol CHEBI:44915 A diether compound consisting of pentane-1,5-diol with both hydroxyls bearing 4-amidinophenyl groups. 7994 CHEBI:45077 CHEBI:7976 ChemIDplus:100-33-4 ChemIDplus:3159790 CiteXplore:11438428 CiteXplore:14603035 CiteXplore:15711592 CiteXplore:18971316 CiteXplore:19966562 CiteXplore:22046004 CiteXplore:22093811 CiteXplore:22200378 CiteXplore:22327112 DrugBank:DB00738 KEGG COMPOUND:100-33-4 KEGG COMPOUND:C07420 KEGG DRUG:D08333 PDBeChem:PNT Patent:EP975608 Patent:GB507565 Patent:US2006235001 Patent:US2008167296 Patent:US2008214569 Patent:US2394003 Patent:US7115665 Reaxys:3159790 Wikipedia:Pentamidine 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide Pentamidine 1,5-bis(4-amidinophenoxy)pentane 4,4'-(1,5-pentanediylbis(oxy))bis-benzenecarboximidamide 4,4'-(pentamethylenedioxy)dibenzamidine 4,4'-Diamidinodiphenoxypentane C19H24N4O2 InChI=1S/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23) InChIKey=XDRYMKDFEDOLFX-UHFFFAOYSA-N NC(=N)c1ccc(OCCCCCOc2ccc(cc2)C(N)=N)cc1 p,p'-(pentamethylenedioxy)dibenzamidine pentamidine CHEBI:45081 Pentamidine pentamidine CHEBI:45081 85762 CHEBI:45409 Ritonavir ritonavir CHEBI:45409 A tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark. 56946 CHEBI:45862 CHEBI:7887 ChemIDplus:33069-62-4 KEGG COMPOUND:33069-62-4 KEGG COMPOUND:C07394 KEGG DRUG:D00491 PDBeChem:TA1 Wikipedia:Paclitaxel 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate Paclitaxel (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine C47H51NO14 InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1 InChIKey=RCINICONZNJXQF-MZXODVADSA-N TAXOL Taxol A [H][C@]12[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c4ccccc4)c4ccccc4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C CHEBI:45863 Paclitaxel paclitaxel CHEBI:45863 A triazole that has formula C13H12F2N6O. 4450 CHEBI:46079 CHEBI:5099 Beilstein:4269710 ChemIDplus:86386-73-4 KEGG DRUG:D00322 PDBeChem:TPF Wikipedia:Fluconazole 2-(2,4-difluorophenyl)-1,3-bis-(1H-1,2,4-triazol-1-yl)propan-2-ol Fluconazole 2,4-difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol 2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL Biozolene C13H12F2N6O Diflucan Elazor InChI=1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2 InChIKey=RFHAOTPXVQNOHP-UHFFFAOYSA-N OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F Triflucan CHEBI:46081 Fluconazole fluconazole CHEBI:46081 The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine. 306674 Beilstein:9967331 ChemIDplus:224785-90-4 CiteXplore:19949666 CiteXplore:19959201 CiteXplore:20859794 CiteXplore:20925442 CiteXplore:21209618 CiteXplore:21235726 CiteXplore:21290241 CiteXplore:21427994 CiteXplore:21496853 CiteXplore:21548209 CiteXplore:21552528 CiteXplore:21771280 CiteXplore:21883954 CiteXplore:21943935 CiteXplore:21950284 DrugBank:DB00862 KEGG DRUG:D08668 PDBeChem:VDN Reaxys:9967331 Wikipedia:Vardenafil 2-{2-ethoxy-5-[(4-ethylpiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE C23H32N6O4S CCCc1nc(C)c2n1[nH]c(nc2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(CC)CC1 InChI=1S/C23H32N6O4S/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30) InChIKey=SECKRCOLJRRGGV-UHFFFAOYSA-N Levitra CHEBI:46295 vardenafil CHEBI:46295 An organofluorine compound that has formula C4H3FN2O2. 4492 CHEBI:2054 CHEBI:46343 Beilstein:127172 ChemIDplus:51-21-8 KEGG COMPOUND:51-21-8 KEGG COMPOUND:C07649 Wikipedia:Fluorouracil 5-Fluorouracil 5-fluoropyrimidine-2,4(1H,3H)-dione 5-fluorouracil 5-FU 5-Fluoropyrimidine-2,4-dione C4H3FN2O2 Fc1c[nH]c(=O)[nH]c1=O Fluorouracil InChI=1S/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9) InChIKey=GHASVSINZRGABV-UHFFFAOYSA-N CHEBI:46345 5-fluorouracil Fluorouracil CHEBI:46345 Ganciclovir is an antiviral drug used to treat or prevent AIDS-related cytomegalovirus infections. 4678 CHEBI:5273 Beilstein:3654487 ChEMBL:10197958 ChEMBL:10377226 ChEMBL:10411487 ChEMBL:10447945 ChEMBL:10560739 ChEMBL:10691698 ChEMBL:10882370 ChEMBL:10882372 ChEMBL:10882374 ChEMBL:10882375 ChEMBL:10888336 ChEMBL:10966740 ChEMBL:10966745 ChEMBL:10999475 ChEMBL:11229780 ChEMBL:11262090 ChEMBL:11412988 ChEMBL:11454465 ChEMBL:11472207 ChEMBL:11495586 ChEMBL:11585457 ChEMBL:11677126 ChEMBL:11708924 ChEMBL:11708929 ChEMBL:11754587 ChEMBL:11814776 ChEMBL:11858989 ChEMBL:11985471 ChEMBL:12408716 ChEMBL:12459010 ChEMBL:12723951 ChEMBL:1310744 ChEMBL:1319491 ChEMBL:1323678 ChEMBL:14521407 ChEMBL:14584954 ChEMBL:14643328 ChEMBL:14643358 ChEMBL:14736238 ChEMBL:15027877 ChEMBL:15081019 ChEMBL:15481985 ChEMBL:15509173 ChEMBL:15509174 ChEMBL:15509175 ChEMBL:15509176 ChEMBL:15615545 ChEMBL:15634003 ChEMBL:15658858 ChEMBL:15658861 ChEMBL:15658873 ChEMBL:15689173 ChEMBL:15745823 ChEMBL:15801851 ChEMBL:16134946 ChEMBL:16392791 ChEMBL:16392824 ChEMBL:16420056 ChEMBL:16480257 ChEMBL:1652016 ChEMBL:16759112 ChEMBL:16814545 ChEMBL:17004726 ChEMBL:17043128 ChEMBL:17092728 ChEMBL:17161946 ChEMBL:17181158 ChEMBL:17181162 ChEMBL:17188402 ChEMBL:17239594 ChEMBL:17298047 ChEMBL:17329103 ChEMBL:17402726 ChEMBL:17434304 ChEMBL:17438061 ChEMBL:17513108 ChEMBL:17518459 ChEMBL:17539622 ChEMBL:17622128 ChEMBL:17672445 ChEMBL:17869124 ChEMBL:17948980 ChEMBL:17960926 ChEMBL:18082410 ChEMBL:1849998 ChEMBL:2157013 ChEMBL:2160539 ChEMBL:2163453 ChEMBL:2163454 ChEMBL:2165163 ChEMBL:2175356 ChEMBL:2329551 ChEMBL:2329561 ChEMBL:2391689 ChEMBL:2500527 ChEMBL:2544723 ChEMBL:2822928 ChEMBL:2826784 ChEMBL:2840500 ChEMBL:2842505 ChEMBL:2846837 ChEMBL:2848125 ChEMBL:2913300 ChEMBL:2989523 ChEMBL:2993615 ChEMBL:3009811 ChEMBL:3016263 ChEMBL:3871860 ChEMBL:465284 ChEMBL:7562929 ChEMBL:7562946 ChEMBL:7562947 ChEMBL:7752205 ChEMBL:7877148 ChEMBL:7932543 ChEMBL:8071942 ChEMBL:8176714 ChEMBL:8254613 ChEMBL:8394933 ChEMBL:8632412 ChEMBL:8709116 ChEMBL:8765514 ChEMBL:8784444 ChEMBL:8784445 ChEMBL:8941388 ChEMBL:9046339 ChEMBL:9057866 ChEMBL:9057867 ChEMBL:9057868 ChEMBL:9216836 ChEMBL:9438017 ChEMBL:9548814 ChEMBL:9575044 ChEMBL:9836613 ChEMBL:9836626 ChEMBL:9871553 ChEMBL:9925738 ChEMBL:9934470 ChEMBL:9934471 ChemIDplus:82410-32-0 DrugBank:82410-32-0 DrugBank:DB01004 KEGG COMPOUND:82410-32-0 KEGG COMPOUND:C07019 KEGG DRUG:82410-32-0 KEGG DRUG:D00333 Patent:US4355032 Wikipedia:Ganciclovir 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one Ganciclovir 2-(6-Amino-purin-9-ylmethoxy)-propane-1,3-diol 2-Amino-9-(2-hydroxy-1-hydroxymethyl-ethoxymethyl)-1,9-dihydro-purin-6-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-1H-purin-6(9H)-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-3H-purin-6(9H)-one 2-amino-9-((1,3-dihydroxypropan-2-yloxy)methyl)-9H-purin-6-ol 2-amino-9-(2-hydroxy-1-hydroxymethylethoxymethyl)-6,9-dihydro-1H-6-purinone 9-((2-Hydroxy-1-(hydroxymethyl)ethoxy)methyl)guanine 9-[(1,3-dihydroxy-2-propoxy)methyl]guanine C9H13N5O4 GA2 InChI=1S/C9H13N5O4/c10-9-12-7-6(8(17)13-9)11-3-14(7)4-18-5(1-15)2-16/h3,5,15-16H,1-2,4H2,(H3,10,12,13,17) InChIKey=IRSCQMHQWWYFCW-UHFFFAOYSA-N Nc1nc2n(COC(CO)CO)cnc2c(=O)[nH]1 ganciclovir ganciclovirum gancyclovir CHEBI:465284 Ganciclovir ganciclovir CHEBI:465284 An organic disulfide that has formula C10H20N2S4. 3554 ChemIDplus:97-77-8 KEGG COMPOUND:97-77-8 KEGG COMPOUND:C01692 KEGG DRUG:D00131 NIST Chemistry WebBook:97-77-8 Wikipedia:Disulfiram 1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane Disulfiram 1,1'-dithiobis(N,N-diethylthioformamide) Antabuse (TN) C10H20N2S4 CCN(CC)C(=S)SSC(=S)N(CC)CC InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3 InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N N,N,N',N'-tetraethylthiuram disulfide bis(diethylthiocarbamoyl) disulfide tetraethylthioperoxydicarbonic diamide tetraethylthiuram disulfide tetraethylthiuram disulphide CHEBI:4659 Disulfiram disulfiram CHEBI:4659 Compounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton. benzoxazoles CHEBI:46700 benzoxazole CHEBI:46700 Compounds in which an acyclic carbonyl group is bonded to one or two nitrogen atoms of a ring or ring system. hidden amides CHEBI:46754 hidden amide CHEBI:46754 Any molecule that contains two amino-acid residues connected by peptide linkages. CHEBI:23835 CHEBI:4634 KEGG COMPOUND:C00107 Dipeptide C4H6N2O3R2 Dipeptid dipeptides CHEBI:46761 dipeptide CHEBI:46761 Organic compounds having two ether functional groups. diether diethers CHEBI:46786 diether CHEBI:46786 N-acylpiperazines CHEBI:46844 N-acylpiperazine CHEBI:46844 N-alkylpiperazines CHEBI:46845 N-alkylpiperazine CHEBI:46845 N-arylpiperazines CHEBI:46848 N-arylpiperazine CHEBI:46848 indolyl carboxylic acids CHEBI:46867 indolyl carboxylic acid CHEBI:46867 imidazotriazines CHEBI:46906 imidazotriazine CHEBI:46906 imidazopyridines CHEBI:46908 imidazopyridine CHEBI:46908 N-sulfonylpiperazines CHEBI:46918 N-sulfonylpiperazine CHEBI:46918 A family of aromatic fatty amides produced as secondary metabolites by chilli peppers. capsaicinoids CHEBI:46931 capsaicinoid CHEBI:46931 Compounds containing an anthracene skeleton. CHEBI:46955 anthracenes CHEBI:46955 tetrahydrofuranols CHEBI:47017 tetrahydrofuranol CHEBI:47017 monohydroxytetrahydrofurans CHEBI:47018 monohydroxytetrahydrofuran CHEBI:47018 A dibenzoazepine that has formula C19H24N2. 5691 CHEBI:47498 CHEBI:5881 Beilstein:256892 ChemIDplus:50-49-7 DrugBank:DB00458 Gmelin:1572523 KEGG COMPOUND:50-49-7 KEGG COMPOUND:C07049 NIST Chemistry WebBook:50-49-7 PDBeChem:IXX Patent:US2554736 Wikipedia:Imipramine 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine Imipramine 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine Antideprin C19H24N2 CN(C)CCCN1c2ccccc2CCc2ccccc12 Imipramin InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 InChIKey=BCGWQEUPMDMJNV-UHFFFAOYSA-N Irmin Melipramine N-(gamma-dimethylaminopropyl)iminodibenzyl imipramine imipraminum imizine CHEBI:47499 Imipramine imipramine CHEBI:47499 Any carboxylic ester where the carboxylic acid component is acetic acid. CHEBI:13244 CHEBI:13799 CHEBI:22189 CHEBI:2406 KEGG COMPOUND:C01883 Acetic ester Acetyl ester C2H3O2R acetate acetate esters acetates acetyl ester acetyl esters CHEBI:47622 acetate ester CHEBI:47622 aminoglycosides CHEBI:47779 aminoglycoside CHEBI:47779 A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. 2597 CHEBI:3754 CHEBI:47359 ChemIDplus:1323477 ChemIDplus:303-49-1 CiteXplore:12007764 CiteXplore:12084414 CiteXplore:16085036 CiteXplore:17471183 CiteXplore:19810911 DrugBank:DB01242 KEGG COMPOUND:303-49-1 KEGG COMPOUND:C06918 NIST Chemistry WebBook:303-49-1 PDBeChem:CXX Patent:CH371799 Patent:US3467650 Reaxys:1323477 Wikipedia:Clomipramine 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine Clomipramine 3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine 3-chloroimipramine C19H23ClN2 CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 G 34586 InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N chlorimipramine monochlorimipramine CHEBI:47780 Clomipramine clomipramine CHEBI:47780 A dibenzoazepine that has formula C18H22N2. 3247 CHEBI:4448 CHEBI:47393 ChemIDplus:1432747 ChemIDplus:50-47-5 DrugBank:DB01151 KEGG COMPOUND:50-47-5 KEGG COMPOUND:C06943 KEGG DRUG:D07791 NIST Chemistry WebBook:50-47-5 PDBeChem:DSM Wikipedia:Desipramine 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine Desipramine 3-(10,11-DIHYDRO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N-METHYLPROPAN-1-AMINE 5-(gamma-methylaminopropyl)iminodibenzyl C18H22N2 CNCCCN1c2ccccc2CCc2ccccc12 DMI Desipramin InChI=1S/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3 InChIKey=HCYAFALTSJYZDH-UHFFFAOYSA-N N-(3-methylaminopropyl)iminobibenzyl demethylimipramine desipramina desipramine desipraminum desmethylimipramine monodemethylimipramine norimipramine CHEBI:47781 Desipramine desipramine CHEBI:47781 CHEBI:13607 CHEBI:1653 CHEBI:20182 KEGG COMPOUND:C01876 3-Oxosteroid 3-oxo steroids 3-oxosteroid 3-oxosteroids CHEBI:47788 3-oxo steroid CHEBI:47788 dibenzoazepine dibenzazepine dibenzoazepines CHEBI:47804 dibenzoazepine CHEBI:47804 A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. 20481 CHEBI:3486 CHEBI:473919 Beilstein:7453587 ChEMBL:473919 ChEMBL:478164 CiteXplore:11084674 CiteXplore:11179650 CiteXplore:11191931 CiteXplore:11260566 CiteXplore:11280610 CiteXplore:11303846 CiteXplore:11306793 CiteXplore:11328792 CiteXplore:11431192 CiteXplore:11442796 CiteXplore:11864944 CiteXplore:11910959 CiteXplore:11964152 CiteXplore:12848746 CiteXplore:14628573 CiteXplore:14642333 CiteXplore:15303411 CiteXplore:15494381 CiteXplore:15830071 CiteXplore:15978309 CiteXplore:15980347 CiteXplore:16207962 CiteXplore:16650951 CiteXplore:16705389 CiteXplore:16930923 CiteXplore:17042189 CiteXplore:17214092 CiteXplore:17323865 CiteXplore:17448937 CiteXplore:17625777 CiteXplore:18025111 CiteXplore:18154532 CiteXplore:18651542 CiteXplore:18673128 CiteXplore:18717040 CiteXplore:19053894 CiteXplore:19304881 CiteXplore:21425867 DrugBank:DB01413 KEGG COMPOUND:88040-23-7 KEGG COMPOUND:C08111 KEGG DRUG:D02376 Patent:DE3307550 Patent:US4406899 Reaxys:7453587 Wikipedia:Cefepime 7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate Cefepime cefepime (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate C19H24N6O5S2 InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1 InChIKey=HVFLCNVBZFFHBT-ZKDACBOMSA-N [H][C@]12SCC(C[N+]3(C)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\c1csc(N)n1)C([O-])=O cefepima cefepime cefepimum CHEBI:478164 cefepime CHEBI:478164 A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). 3827 CHEBI:116847 Beilstein:3657467 ChEMBL:10669559 ChEMBL:116847 ChemIDplus:75847-73-3 DrugBank:DB00584 KEGG COMPOUND:75847-73-3 KEGG COMPOUND:C06977 KEGG DRUG:D07892 Patent:EP12401 Patent:US4374829 Wikipedia:Enalapril ENALAPRIL Enalapril N-[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]-L-alanyl-L-proline (S)-1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-L-proline (S)-1-{(S)-2-[1-((S)-Ethoxycarbonyl)-3-phenyl-propylamino]-propionyl}-pyrrolidine-2-carboxylic acid 1-(N-((S)-1-carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester C20H28N2O5 CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O InChI=1S/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1 InChIKey=GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril enalaprila enalaprilum CHEBI:4784 Enalapril enalapril CHEBI:4784 CHEBI:27220 CHEBI:36947 urea derivatives CHEBI:47857 ureas CHEBI:47857 CHEBI:13600 CHEBI:1619 CHEBI:35949 KEGG COMPOUND:C01656 3-Oxo acid 3-oxo monocarboxylic acids C3H2O3R2 CHEBI:47881 3-oxo monocarboxylic acid CHEBI:47881 CHEBI:13604 CHEBI:1626 CHEBI:20157 KEGG COMPOUND:C00619 3-Oxo-delta4-steroid 3-oxo Delta(4)-steroids 3-oxo-Delta(4)-steroid CHEBI:47909 3-oxo Delta(4)-steroid CHEBI:47909 2',3'-dideoxyribonucleosides CHEBI:47945 2',3'-dideoxyribonucleoside CHEBI:47945 A vinca alkaloid with a norvinblastine skeleton. 39541 Beilstein:9035861 ChEMBL:480999 ChemIDplus:71486-22-1 DrugBank:71486-22-1 DrugBank:DB00361 KEGG DRUG:71486-22-1 KEGG DRUG:D08680 Patent:JP8031096 Patent:US4307100 methyl (2beta,3beta,4beta,5alpha,12beta,19alpha)-4-acetoxy-15-[(6R,8S)-4-ethyl-8-(methoxycarbonyl)-1,3,6,7,8,9-hexahydro-2,6-methanoazecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carboxylate C45H54N4O8 InChI=1S/C45H54N4O8/c1-8-27-19-28-22-44(40(51)55-6,36-30(25-48(23-27)24-28)29-13-10-11-14-33(29)46-36)32-20-31-34(21-35(32)54-5)47(4)38-43(31)16-18-49-17-12-15-42(9-2,37(43)49)39(57-26(3)50)45(38,53)41(52)56-7/h10-15,19-21,28,37-39,46,53H,8-9,16-18,22-25H2,1-7H3/t28-,37-,38+,39+,42+,43+,44-,45+/m0/s1 InChIKey=GBABOYUKABKIAF-GHYRFKGUSA-N Nor-5'-anhydrovinblastine [H][C@]12CN(CC(CC)=C1)Cc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C)[C@@]1([H])[C@@](O)([C@H](OC(C)=O)[C@]3(CC)C=CCN4CC[C@]21[C@]34[H])C(=O)OC vinorelbina vinorelbine vinorelbinum CHEBI:480999 vinorelbine CHEBI:480999 sulfamate esters CHEBI:48199 sulfamate ester CHEBI:48199 Compounds of structure RSSR'. disulfides CHEBI:48343 disulfide CHEBI:48343 CHEBI:48420 biphenylyltetrazole CHEBI:48420 pyrimidine 2',3'-dideoxyribonucleosides CHEBI:48441 pyrimidine 2',3'-dideoxyribonucleoside CHEBI:48441 purine 2',3'-dideoxyribonucleosides CHEBI:48442 purine 2',3'-dideoxyribonucleoside CHEBI:48442 pyrimidinethiones CHEBI:48546 pyrimidinethione CHEBI:48546 hydroxypiperidines CHEBI:48590 hydroxypiperidine CHEBI:48590 piperidinecarboxamides CHEBI:48592 piperidinecarboxamide CHEBI:48592 pyranoindolizinoquinolines CHEBI:48626 pyranoindolizinoquinoline CHEBI:48626 benzothiazepines CHEBI:48684 benzothiazepine CHEBI:48684 Ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone. 4110 CHEBI:133410 CHEBI:659237 CHEBI:678172 Beilstein:6312870 ChEMBL:10649975 ChEMBL:10891117 ChEMBL:10966749 ChEMBL:12182855 ChEMBL:133410 ChEMBL:14695841 ChEMBL:14698152 ChEMBL:15225698 ChEMBL:16005211 ChEMBL:16759086 ChEMBL:16870429 ChEMBL:17210775 ChEMBL:17239593 ChEMBL:17276683 ChEMBL:17315960 ChEMBL:17331717 ChEMBL:17562368 ChEMBL:17851083 ChEMBL:17888665 ChEMBL:19524332 ChEMBL:19648006 ChEMBL:3934384 ChEMBL:659237 ChEMBL:678172 ChemIDplus:74-55-5 DrugBank:DB00330 KEGG COMPOUND:74-55-5 KEGG COMPOUND:C06984 KEGG DRUG:D07925 Wikipedia:Ethambutol (2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol Ethambutol (+)-2,2'-(ethylenediimino)di-1-butanol (+)-N,N'-bis(1-(hydroxymethyl)propyl)ethylenediamine (+)-S,S-ethambutol (+)-ethambutol (2S,7S)-2,7-diethyl-3,6-diazaoctane-1,8-diol (S,S)-ethambutol C10H24N2O2 CC[C@@H](CO)NCCN[C@@H](CC)CO EMB InChI=1S/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1 InChIKey=AEUTYOVWOVBAKS-UWVGGRQHSA-N S,S-Ethambutol etambutol ethambutol ethambutolum CHEBI:4877 Ethambutol ethambutol CHEBI:4877 benzothiadiazoles CHEBI:48864 benzothiadiazole CHEBI:48864 thiadiazolidines CHEBI:48865 thiadiazolidine CHEBI:48865 CHEBI:48901 thiazoles CHEBI:48901 1,2-thiazoles isothiazoles CHEBI:48902 1,2-thiazole CHEBI:48902 A phosphonic acid consisting of (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. Inhibits formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces 42682 CHEBI:63588 ChemIDplus:2809-21-4 CiteXplore:10385693 CiteXplore:17157266 CiteXplore:17214981 CiteXplore:18313802 DrugBank:DB01077 KEGG COMPOUND:2809-21-4 KEGG COMPOUND:C07736 KEGG DRUG:D02373 Patent:US3159581 Reaxys:1789291 Wikipedia:Etidronate (1-hydroxyethane-1,1-diyl)bis(phosphonic acid) (1-Hydroxyethylene)diphosphonic acid (1-Hydroxyethylidene)bis(phosphonic acid) (1-Hydroxyethylidene)bisphosphonic acid (1-Hydroxyethylidene)diphosphonic acid (Hydroxyethylidene)diphosphonic acid 1,1,1-Ethanetriol diphosphonate 1-Hydroxy-1,1-diphosphonoethane 1-Hydroxyethane-1,1-bisphosphonic acid 1-Hydroxyethane-1,1-diphosphonate 1-Hydroxyethane-1,1-diphosphonic acid 1-Hydroxyethanediphosphonic acid 1-Hydroxyethylidene-1,1-bisphosphonate 1-Hydroxyethylidene-1,1-diphosphonic acid Acetodiphosphonic acid C2H8O7P2 CC(O)(P(O)(O)=O)P(O)(O)=O EHDP Ethane-1-hydroxy-1,1-diphosphonate Ethane-1-hydroxy-1,1-diphosphonic acid Etidronsaeure HEDP Hydroxyethanediphosphonic acid InChI=1S/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9) InChIKey=DBVJJBKOTRCVKF-UHFFFAOYSA-N Oxyethylidenediphosphonic acid acide etidronique acido etidronico acidum etidronicum ethane-1-hydroxy-1,1-bisphosphonic acid etidronate etidronic acid CHEBI:4907 Etidronate etidronic acid CHEBI:4907 A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. 3364 CHEBI:158219 CHEBI:39738 CHEBI:4516 CHEBI:475381 CHEBI:668806 Beilstein:3619529 ChEMBL:10386939 ChEMBL:158219 ChEMBL:1619614 ChEMBL:17046264 ChEMBL:475381 ChEMBL:490877 ChEMBL:668806 ChemIDplus:69655-05-6 CiteXplore:18549801 DrugBank:DB00900 KEGG COMPOUND:69655-05-6 KEGG COMPOUND:C06953 KEGG DRUG:D00296 PDBeChem:2DI Patent:EP206497 Wikipedia:Didanosine 2',3'-dideoxyinosine Didanosine 2,3-dideoxyinosine 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one C10H12N4O3 DDI InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1 InChIKey=BXZVVICBKDXVGW-NKWVEPMBSA-N OC[C@@H]1CC[C@@H](O1)n1cnc2c1nc[nH]c2=O ddI ddIno didanosina didanosine didanosinum dideoxyinosine CHEBI:490877 Didanosine didanosine CHEBI:490877 A beta-D-glucoside that has formula C29H32O13. 4179 ChemIDplus:33419-42-0 DrugBank:DB00773 KEGG COMPOUND:33419-42-0 KEGG COMPOUND:C01576 KEGG DRUG:D00125 Patent:US3524844 Wikipedia:Etoposide (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside Etoposide (-)-etoposide 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside) 4-demethylepipodophyllotoxin beta-D-ethylideneglucoside 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one C29H32O13 Eposin Etopophos Etoposido InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1 InChIKey=VJJPUSNTGOMMGY-MRVIYFEKSA-N Lastet Toposar VP-16 Vepesid [H][C@]12COC(=O)[C@]1([H])[C@H](c1cc(OC)c(O)c(OC)c1)c1cc3OCOc3cc1[C@H]2O[C@@H]1O[C@@H]2CO[C@@H](C)O[C@H]2[C@H](O)[C@H]1O etoposide etoposidum trans-Etoposide CHEBI:4911 Etoposide etoposide CHEBI:4911 A hydroxyphenylalanine that has formula C9H11NO4. Beilstein:1462084 ChemIDplus:63-84-3 Gmelin:51382 NIST Chemistry WebBook:63-84-3 2-amino-3-(3,4-dihydroxyphenyl)propanoic acid dopa (+-)-3-(3,4-dihydroxyphenyl)alanine (+-)-dopa (R,S)-dopa 3',4'-dihydroxyphenylalanine 3-hydroxy-DL-tyrosine 3-hydroxytyrosine C9H11NO4 DL-3,4-dopa DL-beta-(3,4-dihydroxyphenyl)alanine DL-dihydroxyphenylalanine DL-dioxyphenylalanine InChI=1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14) InChIKey=WTDRDQBEARUVNC-UHFFFAOYSA-N NC(Cc1ccc(O)c(O)c1)C(O)=O beta-(3,4-dihydroxyphenyl)-DL-alpha-alanine dl-beta-(3,4-dihydroxyphenyl)-alpha-alanine CHEBI:49168 dopa CHEBI:49168 Androsta-1,4-diene-3,17-dione in which the hydrogens at position 6 are replaced by a double bond to a methylene group.a selective inhibitor of the aromatase (oestrogen synthase) system, it is used in the treatment of advanced breast cancer. 258494 ChemIDplus:107868-30-4 CiteXplore:10882163 DrugBank:DB00990 KEGG COMPOUND:107868-30-4 KEGG COMPOUND:C08162 KEGG DRUG:D00963 Wikipedia:Exemestane 6-methylideneandrosta-1,4-diene-3,17-dione Exemestane 6-methyleneandrosta-1,4-diene-3,17-dione C20H24O2 InChI=1S/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1 InChIKey=BFYIZQONLCFLEV-DAELLWKTSA-N [H][C@@]12CC(=C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)C(=O)CC[C@@]21[H] exemestane exemestano exemestanum CHEBI:4953 exemestane CHEBI:4953 An indole-3-acetic acid that has formula C19H16ClNO4. 5781 CHEBI:49660 CHEBI:5918 Beilstein:497341 ChemIDplus:53-86-1 Gmelin:1446006 KEGG COMPOUND:53-86-1 KEGG COMPOUND:C01926 KEGG DRUG:D00141 NIST Chemistry WebBook:53-86-1 PDBeChem:IMN Wikipedia:Indomethacin INDOMETHACIN Indomethacin [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid C19H16ClNO4 COc1ccc2n(C(=O)c3ccc(Cl)cc3)c(C)c(CC(O)=O)c2c1 InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23) InChIKey=CGIGDMFJXJATDK-UHFFFAOYSA-N Indocin Indometacin CHEBI:49662 Indomethacin indomethacin CHEBI:49662 A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups. organic amino compounds CHEBI:50047 organic amino compound CHEBI:50047 dihydropyridine dihydropyridines CHEBI:50075 dihydropyridine CHEBI:50075 A phenethylamine alkaloid that has formula C13H17N. 9639 Beilstein:2092580 N-methyl-N-(1-methyl-2-phenylethyl)prop-2-yn-1-amine C13H17N CC(Cc1ccccc1)N(C)CC#C InChI=1S/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3 InChIKey=MEZLKOACVSPNER-UHFFFAOYSA-N selegilina selegiline selegilinum CHEBI:50217 Selegiline selegiline CHEBI:50217 A 3-oxo steroid that has formula C22H30O5. Beilstein:7113955 11beta,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione (11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione C22H30O5 InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12?,14-,15-,17-,19+,20-,21-,22-/m0/s1 InChIKey=VHRSUDSXCMQTMA-UWKORSIYSA-N [H][C@@]12CC(C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO CHEBI:50366 6-methylprednisolone CHEBI:50366 taxane diterpenoid taxane diterpenoids CHEBI:50367 taxane diterpenoid CHEBI:50367 CHEBI:50453 desferrioxamine CHEBI:50453 CHEBI:50454 acyclic desferrioxamine CHEBI:50454 Any compound containing the thiocarbonyl group, C=S. thiocarbonyl compounds CHEBI:50492 thiocarbonyl compound CHEBI:50492 A thiocarbonyl compound that has formula C4H6N2S. 6835 CHEBI:44168 CHEBI:6828 Beilstein:108646 ChemIDplus:60-56-0 DrugBank:DB00763 KEGG DRUG:D00401 NIST Chemistry WebBook:60-56-0 PDBeChem:MMZ Wikipedia:Methimazole 1-methyl-1,3-dihydro-2H-imidazole-2-thione 1-METHYL-1,3-DIHYDRO-2H-IMIDAZOLE-2-THIONE 1-Methylimidazole-2(3H)-thione C4H6N2S Cn1cc[nH]c1=S Danantizol Favistan InChI=1S/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7) InChIKey=PMRYVIKBURPHAH-UHFFFAOYSA-N Strumazol Tapazole Thacapzol USAF el-30 thiamazol thiamazole thiamazolum tiamazol CHEBI:50673 Methimazole methimazole CHEBI:50673 A hydroxyanthraquinone that has formula C22H28N4O6. 7005 CHEBI:43919 CHEBI:6955 Beilstein:2795126 ChemIDplus:65271-80-9 DrugBank:DB01204 KEGG COMPOUND:65271-80-9 KEGG COMPOUND:C11195 PDBeChem:MIX Patent:DE2835661 Patent:US4197249 Wikipedia:Mitoxantrone 1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione Mitoxantrone 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE C22H28N4O6 InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2 InChIKey=KKZJGLLVHKMTCM-UHFFFAOYSA-N OCCNCCNc1ccc(NCCNCCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12 mitoxantrona mitoxantrone mitoxantronum CHEBI:50729 Mitoxantrone mitoxantrone CHEBI:50729 An alkyl sulfide that has formula C35H36ClNO3S. 88249 CHEBI:49756 CHEBI:6992 Beilstein:7896575 ChemIDplus:158966-92-8 DrugBank:DB00471 KEGG COMPOUND:158966-92-8 KEGG COMPOUND:C07482 PDBeChem:MTK Patent:EP1886997 Wikipedia:Montelukast MONTELUKAST Montelukast {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid (R-(E))-1-(((1-(3-(2-(7-Chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid 1-[[[(1 R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl] phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]sulfanyl]methyl]cyclopropaneacetic acid C35H36ClNO3S CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC1)CC(O)=O)c1cccc(\C=C\c2ccc3ccc(Cl)cc3n2)c1 InChI=1S/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1 InChIKey=UCHDWCPVSPXUMX-TZIWLTJVSA-N montelukast CHEBI:50730 montelukast CHEBI:50730 A steroid which is substituted with one or more fluorine atoms in any position. CHEBI:50830 fluorinated steroid CHEBI:50830 A natural or synthetic analogue of the hormones secreted by the adrenal gland. corticoides corticosteroides corticosteroids CHEBI:50858 corticosteroid CHEBI:50858 Any molecular entity that contains carbon. CHEBI:25700 CHEBI:33244 organic compounds organic entity organic molecular entities CHEBI:50860 organic molecular entity CHEBI:50860 CHEBI:50990 thiazolidenediones CHEBI:50990 A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. primary amino compounds CHEBI:50994 primary amino compound CHEBI:50994 A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. secondary amino compounds CHEBI:50995 secondary amino compound CHEBI:50995 A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. tertiary amino compounds CHEBI:50996 tertiary amino compound CHEBI:50996 An organofluorine compound that has formula C4H4FN3O. 4451 ChemIDplus:2022-85-7 KEGG DRUG:2022-85-7 KEGG DRUG:D00323 Wikipedia:Flucytosine 4-amino-5-fluoropyrimidin-2(1H)-one Flucytosine 5-FC 5-Fluorocystosine 5-Fluorocytosine Ancobon (TN) C4H4FN3O InChI=1S/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9) InChIKey=XRECTZIEBJDKEO-UHFFFAOYSA-N Nc1nc(=O)[nH]cc1F CHEBI:5100 Flucytosine flucytosine CHEBI:5100 CHEBI:25556 CHEBI:7594 KEGG COMPOUND:C06061 Nitrogenous compounds nitrogen compounds nitrogen molecular entities CHEBI:51143 nitrogen molecular entity CHEBI:51143 A benzenoid aromatic compound that has formula C17H18F3NO. 4493 Beilstein:39914106 ChemIDplus:54910-89-3 DrugBank:DB00472 KEGG DRUG:54910-89-3 KEGG DRUG:D00326 Patent:DE2500110 Patent:US4314081 Wikipedia:Fluoxetine N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine (+-)-N-methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine (+-)-N-methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine C17H18F3NO CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1 InChI=1S/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3 InChIKey=RTHCYVBBDHJXIQ-UHFFFAOYSA-N Prozac fluoxetina fluoxetine fluoxetinum CHEBI:5118 Fluoxetine fluoxetine CHEBI:5118 Gmelin:101110 NIST Chemistry WebBook:14913-33-8 diamminedichloridoplatinum diamminedichloridoplatinum(II) diamminedichloroplatinum diamminedichloroplatinum(II) Cl2H6N2Pt diammine(dichloro)platinum diammineplatinum dichloride CHEBI:51214 diamminedichloroplatinum CHEBI:51214 Polycyclic aromatic hydrocarbons consisting of fused benzene rings in a rectilinear arrangement and their substitution derivatives. CHEBI:51269 acenes CHEBI:51269 Quinones containing an acene fused ring system. acenoquinone acenoquinones CHEBI:51285 acenoquinone CHEBI:51285 Compounds containing an adamantane skeleton. CHEBI:51339 adamantanes CHEBI:51339 A 5-methoxyvalerophenone O-(2-aminoethyl)oxime that has formula C15H21F3N2O2. 42355 Beilstein:5583954 ChemIDplus:54739-18-3 DrugBank:DB00176 KEGG COMPOUND:54739-18-3 KEGG COMPOUND:C07571 Patent:NL7503310 Patent:US4085225 Wikipedia:Fluvoxamine (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime Fluvoxamine C15H21F3N2O2 COCCCC\C(c1ccc(cc1)C(F)(F)F)=N/OCCN InChI=1S/C15H21F3N2O2/c1-21-10-3-2-4-14(20-22-11-9-19)12-5-7-13(8-6-12)15(16,17)18/h5-8H,2-4,9-11,19H2,1H3/b20-14+ InChIKey=CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamina fluvoxamine fluvoxaminum CHEBI:5138 Fluvoxamine fluvoxamine CHEBI:5138 Cyclopropane and its derivatives formed by substitution. CHEBI:51454 cyclopropanes CHEBI:51454 Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton, with the O atom positioned adjacent to one of the positions of ring fusion. CHEBI:51545 1,2-benzoxazoles CHEBI:51545 Compounds based on a fused 1,2-oxazole and benzene bicyclic ring skeleton. benzisoxazoles CHEBI:51549 benzisoxazole CHEBI:51549 Compounds containing a mono-unsaturated furan ring skeleton. dihydrofurans CHEBI:51659 dihydrofuran CHEBI:51659 An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. C3OR4 [*]\C([*])=C(\[*])C([*])=O enones CHEBI:51689 enone CHEBI:51689 A ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) or R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the ketonic C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position. alpha,beta-unsaturated ketones CHEBI:51721 alpha,beta-unsaturated ketone CHEBI:51721 organic polycyclic compounds CHEBI:51958 organic polycyclic compound CHEBI:51958 organic tricyclic compounds CHEBI:51959 organic tricyclic compound CHEBI:51959 A terpenoid having a C20 tetracyclic skeleton. tetracyclic diterpenoids CHEBI:52557 tetracyclic diterpenoid CHEBI:52557 Any organic heterotricyclic compound based on a skeleton comprised of an oxazine ring fused onto a quinoline system. oxazinoquinolines CHEBI:53665 oxazinoquinoline CHEBI:53665 Compounds containing an ifosfamide skeleton. isosfamides CHEBI:55369 ifosfamides CHEBI:55369 An imidazolidine containing one or more oxo groups. imidazolidinones CHEBI:55370 imidazolidinone CHEBI:55370 Oxazoles in which the N and O atoms are adjacent. CHEBI:46813 isoxazoles 1,2-oxazoles CHEBI:55373 isoxazoles CHEBI:55373 A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4; and an N-linked p-fluorobutyrophenone moiety. 5093 Beilstein:331267 ChemIDplus:52-86-8 CiteXplore:7602118 DrugBank:DB00502 KEGG COMPOUND:52-86-8 KEGG COMPOUND:C01814 KEGG DRUG:D00136 NIST Chemistry WebBook:52-86-8 Patent:BE577977 Patent:GB895309 Patent:US3438991 Wikipedia:Haloperidol 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one 1-(3-p-fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone 4'-fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone 4-(4-(para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one C21H23ClFNO2 Haldol InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2 InChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c1ccc(Cl)cc1 gamma-(4-(p-chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone haloperidol haloperidolum CHEBI:5613 Haloperidol haloperidol CHEBI:5613 2'-Deoxyadenosine in which the hydrogen at position 2 on the purine ring has been substituted by chlorine. It inhibits the synthesis and repair of DNA, particularly in lymphocytes and monocytes, and is used as an antimetabolite antineoplastic drug for the treatment of lymphoid malignancies including hairy-cell leukaemia and chronic lymphocytic leukaemia. 44157 CHEBI:31407 CHEBI:568373 Beilstein:624220 ChEMBL:17526755 ChEMBL:18570408 ChEMBL:567361 ChEMBL:568373 ChemIDplus:4291-63-8 DrugBank:DB00242 KEGG DRUG:4291-63-8 KEGG DRUG:D01370 Patent:EP173059 Patent:US4760137 Wikipedia:Cladribine 2-chloro-2'-deoxyadenosine Cladribine (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol 2-CdA 2-chloro-2'-deoxy-beta-adenosine 2-chloro-6-amino-9-(2-deoxy-beta-D-erythro-pentofuranosyl)purine 2-chloro-deoxyadenosine 2-chlorodeoxyadenosine 2ClAdo C10H12ClN5O3 CldAdo InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1 InChIKey=PTOAARAWEBMLNO-KVQBGUIXSA-N Nc1nc(Cl)nc2n(cnc12)[C@H]1C[C@H](O)[C@@H](CO)O1 cladribina cladribine cladribinum CHEBI:567361 Cladribine cladribine CHEBI:567361 A cyclic compound having as ring members atoms of at least two different elements. Heterocyclic compound compuesto heterociclico compuestos heterociclicos heterocycle heterocyclic compounds CHEBI:5686 heterocyclic compound CHEBI:5686 A nitrogen mustard alkylating agent used in the treatment of cancer 5657 CHEBI:219640 Beilstein:611835 ChEMBL:219640 ChemIDplus:3778-73-2 DrugBank:DB01181 KEGG COMPOUND:3778-73-2 KEGG COMPOUND:C07047 KEGG DRUG:D00343 Wikipedia:Ifosfamide N,3-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide C7H15Cl2N2O2P ClCCNP1(=O)OCCCN1CCCl InChI=1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12) InChIKey=HOMGKSMUEGBAAB-UHFFFAOYSA-N Iphosphamide Isofosfamide Isophosphamide ifosfamida ifosfamide ifosfamidum isosfamide CHEBI:5864 Ifosfamide ifosfamide CHEBI:5864 A compound having the structure RR'C(OR'')(OR''') (R'', R''' =/= H) and thus diethers of geminal diols. Originally, the term was confined by IUPAC to derivatives of aldehydes (R = H), but it now applies equally to derivatives of ketones (neither R nor R' = H ). Mixed acetals have R'' and R''' groups which differ. acetals CHEBI:59769 acetal CHEBI:59769 An acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals. ketals CHEBI:59777 ketal CHEBI:59777 A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring. cyclic ketals CHEBI:59779 cyclic ketal CHEBI:59779 The trihydrate form of docetaxel. It is used for the treatment of breast, ovarian, and non-small cell lung cancer, and with prednisone or prednisolone in hormone-refractory metastatic prostate cancer. 72962 Beilstein:10054412 ChemIDplus:148408-66-6 DrugBank:DB01248 KEGG DRUG:148408-66-6 KEGG DRUG:D02165 Patent:EP253738 Patent:US4814470 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate--water (1/3) C43H59NO17 InChI=1S/C43H53NO14.3H2O/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45;;;/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52);3*1H2/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+;;;/m0.../s1 InChIKey=XCDIRYDKECHIPE-QHEQPUDQSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel trihydrate N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol trihydrate O.O.O.[H][C@@]1(C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)[C@]3([H])[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C(=O)[C@H](O)C(=C1C)C2(C)C)OC(C)=O)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c1ccccc1 docetaxel CHEBI:59809 docetaxel docetaxel trihydrate CHEBI:59809 A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types. Chemische Substanz CHEBI:59999 chemical substance CHEBI:59999 A mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind. Mischung CHEBI:60004 mixture CHEBI:60004 A nucleoside having a purine base covalently bonded to a deoxyribose. purine deoxyribonucleosides CHEBI:60173 purine deoxyribonucleoside CHEBI:60173 A carbohydrazide obtained by formal condensation between pyridine-4-carboxylic acid and hydrazine. 6038 Beilstein:119374 ChemIDplus:54-85-3 CiteXplore:18220565 CiteXplore:19183459 CiteXplore:445303 Gmelin:82804 KEGG COMPOUND:54-85-3 KEGG COMPOUND:C07054 NIST Chemistry WebBook:54-85-3 Reaxys:119374 Wikipedia:Isoniazid pyridine-4-carbohydrazide 4-pyridinecarbohydrazide C6H7N3O InChI=1S/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10) InChIKey=QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Isonicotinsaeurehydrazid NNC(=O)c1ccncc1 isonicotinic acid hydrazide isonicotinic hydrazide isonicotinohydrazide isonicotinoylhydrazide pyridine-4-carboxylic acid hydrazide CHEBI:6030 isoniazid isoniazide CHEBI:6030 A pyridinemonocarboxylic acid that has formula C6H5NO2. Beilstein:109599 ChemIDplus:55-22-1 Gmelin:68876 KEGG COMPOUND:55-22-1 KEGG COMPOUND:C07446 NIST Chemistry WebBook:55-22-1 Wikipedia:Isonicotinic_Acid Isonicotinic acid isonicotinic acid pyridine-4-carboxylic acid 4-carboxypyridine 4-pyridinecarboxylic acid C6H5NO2 InChI=1S/C6H5NO2/c8-6(9)5-1-3-7-4-2-5/h1-4H,(H,8,9) InChIKey=TWBYWOBDOCUKOW-UHFFFAOYSA-N OC(=O)c1ccncc1 gamma-picolinic acid gamma-pyridinecarboxylic acid p-pyridinecarboxylic acid CHEBI:6032 isonicotinic acid CHEBI:6032 A dioxolane that has formula C35H38Cl2N8O4. 28031 ChemIDplus:84625-61-6 KEGG DRUG:84625-61-6 KEGG DRUG:D00350 Wikipedia:Itraconazole 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one Itraconazole C35H38Cl2N8O4 CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1 InChIKey=VHVPQPYKVGDNFY-ZPGVKDDISA-N Itrizole (TN) Oriconazole Sporanox (TN) CHEBI:6076 Itraconazole itraconazole CHEBI:6076 An analogue of a nucleoside, being an N-glycosyl compound in which the nitrogen-containing moiety is a modified nucleotide base. They are commonly used as antiviral products to prevent viral replication in infected cells. nucleoside analogues CHEBI:60783 nucleoside analogue CHEBI:60783 The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline. 35780 Reaxys:253266 N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide (+-)-ropivacaine 1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide 1-propyl-2',6'-pipecoloxylidide C17H26N2O CCCN1CCCCC1C(=O)Nc1c(C)cccc1C DL-ropivacaine InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20) InChIKey=ZKMNUMMKYBVTFN-UHFFFAOYSA-N N-n-propylpipecolic acid-2,6-xylidide rac-ropivacaine racemic ropivacaine CHEBI:60802 ropivacaine CHEBI:60802 A racemate is an equimolar mixture of a pair of enantiomers. melange racemique racemic mixture CHEBI:60911 racemate CHEBI:60911 A mixture composed of two or more diastereoisomers (stereoisomers not related as mirror images). diastereomeric mixture CHEBI:60915 diastereoisomeric mixture CHEBI:60915 A glucoside in which the anomeric carbon of the glycosidic bond is in a beta configuration beta-glucosides CHEBI:60980 beta-glucoside CHEBI:60980 A hydrate that is the monohydrate form of tacrolimus. 42316 ChemIDplus:109581-93-3 DrugBank:DB00864 KEGG DRUG:109581-93-3 KEGG DRUG:D00107 Reaxys:6265275 (3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone--water (1/1) (-)-(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-3H-15,19-epoxypyrido[2,1-c][1,4]oxazacyclotricosine-1,7,20,21(4H,23H)-tetrone monohydrate C44H71NO13 InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1 InChIKey=NWJQLQGQZSIBAF-MLAUYUEBSA-N O.CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@H]([C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC)[C@H](C[C@H]2C)OC Prograf Protopic tacrolimus tacrolimus monohydrate tsukubaenolide hydrate CHEBI:61057 Tacrolimus tacrolimus hydrate CHEBI:61057 Any compound that has a nucleobase as a part. nucleobase-containing compound nucleobase-containing compounds nucleobase-containing molecular entities CHEBI:61120 nucleobase-containing molecular entity CHEBI:61120 A steroid compound with a structure based on a 21-carbon (pregnane) skeleton. CHEBI:61313 C21-steroid CHEBI:61313 Any hydroxy carboxylic acid which contains a hydroxy group located beta- to the carboxylic acid group. 3-hydroxy carboxylic acids beta-hydroxy carboxylic acid beta-hydroxy carboxylic acids CHEBI:61355 3-hydroxy carboxylic acid CHEBI:61355 A carbohydrate derivative arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to an oxygen, carbon, nitrogen or sulfur atom of a separate entity. glycosyl compounds CHEBI:63161 glycosyl compound CHEBI:63161 Any organooxygen compound derived from a carbohydrate by replacement of one or more hydroxy group(s) by an amino group, a thiol group or similar heteroatomic groups. The term also includes derivatives of these compounds. carbohydrate derivatives derivatised carbohydrate derivatised carbohydrates derivatized carbohydrate derivatized carbohydrates CHEBI:63299 carbohydrate derivative CHEBI:63299 A carbohydrate derivative that is formally obtained from a monosaccharide. monosaccharide derivatives CHEBI:63367 monosaccharide derivative CHEBI:63367 A monosaccharide derivative that is formally obtained from a hexose. hexose derivatives CHEBI:63385 hexose derivative CHEBI:63385 A hexose derivative that is formally obtained from a ketohexose. ketohexose derivatives CHEBI:63391 ketohexose derivative CHEBI:63391 A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. An inhibitor of HCV polymerase. 9344 CHEBI:8840 ChemIDplus:36791-04-5 ChemIDplus:892462 CiteXplore:21827730 CiteXplore:22052088 CiteXplore:22052220 CiteXplore:22156853 CiteXplore:22158703 CiteXplore:22212566 CiteXplore:22212568 CiteXplore:22212569 CiteXplore:22212572 CiteXplore:22212576 CiteXplore:22212579 CiteXplore:22220723 CiteXplore:22239498 CiteXplore:22239511 DrugBank:DB00811 KEGG DRUG:36791-04-5 KEGG DRUG:D00423 Reaxys:892462 Wikipedia:Ribavirin 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide C8H12N4O5 InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RBV ribavirin ribavirina ribavirine ribavirinum CHEBI:63580 Ribavirin ribavirin CHEBI:63580 A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase 59763 CHEBI:9253 ChemIDplus:3056-17-5 DrugBank:DB00649 KEGG COMPOUND:3056-17-5 KEGG COMPOUND:C07312 KEGG DRUG:D00445 Patent:EP334368 Patent:US5130421 Reaxys:618327 Wikipedia:Stavudine 1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione Stavudine 1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine 2',3'-Didehydro-3'-deoxythimidine 3'-Deoxy-2'-thymidinene C10H12N2O4 Cc1cn([C@@H]2O[C@H](CO)C=C2)c(=O)[nH]c1=O InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1 InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N STV Sanilvudine d4T estavudina stavudine stavudinum CHEBI:63581 Stavudine stavudine CHEBI:63581 An N-glycosyl compound that consists of any triazole having a glycosyl residue attached at position 1. 1-glycosyltriazoles CHEBI:63593 1-glycosyltriazole CHEBI:63593 CHEBI:63594 1-ribosyltriazole CHEBI:63594 An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase 82122 CHEBI:6440 ChemIDplus:100986-85-4 CiteXplore:21075586 CiteXplore:21965436 CiteXplore:21974858 CiteXplore:22088660 CiteXplore:22221614 DrugBank:DB01137 HMDB:HMDB01929 KEGG COMPOUND:100986-85-4 KEGG COMPOUND:C07660 KEGG DRUG:D08120 Reaxys:5385660 Wikipedia:Levofloxacin (3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (-)-Ofloxacin (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid (S)-Ofloxacin C18H20FN3O4 C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1 InChIKey=GSDSWSVVBLHKDQ-JTQLQIEISA-N L-Ofloxacin Ofloxacin S-(-)-form levofloxacin levofloxacine levofloxacino levofloxacinum CHEBI:63598 Levofloxacin levofloxacin CHEBI:63598 A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown. 6694 CHEBI:6718 ChemIDplus:53230-10-7 CiteXplore:21118921 CiteXplore:21853223 CiteXplore:21861987 CiteXplore:22006004 CiteXplore:22217970 CiteXplore:22223333 CiteXplore:22232280 CiteXplore:22233563 CiteXplore:22236373 CiteXplore:22245668 CiteXplore:22246492 DrugBank:DB00358 KEGG COMPOUND:53230-10-7 KEGG COMPOUND:C07633 KEGG DRUG:D04895 Reaxys:5306591 Wikipedia:Mefloquine rac--(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol Racemic mefloquine [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol [DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)]-4-quinolinemethanol mefloquina mefloquine mefloquinum CHEBI:63609 Mefloquine mefloquine CHEBI:63609 A diastereoisomeric mixture composed of approximately equal amounts of a double racemate of four of the sixteen possible diastereoisomers of methyl (13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate that is racemic prostaglandin E1 which is lacking the hydroxy group at position 15, but which has an additional hydroxy group at position 16. It is a synthetic prostaglandin E1 analogue, used in the treatment of gastric and duodenal ulcers. A weak abortifacient, it is also used for cervical ripening prior to surgical termination of pregnancy. The (11R,16S)-diastereoisomer is the pharmacologically active form. 42331 CHEBI:6952 ChemIDplus:59122-46-2 CiteXplore:10945193 CiteXplore:10949752 CiteXplore:11136959 CiteXplore:1417145 CiteXplore:18690850 CiteXplore:19740175 CiteXplore:2109814 CiteXplore:3080288 DrugBank:DB00929 KEGG DRUG:59122-46-2 KEGG DRUG:D00419 Patent:BE827127 Patent:US3965143 Reaxys:4155643 Wikipedia:Misoprostol (+-)-methyl (1R,2R,3R)-3-hydroxy-2-((E)-(4RS)-4-hydroxy-4-methyl-1-octenyl)-5-oxocyclopentaneheptanoate (11-alpha,13E)-(+-)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oic acid methyl ester Arthrotec Cytotec Methyl (+-)-11-alpha,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate misoprostol misoprostolum CHEBI:63610 Misoprostol misoprostol CHEBI:63610 A quinolone that consits of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents. 139462 CHEBI:7007 ChemIDplus:151096-09-2 DrugBank:DB00218 KEGG COMPOUND:C07663 KEGG DRUG:D08237 Patent:EP550903 Reaxys:8365827 Wikipedia:Moxifloxacin 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid Moxifloxacin 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid C21H24FN3O4 InChI=1S/C21H24FN3O4/c1-29-20-17-13(19(26)14(21(27)28)9-25(17)12-4-5-12)7-15(22)18(20)24-8-11-3-2-6-23-16(11)10-24/h7,9,11-12,16,23H,2-6,8,10H2,1H3,(H,27,28)/t11-,16+/m0/s1 InChIKey=FABPRXSRWADJSP-MEDUHNTESA-N [H][C@@]12CCCN[C@]1([H])CN(C2)c1c(F)cc2c(c1OC)n(cc(C(O)=O)c2=O)C1CC1 moxifloxacin CHEBI:63611 moxifloxacin CHEBI:63611 A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction. 8047 CHEBI:8020 ChemIDplus:66104-22-1 CiteXplore:11852289 CiteXplore:15180134 CiteXplore:16845152 CiteXplore:18071034 CiteXplore:2012117 DrugBank:DB01186 KEGG COMPOUND:66104-22-1 KEGG COMPOUND:C07425 KEGG DRUG:D08339 Patent:US4166182 Reaxys:5091461 Wikipedia:Pergolide (8beta)-8-[(methylsulfanyl)methyl]-6-propylergoline C19H26N2S InChI=1S/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1 InChIKey=YEHCICAEULNIGD-MZMPZRCHSA-N [H][C@@]12Cc3c[nH]c4cccc(c34)[C@@]1([H])C[C@@H](CSC)CN2CCC pergolida pergolide pergolidum CHEBI:63617 Pergolide pergolide CHEBI:63617 A carboxylic ester resulting from the formal condensation or (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin. 42463 CHEBI:8360 ChemIDplus:81093-37-0 CiteXplore:21749370 CiteXplore:21851379 DrugBank:DB00175 HMDB:HMDB05022 KEGG COMPOUND:81093-37-0 KEGG COMPOUND:C01844 KEGG DRUG:D08410 Reaxys:4825538 Wikipedia:Pravastatin (3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid (+)-(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid C23H36O7 InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1 InChIKey=TUZYXOIXSAXUGO-PZAWKZKUSA-N [H][C@]12[C@H](C[C@H](O)C=C1C=C[C@H](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC pravastatin pravastatin acid pravastatina pravastatine pravastatinum CHEBI:63618 Pravastatin pravastatin CHEBI:63618 A ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias. 8754 CHEBI:8465 ChemIDplus:54063-53-5 CiteXplore:8777484 DrugBank:DB01182 KEGG COMPOUND:54063-53-5 KEGG COMPOUND:C07381 KEGG DRUG:D08435 Patent:DE2001431 Reaxys:2175182 Wikipedia:Propafenone 1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone 2-(2'-hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone C21H27NO3 CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1 InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3 InChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N propafenona propafenone propafenonum CHEBI:63619 Propafenone propafenone CHEBI:63619 A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is sustituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. 9947 CHEBI:9206 ChemIDplus:3930-20-9 CiteXplore:20562595 CiteXplore:21553267 CiteXplore:21854895 DrugBank:DB00489 KEGG COMPOUND:3930-20-9 KEGG COMPOUND:C07309 KEGG DRUG:D08525 Reaxys:2380820 Wikipedia:Sotalol N-{4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl}methanesulfonamide Sotalol 4'-(1-hydroxy-2-(isopropylamino)ethyl)methane sulfonanilide C12H20N2O3S CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1 InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3 InChIKey=ZBMZVLHSJCTVON-UHFFFAOYSA-N beta-cardone sotalol sotalolum CHEBI:63622 Sotalol sotalol CHEBI:63622 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent. 10612 CHEBI:32227 CiteXplore:5458368 DrugBank:DB00911 KEGG DRUG:D01426 Patent:US3376311 Reaxys:618182 Wikipedia:Tinidazole 1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole C8H13N3O4S CCS(=O)(=O)CCn1c(C)ncc1[N+]([O-])=O InChI=1S/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3 InChIKey=HJLSLZFTEKNLFI-UHFFFAOYSA-N timidazole CHEBI:63627 Tinidazole tinidazole CHEBI:63627 A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor. 190548 ChemIDplus:174484-41-4 CiteXplore:17620375 CiteXplore:20368406 CiteXplore:21041916 CiteXplore:21571982 CiteXplore:21576452 CiteXplore:21825300 CiteXplore:21871444 CiteXplore:22007990 CiteXplore:22096044 CiteXplore:22258921 DrugBank:DB00932 KEGG DRUG:D08605 Reaxys:7698323 N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide 3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide C31H33F3N2O5S CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(cn3)C(F)(F)F)c2)C(=O)O1 InChI=1S/C31H33F3N2O5S/c1-3-16-30(17-15-21-9-6-5-7-10-21)19-26(37)28(29(38)41-30)25(4-2)22-11-8-12-24(18-22)36-42(39,40)27-14-13-23(20-35-27)31(32,33)34/h5-14,18,20,25,36-37H,3-4,15-17,19H2,1-2H3/t25-,30-/m1/s1 InChIKey=SUJUHGSWHZTSEU-FYBSXPHGSA-N tipranavir CHEBI:63628 tipranavir CHEBI:63628 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites. 57258 CHEBI:9608 ChemIDplus:51322-75-9 ChemIDplus:618691 CiteXplore:21317414 CiteXplore:21733633 CiteXplore:21982341 CiteXplore:22196407 CiteXplore:22223284 DrugBank:DB00697 KEGG COMPOUND:51322-75-9 KEGG COMPOUND:C07452 KEGG DRUG:D08611 Patent:US3843668 Reaxys:618691 Wikipedia:Tizanidine 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine Tizanidine 5-Chloro-4-(2-imidazolin-2-ylamino)-2,1,3-benzothiadiazole C9H8ClN5S Clc1ccc2nsnc2c1NC1=NCCN1 InChI=1S/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13) InChIKey=XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidina tizanidine tizanidinum CHEBI:63629 tizanidine CHEBI:63629 A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine. 38404 CHEBI:9633 ChemIDplus:97240-79-4 CiteXplore:22233396 CiteXplore:22249827 DrugBank:DB00273 KEGG COMPOUND:97240-79-4 KEGG COMPOUND:C07502 KEGG DRUG:D00537 Patent:US4513006 Reaxys:5988957 Wikipedia:Topiramate Topiramate 2,3:4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose sulfamate C12H21NO8S CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1 InChI=1S/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1 InChIKey=KJADKKWYZYXHBB-XBWDGYHZSA-N McN-4853 RWJ-17021 TPM Topamax tipiramate tipiramato topiramate topiramato topiramatum CHEBI:63631 topiramate CHEBI:63631 A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks. 57308 CHEBI:9634 ChemIDplus:123948-87-8 CiteXplore:20574789 CiteXplore:21255983 CiteXplore:21352915 CiteXplore:21910214 CiteXplore:22028494 CiteXplore:22075006 CiteXplore:22136714 CiteXplore:22190039 DrugBank:DB01030 KEGG COMPOUND:123948-87-8 KEGG COMPOUND:C11158 KEGG DRUG:D08618 Patent:EP321122 Reaxys:4279441 Wikipedia:Topotecan (4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione Topotecan 9-[(dimethylamino)methyl]-10-hydroxy-(4S)-camptothecin C23H23N3O5 CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O InChI=1S/C23H23N3O5/c1-4-23(30)16-8-18-20-12(9-26(18)21(28)15(16)11-31-22(23)29)7-13-14(10-25(2)3)19(27)6-5-17(13)24-20/h5-8,27,30H,4,9-11H2,1-3H3/t23-/m0/s1 InChIKey=UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan topotecane topotecanum CHEBI:63632 Topotecan topotecan CHEBI:63632 Any organic heterobicyclic compound containing ortho-fused pyrrolidine and piperidine rings. CHEBI:63697 pyrrolidinopiperidine CHEBI:63697 A sulfoxide that has formula C16H14F3N3O2S. 17128 Beilstein:4333393 ChemIDplus:103577-45-3 KEGG DRUG:D00355 Patent:EP174726 Patent:US4628098 Wikipedia:Lansoprazole 2-({[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole AG 1749 Bamalite C16H14F3N3O2S Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1 InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) InChIKey=MJIHNNLFOKEZEW-UHFFFAOYSA-N Lanzol Lanzopral Lanzul Limpidex Monolitum Ogastro Opiren Prevacid lansoprazol lansoprazolum CHEBI:6375 lansoprazole CHEBI:6375 An isoxazole that has formula C12H9F3N2O2. 27169 Beilstein:4323174 ChemIDplus:75706-12-6 KEGG COMPOUND:75706-12-6 KEGG COMPOUND:C07905 KEGG DRUG:D00749 Wikipedia:Leflunomide 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Leflunomide 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide Arava (TN) C12H9F3N2O2 Cc1oncc1C(=O)Nc1ccc(cc1)C(F)(F)F InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) InChIKey=VHOGYURTWQBHIL-UHFFFAOYSA-N alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide CHEBI:6402 leflunomide CHEBI:6402 An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty. 42375 ChemIDplus:53714-56-0 DrugBank:DB00007 KEGG COMPOUND:53714-56-0 KEGG COMPOUND:C07612 KEGG DRUG:D08113 Patent:DE2446005 Patent:US4005063 Reaxys:741818 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide (D-Leu(6),des-Gly-NH2(10),Pro-ethylamide(9))-gonadotropin-releasing hormone C59H84N16O12 CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1 InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1 InChIKey=GFIJNRVAKGFPGQ-LIJARHBVSA-N L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-leucyl-L-leucyl-L-arginyl-L-proline ethylamide Leuprorelin leuprorelina leuproreline leuprorelinum pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHC2H5 pGlu-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEt CHEBI:6427 Leuprolide leuprolide CHEBI:6427 CHEBI:64459 biaryl CHEBI:64459 A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position 52175 Beilstein:4770867 ChemIDplus:114798-26-4 CiteXplore:15703421 DrugBank:DB00678 KEGG COMPOUND:114798-26-4 KEGG COMPOUND:C07072 KEGG DRUG:D08146 Patent:EP253310 Patent:US5138069 Reaxys:4770867 Wikipedia:Losartan (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol Losartan (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole C22H23ClN6O CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1 InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) InChIKey=PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan CHEBI:6541 Losartan losartan CHEBI:6541 A 17alpha-hydroxy steroid that has formula C22H30O3. 6703 Beilstein:3164843 ChemIDplus:3562-63-8 DrugBank:DB00351 KEGG COMPOUND:C07120 KEGG DRUG:D08167 17-hydroxypregna-4,6-diene-3,20-dione Megestrol 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione C22H30O3 InChI=1S/C21H28O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4-5,12,16-18,24H,6-11H2,1-3H3/t16-,17+,18+,19+,20+,21+/m1/s1 InChIKey=JBVNBBXAMBZTMQ-CEGNMAFCSA-N [H][C@]12CC[C@@]3(C)[C@@]([H])(CC[C@]3(O)C(C)=O)[C@]1([H])C=CC1=CC(=O)CC[C@]21C megestrol megestrolum CHEBI:6722 Megestrol megestrol CHEBI:6722 An aromatic amine comprising salicylic acid having an amino group at the 5-position. 52582 Beilstein:2090421 DrugBank:DB00244 KEGG DRUG:D00377 Wikipedia:Mesalamine 5-amino-2-hydroxybenzoic acid 3-carboxy-4-hydroxyaniline 5-ASA 5-Aminosalicylic acid Asacol Asacolitin C7H7NO3 Canasa Claversal Fisalamine Iialda InChI=1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11) InChIKey=KBOPZPXVLCULAV-UHFFFAOYSA-N Lixacol Mesalazina Mesalazine Mesalazinum Mesasal Nc1ccc(O)c(c1)C(O)=O Pentasa Rowasa Salofalk m-Aminosalicylic acid mesalazine p-Aminosalicylsaeure CHEBI:6775 mesalamine CHEBI:6775 A guanidine that has formula C4H11N5. 6809 ChemIDplus:657-24-9 KEGG COMPOUND:657-24-9 KEGG COMPOUND:C07151 Wikipedia:Metformin Metformin N,N-dimethylimidodicarbonimidic diamide 1,1-Dimethylbiguanide C4H11N5 CN(C)C(=N)NC(N)=N InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8) InChIKey=XZWYZXLIPXDOLR-UHFFFAOYSA-N CHEBI:6801 Metformin metformin CHEBI:6801 A 6-methylprednisolone that has formula C22H30O5. 6902 Beilstein:2340300 ChemIDplus:83-43-2 DrugBank:DB00959 KEGG DRUG:D00407 NIST Chemistry WebBook:83-43-2 Patent:US2897218 Patent:US3053832 Wikipedia:Methylprednisolone 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione 1-dehydro-6alpha-methylhydrocortisone 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione C22H30O5 Delta(1)-6alpha-methylhydrocortisone InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 InChIKey=VHRSUDSXCMQTMA-PJHHCJLFSA-N Medrate Medrol Medrone Methylprednisolon Solomet Urbason [H][C@@]12C[C@H](C)C3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO methylprednisolone methylprednisolonum metilprednisolona CHEBI:6888 6alpha-methylprednisolone Methylprednisolone CHEBI:6888 Imidazole substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. 6922 CHEBI:63636 Beilstein:611683 ChemIDplus:443-48-1 CiteXplore:11906111 CiteXplore:14702395 CiteXplore:15739364 CiteXplore:16901452 CiteXplore:18397330 CiteXplore:19485831 CiteXplore:22226009 CiteXplore:22252819 DrugBank:DB00916 KEGG DRUG:D00409 NIST Chemistry WebBook:443-48-1 Patent:US2944061 Reaxys:611683 Wikipedia:Metronidazole 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol 1-(beta-Ethylol)-2-methyl-5-nitro-3-azapyrrole Arilin C6H9N3O3 Cc1ncc(n1CCO)[N+]([O-])=O Clont Efloran Elyzol Entizol Flagyl Fossyol InChI=1S/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3 InChIKey=VAOCPAMSLUNLGC-UHFFFAOYSA-N Klion Klont Metrocream Metrogel Metrogel-Vaginal Metrolyl Metrotop Nalox Nidagel Noritate Novonidazol Protostat Trichex Trichopol Tricowas B Trikacide Trikozol Vagilen Vagimid Vertisal Zadstat metronidazole CHEBI:6909 Metronidazole metronidazole CHEBI:6909 7454 CHEBI:7591 Nitrofurantoin nitrofurantoin CHEBI:7591 A tricyclic antidepressant that has formula C19H21N. 7531 ChemIDplus:2216786 ChemIDplus:72-69-5 KEGG COMPOUND:72-69-5 KEGG COMPOUND:C07274 NIST Chemistry WebBook:72-69-5 Wikipedia:Nortriptyline 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine Nortriptyline 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine Ateben Avantyl Aventyl C19H21N CNCCC=C1c2ccccc2CCc2ccccc12 InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 InChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N Noritren Psychostyl Sensaval demethylamitriptyline desmethylamitriptyline CHEBI:7640 Nortriptyline nortriptyline CHEBI:7640 A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. 7623 CHEBI:100146 ChEMBL:100146 CiteXplore:11710934 DrugBank:DB01165 KEGG COMPOUND:82419-36-1 KEGG COMPOUND:C07321 KEGG DRUG:D00453 Wikipedia:Ofloxacin 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid 8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid C18H20FN3O4 CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O InChI=1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25) InChIKey=GSDSWSVVBLHKDQ-UHFFFAOYSA-N OFLX ofloxacin CHEBI:7731 Ofloxacin ofloxacin CHEBI:7731 A sulfoxide having 3-methoxybenzimidazol-3-yl and 4-methoxy-3,5-dimethylpyridin-2-ylmethyl groups attached to the sulfur. 7646 Beilstein:3628192 ChemIDplus:73590-58-6 CiteXplore:11060758 CiteXplore:11208500 CiteXplore:11210716 CiteXplore:11304936 CiteXplore:11321383 CiteXplore:11395292 CiteXplore:11404722 CiteXplore:11459434 CiteXplore:11568514 CiteXplore:11700946 CiteXplore:11774962 CiteXplore:11807212 CiteXplore:11851112 CiteXplore:11903739 CiteXplore:11962536 CiteXplore:12072663 CiteXplore:12135028 CiteXplore:12235248 CiteXplore:12495367 CiteXplore:12683615 CiteXplore:13680386 CiteXplore:14616415 CiteXplore:14708212 CiteXplore:14725575 CiteXplore:15004262 CiteXplore:15125696 CiteXplore:15586641 CiteXplore:15598025 CiteXplore:15684503 CiteXplore:15707461 CiteXplore:15774534 CiteXplore:16080278 CiteXplore:16129922 CiteXplore:16259581 CiteXplore:16276979 CiteXplore:16380990 CiteXplore:16386527 CiteXplore:16397810 CiteXplore:16440530 CiteXplore:16998872 CiteXplore:17049542 CiteXplore:17384694 CiteXplore:17532167 CiteXplore:18294333 CiteXplore:18366242 CiteXplore:18416943 CiteXplore:18448060 CiteXplore:18498918 CiteXplore:18520598 CiteXplore:18571645 CiteXplore:18616070 CiteXplore:18793272 CiteXplore:18818790 CiteXplore:19150046 CiteXplore:19166730 CiteXplore:19176055 CiteXplore:19236757 CiteXplore:19327607 CiteXplore:19383986 CiteXplore:19434360 CiteXplore:19470853 CiteXplore:19517893 CiteXplore:19746659 CiteXplore:19796313 CiteXplore:19801857 CiteXplore:19937171 DrugBank:DB00338 KEGG COMPOUND:C07324 KEGG DRUG:D00455 Patent:EP5129 Patent:US4255431 Patent:US5693818 Reaxys:3628192 Wikipedia:Omeprazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Antra Audazol Belmazol C17H19N3O3S COc1ccc2[nH]c(nc2c1)S(=O)Cc1ncc(C)c(OC)c1C Ceprandal Danlox Desec Elgam Emeproton Gasec Gastrimut InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20) InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N Indurgan Inhibitron Losec OMEP OMP OMZ Olit Omapren Omebeta Prazidec Procelac Sanamidol Ulceral Ulcesep Ultop omeprazol omeprazole omeprazolum CHEBI:7772 Omeprazole omeprazole CHEBI:7772 A benzimidazole that has formula C16H15F2N3O4S. 40790 Beilstein:5361474 ChemIDplus:102625-70-7 DrugBank:DB00213 KEGG COMPOUND:C11806 KEGG DRUG:D05353 Patent:EP166287 Patent:US4758579 Wikipedia:Pantoprazole 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole C16H15F2N3O4S COc1ccnc(CS(=O)c2nc3cc(OC(F)F)ccc3[nH]2)c1OC InChI=1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21) InChIKey=IQPSEEYGBUAQFF-UHFFFAOYSA-N pantoprazol pantoprazole pantoprazolum CHEBI:7915 pantoprazole CHEBI:7915 A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo. 32937 Beilstein:7467879 ChemIDplus:61869-08-7 CiteXplore:11009210 CiteXplore:11169163 CiteXplore:11271409 CiteXplore:11281965 CiteXplore:11324355 CiteXplore:11360029 CiteXplore:11513198 CiteXplore:11563413 CiteXplore:11565622 CiteXplore:11819027 CiteXplore:11893234 CiteXplore:11910269 CiteXplore:12027788 CiteXplore:12088162 CiteXplore:12369443 CiteXplore:12421645 CiteXplore:12818234 CiteXplore:12820211 CiteXplore:12906023 CiteXplore:12920419 CiteXplore:14516531 CiteXplore:14521492 CiteXplore:14566196 CiteXplore:14566200 CiteXplore:14619895 CiteXplore:14624192 CiteXplore:14673053 CiteXplore:14689334 CiteXplore:14978354 CiteXplore:15048901 CiteXplore:15199661 CiteXplore:15241233 CiteXplore:15264994 CiteXplore:15374134 CiteXplore:15376524 CiteXplore:15544025 CiteXplore:15613191 CiteXplore:15845695 CiteXplore:15853570 CiteXplore:15903129 CiteXplore:15963219 CiteXplore:15992089 CiteXplore:16395417 CiteXplore:16397315 CiteXplore:16426087 CiteXplore:16765127 CiteXplore:16822276 CiteXplore:16913391 CiteXplore:17122538 CiteXplore:17162096 CiteXplore:17219219 CiteXplore:17286545 CiteXplore:17452166 CiteXplore:17559097 CiteXplore:17612590 CiteXplore:17652957 CiteXplore:17874333 CiteXplore:18273418 CiteXplore:18345955 CiteXplore:18808757 CiteXplore:18983224 CiteXplore:19687003 CiteXplore:19851065 CiteXplore:21404089 CiteXplore:21452176 CiteXplore:21739267 CiteXplore:21908494 CiteXplore:21909633 CiteXplore:21922171 CiteXplore:21939725 CiteXplore:22153922 CiteXplore:22198456 CiteXplore:22212003 CiteXplore:22240860 CiteXplore:22263916 CiteXplore:22283559 CiteXplore:22353759 CiteXplore:22377745 DrugBank:DB00715 KEGG COMPOUND:61869-08-7 KEGG COMPOUND:C07415 KEGG DRUG:D02362 Reaxys:7467879 Wikipedia:Paroxetine (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine Paroxetine (-)-(3S,4R)-4-(p-fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine (3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine C19H20FNO3 InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 InChIKey=AHOUBRCZNHFOSL-YOEHRIQHSA-N [H][C@]1(CCNC[C@H]1COc1ccc2OCOc2c1)c1ccc(F)cc1 paroxetina paroxetinum CHEBI:7936 Paroxetine paroxetine CHEBI:7936 A imidazolidine-2,4-dione that consists of hydantoin bearing two phenyl substituents at position 5. 8183 CHEBI:100921 Beilstein:384532 ChEMBL:100921 ChemIDplus:57-41-0 CiteXplore:7602118 DrugBank:DB00252 KEGG COMPOUND:57-41-0 KEGG COMPOUND:C07443 KEGG DRUG:D00512 Wikipedia:Phenytoin 5,5-diphenylimidazolidine-2,4-dione 5,5-Diphenyl-imidazolidine-2,4-dione 5,5-diphenylimidazolidine-2,4-dione 5,5-diphenyltetrahydro-1H-2,4-imidazoledione C15H12N2O2 DILANTIN InChI=1S/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19) InChIKey=CXOFVDLJLONNDW-UHFFFAOYSA-N O=C1NC(=O)C(N1)(c1ccccc1)c1ccccc1 PHENTYTOIN CHEBI:8107 Phenytoin phenytoin CHEBI:8107 A thiazolidenedione that has formula C19H20N2O3S. 33738 Beilstein:3595485 ChemIDplus:111025-46-8 DrugBank:DB01132 KEGG COMPOUND:111025-46-8 KEGG COMPOUND:C07675 Patent:EP193256 Patent:US4687777 Wikipedia:Pioglitazone 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione Pioglitazone (+-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione C19H20N2O3S CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1 InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23) InChIKey=HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazona pioglitazone pioglitazonum CHEBI:8228 pioglitazone CHEBI:8228 A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively. 746741 Beilstein:6479326 ChemIDplus:104632-26-0 DrugBank:DB00413 KEGG DRUG:D05575 Patent:EP186087 Patent:US4886812 Wikipedia:Pramipexole (6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine (-)-Pramipexole 2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N(sup 6)-propyl-, (S)- C10H17N3S CCCN[C@H]1CCc2nc(N)sc2C1 InChI=1S/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1 InChIKey=FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexol pramipexole pramipexolum CHEBI:8356 Pramipexole pramipexole CHEBI:8356 A 21-hydroxy steroid that has formula C21H28O5. 8638 ChemIDplus:1354103 ChemIDplus:50-24-8 KEGG COMPOUND:50-24-8 KEGG COMPOUND:C07369 Wikipedia:Prednisolone 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione Prednisolone (11beta)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione 1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione 1,4-pregnadiene-3,20-dione-11beta,17alpha,21-triol 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene C21H28O5 Delta(1)-dehydrocortisol Delta(1)-dehydrohydrocortisone Delta(1)-hydrocortisone InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 InChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO hydroretrocortine metacortandralone CHEBI:8378 prednisolone CHEBI:8378 A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group. 8794 Beilstein:130039 ChemIDplus:51-52-5 CiteXplore:11005705 CiteXplore:11036881 CiteXplore:11350963 CiteXplore:11401533 CiteXplore:12135875 CiteXplore:12922945 CiteXplore:14692727 CiteXplore:14745920 CiteXplore:16380675 CiteXplore:16498810 CiteXplore:16880639 CiteXplore:17365943 CiteXplore:17497002 CiteXplore:17878268 CiteXplore:18055877 CiteXplore:18710353 CiteXplore:19530273 CiteXplore:19578601 CiteXplore:20166204 CiteXplore:21749382 CiteXplore:6387489 DrugBank:DB00550 Gmelin:1998546 KEGG COMPOUND:51-52-5 KEGG COMPOUND:C07569 KEGG DRUG:D00562 NIST Chemistry WebBook:51-52-5 Reaxys:130039 Wikipedia:Propylthiouracil 6-propyl-2-sulfanylidene-2,3-dihydropyrimidin-4(1H)-one 6-propyl-2-thiouracil 2,3-dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone 2-Mercapto-6-propyl-4-pyrimidone 2-Mercapto-6-propylpyrimid-4-one 2-Thio-4-oxo-6-propyl-1,3-pyrimidine 2-Thio-6-propyl-1,3-pyrimidin-4-one 4-Propyl-2-thiouracil 4-propyl-2-thiouracil 6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione 6-Propylthiouracil 6-Thio-4-propyluracil 6-propyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one C7H10N2OS CCCc1cc(=O)[nH]c(=S)[nH]1 InChI=1S/C7H10N2OS/c1-2-3-5-4-6(10)9-7(11)8-5/h4H,2-3H2,1H3,(H2,8,9,10,11) InChIKey=KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracil propiltiouracilo propylthiouracil propylthiouracile propylthiouracilum CHEBI:8502 6-propyl-2-thiouracil Propylthiouracil CHEBI:8502 A tricyclic antidepressant that has formula C19H21N. 8886 ChemIDplus:2217411 ChemIDplus:438-60-8 KEGG COMPOUND:438-60-8 KEGG COMPOUND:C07408 NIST Chemistry WebBook:438-60-8 Wikipedia:Protriptyline 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine Protriptyline 3-(5H-dibenzo[a,d]cyclohepten-5-yl)-N-methyl-1-propanamine 5-(3-methylaminopropyl)-5H-dibenzo[a,d]cycloheptene 7-(3-methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene C19H21N CNCCCC1c2ccccc2C=Cc2ccccc12 InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3 InChIKey=BWPIARFWQZKAIA-UHFFFAOYSA-N N-methyl-5H-dibenzo[a,d]cycloheptene-5-propanamine N-methyl-5H-dibenzo[a,d]cycloheptene-5-propylamine amimetilina CHEBI:8597 Protriptyline protriptyline CHEBI:8597 A sulfoxide that has formula C18H21N3O3S. 114979 Beilstein:8159014 ChemIDplus:117976-89-3 DrugBank:DB01129 KEGG COMPOUND:117976-89-3 KEGG COMPOUND:C07864 Wikipedia:Rabeprazole 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole Rabeprazole C18H21N3O3S COCCCOc1ccnc(CS(=O)c2nc3ccccc3[nH]2)c1C Clofezone InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21) InChIKey=YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole CHEBI:8768 rabeprazole CHEBI:8768 A cyclopentapyrrole that has formula C23H32N2O5. 35296 Beilstein:4214464 ChemIDplus:87333-19-5 KEGG DRUG:87333-19-5 KEGG DRUG:D00421 Wikipedia:Ramipril (2S,3aS,6aS)-1-[(2S)-2-{[(1S)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid Ramipril (2S-(1(R*(R*)),2alpha,3abeta,6abeta))-1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid. Altace (TN) C23H32N2O5 InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1 InChIKey=HDACQVRGBOVJII-JBDAPHQKSA-N Tritace [H][C@@]12CCC[C@]1([H])N([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC CHEBI:8774 Ramipril ramipril CHEBI:8774 An indolone that has formula C16H24N2O. 72302 Beilstein:6062222 ChemIDplus:91374-21-9 DrugBank:DB00268 KEGG COMPOUND:C07564 Patent:US4452808 Wikipedia:Ropinirole 4-[2-(dipropylamino)ethyl]-1,3-dihydro-2H-indol-2-one Ropinirole C16H24N2O CCCN(CCC)CCc1cccc2NC(=O)Cc12 InChI=1S/C16H24N2O/c1-3-9-18(10-4-2)11-8-13-6-5-7-15-14(13)12-16(19)17-15/h5-7H,3-4,8-12H2,1-2H3,(H,17,19) InChIKey=UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirol ropinirole ropinirolum CHEBI:8888 ropinirole CHEBI:8888 A fatty acid ester comprising a dihydroxyheptanoic acid unit condensed into a lactone; a partially reduced naphthalene structure; and a 2,2-dimethylbutyric acyl substituent at C17. It is used as a cholesterol-lowering and anti-cardiovascular disease drug. 36567 CHEBI:45577 Beilstein:4768037 ChemIDplus:79902-63-9 DrugBank:DB00641 KEGG DRUG:79902-63-9 KEGG DRUG:D00434 Patent:EP33538 Patent:US4444784 Wikipedia:Simvastatin (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate Simvastatin 2,2-dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one C25H38O5 InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1 InChIKey=RYMZZMVNJRMUDD-HGQWONQESA-N MK-733 Simvastatina Simvastatine Simvastatinum Zocor [H][C@]12[C@H](C[C@@H](C)C=C1C=C[C@H](C)[C@@H]2CC[C@@H]1C[C@@H](O)CC(=O)O1)OC(=O)C(C)(C)CC simvastatin CHEBI:9150 Simvastatin simvastatin CHEBI:9150 An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position. 9524 CHEBI:101223 Beilstein:356241 Beilstein:8132868 ChemIDplus:599-79-1 CiteXplore:2434548 DrugBank:DB00795 Gmelin:2666050 KEGG COMPOUND:599-79-1 KEGG COMPOUND:C07316 KEGG DRUG:D00448 Patent:US2396145 Reaxys:8132868 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid Sulfasalazine 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid Azulfidine C18H14N4O5S InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+ InChIKey=NCEXYHBECQHGNR-QZQOTICOSA-N OC(=O)c1cc(ccc1O)\N=N\c1ccc(cc1)S(=O)(=O)Nc1ccccn1 Salazosulfapiridina Salazosulfapyridine Salazosulfapyridinum Salicylazosulfapyridine Sulfasalazina Sulfasalazinum sulfasalazine CHEBI:9334 Sulfasalazine sulfasalazine CHEBI:9334 A thienopyridine that has formula C14H14ClNS. 10594 ChemIDplus:55142-85-3 DrugBank:DB00208 KEGG COMPOUND:C07140 Patent:DE2404308 Patent:US4051141 Patent:US4127580 Wikipedia:Ticlopidine 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine C14H14ClNS Clc1ccccc1CN1CCc2sccc2C1 InChI=1S/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2 InChIKey=PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidina ticlopidine ticlopidinum CHEBI:9588 Ticlopidine ticlopidine CHEBI:9588 10759 CHEBI:9667 Triamcinolone CHEBI:9667 A dibenzoazepine that has formula C20H26N2. 10834 ChemIDplus:1321466 ChemIDplus:739-71-9 KEGG DRUG:D00394 NIST Chemistry WebBook:739-71-9 Wikipedia:Trimipramine 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine Trimipramine 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine C20H26N2 CC(CN(C)C)CN1c2ccccc2CCc2ccccc12 InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3 InChIKey=ZSCDBOWYZJWBIY-UHFFFAOYSA-N RP-7162 Sapilent Trimeprimine beta-methylimipramine trimeproprimine CHEBI:9738 Trimipramine trimipramine CHEBI:9738 A cyclohexanol that has formula C17H27NO2. 39786 Beilstein:4234848 ChemIDplus:93413-69-5 DrugBank:DB00285 KEGG COMPOUND:93413-69-5 KEGG COMPOUND:C07187 Wikipedia:Venlafaxine 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol Venlafaxine C17H27NO2 COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1 Elafax InChI=1S/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3 InChIKey=PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxina venlafaxine venlafaxinum CHEBI:9943 venlafaxine CHEBI:9943 A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. CALOHA:TS-2035 FMA:68646 GO:0005623 KUPO:0000002 VHOG:0001533 WBbt:0004017 XAO:0003012 cell CL:0000000 The definition of cell is intended to represent all cells, and thus a cell is defined as a material entity and not an anatomical structure, which implies that it is part of an organism (or the entirety of one). cell CL:0000000 A cell that is found in a natural setting, which includes multicellular organism cells 'in vivo' (i.e. part of an organism), and unicellular organisms 'in environment' (i.e. part of a natural environment). CARO:0000013 cell in vivo cell CL:0000003 To accommodate unicellular organisms better, 'cell in vivo' has been re-labeled 'native cell' to better represent its intended meaning - that is, that it is a cell in the context of a multicellular organism or in a natural environment. 'Native' is intended to contrast with 'in vitro', which refers to cells or other biological entities that have been intentionally placed in a controlled, non-natural setting for the purpose of study or manipulation. (MAH 1.12.12). native cell CL:0000003 neuronal receptor cell (sensu Animalia) cell CL:0000006 neuronal receptor cell CL:0000006 A cell that will develop into a neuron often after a migration phase. BTO:0000930 FBbt:00005146 FMA:70563 cell CL:0000031 neuroblast CL:0000031 A relatively undifferentiated cell that retains the ability to divide and proliferate throughout life to provide progenitor cells that can differentiate into specialized cells. CALOHA:TS-2086 FMA:63368 cell CL:0000034 stem cell CL:0000034 Neural stem cell is characterized as an undifferentiated cell that originates from the neuroectoderm and has the capacity both to perpetually self-renew without differentiating and to generate multiple types of lineage-restricted progenitors. BTO:0002881 CALOHA:TS-2360 FMA:86684 NSC neural stem cell cell CL:0000047 neuronal stem cell CL:0000047 A stem cell that can give rise to multiple lineages of cells. FMA:84789 multi-fate stem cell multifate stem cell multipotent cell multipotent stem cell cell CL:0000048 multi fate stem cell CL:0000048 A stem cell from which all cells of the body can form. FMA:84790 totipotential stem cell cell CL:0000052 totipotent stem cell CL:0000052 A precursor cell with a limited number of potential fates. BTO:0000125 FMA:84782 blast cell cell CL:0000055 define using PATO mulit-potent or oligopotent? non-terminally differentiated cell CL:0000055 Any neuron having a sensory function; an afferent neuron conveying sensory impulses. BTO:0001037 FBbt:00005124 FMA:84649 WBbt:0005759 cell CL:0000101 sensory neuron CL:0000101 Ectoderm destined to be nervous tissue. neurectoderm cell cell CL:0000133 neurectodermal cell CL:0000133 A pigment cell is a cell that contains pigment granules. VHOG:0001678 chromatocyte chromatophore cell CL:0000147 pigment cell CL:0000147 pigment cell cell CL:0000149 visual pigment cell CL:0000149 cell CL:0000197 receptor cell CL:0000197 A cell specialized to detect and transduce light. BTO:0001060 CALOHA:TS-0868 FBbt:00004211 FMA:86740 cell CL:0000210 photoreceptor cell CL:0000210 A cell whose function is determined by the generation or the reception of an electric signal. cell CL:0000211 electrically active cell CL:0000211 A cell of the outer of the three germ layers of the embryo. FMA:72549 ectoderm cell cell CL:0000221 ectodermal cell CL:0000221 cell CL:0000255 eukaryotic cell CL:0000255 A cell that is specialised to accumulate a particular substance(s). cell CL:0000325 stuff accumulating cell CL:0000325 A cell of the outer layer of a blastula that gives rise to the ectoderm after gastrulation. cell CL:0000352 epiblast cell CL:0000352 A cell whose function is determined by its response to an electric signal. cell CL:0000393 electrically responsive cell CL:0000393 A cell that initiates an electrical signal and passes that signal to another cell. cell CL:0000404 electrically signaling cell CL:0000404 A neuron which conveys sensory information centrally from the periphery. FMA:87653 input neuron cell CL:0000526 afferent neuron CL:0000526 The basic cellular unit of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the nervous system. BTO:0000938 CALOHA:TS-0683 FBbt:00005106 FMA:54527 VHOG:0001483 WBbt:0003679 nerve cell cell CL:0000540 These cells are also reportedly CD4-negative and CD200-positive. They are also capable of producing CD40L and IFN-gamma. neuron CL:0000540 cell CL:0000548 animal cell CL:0000548 A stem cell that can give rise to cell types of the body other than those of the germ-line. CALOHA:TS-2086 FMA:63368 cell CL:0000723 somatic stem cell CL:0000723 A cell that is part of the nervous system. tmeehan 2010-09-15T01:34:57Z CALOHA:TS-2040 FMA:70333 cell CL:0002319 neural cell CL:0002319 A cell of the embryo. tmeehan 2010-09-15T03:39:21Z CALOHA:TS-0263 FMA:82840 FMA:82841 WBbt:0007028 cell CL:0002321 embryonic cell CL:0002321 A cell of an organism that does not pass on its genetic material to the organism's offspring (i.e. a non-germ line cell). tmeehan 2010-09-24T09:44:42Z BTO:0001268 FMA:72300 WBbt:0008378 cell CL:0002371 somatic cell CL:0002371 DRON:00000001 the role of a material entity to prevent, diagnose, treat, or study disease and/or its effects William Hogan William Hogan clinical drug role DRON:00000005 a material entity (1) containing at least one scattered molecular aggregate as part (the active ingredient) and (2) that is the bearer of a clinical drug role William Hogan William Hogan drug product DRON:00010174 5296 Altretamine DRON:00010402 194000 capecitabine DRON:00010449 221072 Cerivastatin sodium NDF-RT: N0000022124 RxNORM: RXNORM/221072 DRON:00010568 83816 Delavirdine NDF-RT: N0000022056 RxNORM: RXNORM/83816 DRON:00010978 28872 lomefloxacin DRON:00011221 32385 olsalazine DRON:00011289 7975 Penicillamine DRON:00011432 8702 Procarbazine DRON:00011589 3446 Succimer DRON:00011676 72937 tolcapone DRON:00011680 10636 Tolmetin DRON:00012123 41127 fluvastatin DRON:00012887 191831 infliximab NDF-RT: N0000148580 RxNORM: RXNORM/191831 DRON:00012978 14851 Vigabatrin DRON:00012980 70223 Aldesleukin DRON:00012990 10362 Teniposide DRON:00012997 196102 basiliximab NDF-RT: N0000148568 RxNORM: RXNORM/196102 DRON:00013025 224905 trastuzumab DRON:00013028 190376 linezolid DRON:00013030 18330 arsenic trioxide DRON:00013042 121191 rituximab DRON:00013467 1227 Auranofin DRON:00013468 16818 Acitretin DRON:00013476 35302 Sirolimus DRON:00013638 2105 Carmustine DRON:00013678 44281 cevimeline NDF-RT: N0000148658 RxNORM: RXNORM/44281 DRON:00013752 236646 Insulin, Protamine Zinc, Human DRON:00013763 231049 eletriptan NDF-RT: N0000148791 RxNORM: RXNORM/231049 DRON:00013779 68149 mycophenolate mofetil DRON:00013784 233272 bexarotene DRON:00013809 3363 Zalcitabine DRON:00013975 85248 alosetron DRON:00014193 139896 enfuvirtide NDF-RT: N0000148793 RxNORM: RXNORM/139896 DRON:00014194 135775 zolmitriptan DRON:00014197 138099 gemifloxacin NDF-RT: N0000148804 RxNORM: RXNORM/138099 DRON:00014250 22299 Daptomycin NDF-RT: N0000148828 RxNORM: RXNORM/22299 DRON:00014262 68446 pemetrexed DRON:00014428 8698 Probenecid DRON:00014630 2346 Chlorambucil NDF-RT: N0000147072 RxNORM: RXNORM/2346 DRON:00015719 232158 rofecoxib DRON:00015855 10179 Sulfamethizole DRON:00015922 10432 Thalidomide DRON:00015990 6916 Metolazone DRON:00016171 83395 Saquinavir DRON:00016203 4441 Flecainide DRON:00016418 50975 histrelin DRON:00016437 134748 rasagiline DRON:00016731 228476 gatifloxacin DRON:00016762 8120 Phenazopyridine DRON:00016899 183379 rivastigmine DRON:00016933 5966 Iopamidol DRON:00016952 253453 peginterferon alfa-2b DRON:00017214 38782 Triptorelin DRON:00017540 24698 fludarabine DRON:00017693 195085 efavirenz DRON:00017760 187832 pregabalin DRON:00017772 68244 Lamivudine DRON:00017827 6719 Memantine DRON:00017960 25480 gabapentin DRON:00018005 53654 Nevirapine DRON:00018093 214525 doxorubicin liposome NDF-RT: N0000147829 RxNORM: RXNORM/3639 DRON:00018173 41126 fluticasone DRON:00018221 136411 sildenafil DRON:00018348 279645 almotriptan NDF-RT: N0000148709 RxNORM: RXNORM/279645 DRON:00018583 278567 valdecoxib DRON:00018677 402316 Miglustat DRON:00018681 343047 Atazanavir NDF-RT: N0000022320 RxNORM: RXNORM/343047 DRON:00018683 358258 bortezomib DRON:00018685 358263 tadalafil DRON:00018691 358255 aprepitant NDF-RT: N0000148809 RxNORM: RXNORM/358255 DRON:00018693 282388 imatinib DRON:00018756 337525 erlotinib NDF-RT: N0000148872 RxNORM: RXNORM/337525 DRON:00018768 461016 Eszopiclone NDF-RT: N0000023088 RxNORM: RXNORM/461016 DRON:00018834 495881 sorafenib DRON:00018841 342369 lenalidomide NDF-RT: N0000171749 RxNORM: RXNORM/342369 DRON:00018842 274771 nelarabine DRON:00018864 618425 Nalidixate DRON:00018901 475342 dasatinib NDF-RT: N0000176043 RxNORM: RXNORM/475342 DRON:00018916 282446 posaconazole DRON:00018974 620216 maraviroc NDF-RT: N0000176115 RxNORM: RXNORM/620216 DRON:00018981 337523 ixabepilone NDF-RT: N0000176119 RxNORM: RXNORM/337523 DRON:00018985 662281 nilotinib DRON:00018993 475969 etravirine NDF-RT: N0000176133 RxNORM: RXNORM/475969 DRON:00019003 754763 Fosaprepitant dimeglumine NDF-RT: N0000176136 RxNORM: RXNORM/754763 DRON:00019225 819300 golimumab NDF-RT: N0000178413 RxNORM: RXNORM/819300 DRON:00019228 709271 certolizumab pegol DRON:00019457 275891 valganciclovir DRON:00019501 877015 levoleucovorin NDF-RT: N0000177954 RxNORM: RXNORM/877015 DRON:00019582 474128 telbivudine DRON:00019607 612865 tocilizumab DRON:00019850 968804 Cytarabine liposome NDF-RT: N0000146419 RxNORM: RXNORM/3041 DRON:00019892 996051 cabazitaxel NDF-RT: N0000181529 RxNORM: RXNORM/996051 DRON:00020017 1044584 tesamorelin DRON:00020018 1045453 eribulin NDF-RT: N0000182260 RxNORM: RXNORM/1045453 DRON:00020050 1094833 ipilimumab NDF-RT: N0000182641 RxNORM: RXNORM/1094833 DRON:00020131 1147220 Vemurafenib DRON:00020139 1148495 crizotinib NDF-RT: N0000183253 RxNORM: RXNORM/1148495 DRON:00020212 1291301 avanafil DRON:00020261 1302966 carfilzomib DRON:00020281 276237 emtricitabine DRON:00020282 300195 tenofovir disoproxil DRON:00020307 1310520 teriflunomide DRON:00020323 non-activating competitive beta-adrenergic receptor binding disposition DRON:00020324 function-inhibiting hydrogen/potassium adenosine triphosphatase enzyme (H+/K+ ATPase) binding disposition DRON:00020325 function-inhibiting L-type voltage-gated calcium channel binding disposition DRON:00020336 96819 Triamcinolone Oral Tablet NDF-RT: N0000145980 RxNORM: RXNORM/10759 DRON:00020337 103217 Dexamethasone Ophthalmic Ointment NDF-RT: N0000146273 RxNORM: RXNORM/3264 DRON:00020345 108133 Hydrocortisone Ophthalmic Ointment DRON:00020394 239053 Colchicine / Probenecid Oral Tablet NDF-RT: N0000145804 RxNORM: RXNORM/2683 DRON:00020444 361834 fluticasone Inhalant Powder DRON:00020458 370496 Carmustine Injectable Solution NDF-RT: N0000146473 RxNORM: RXNORM/2105 DRON:00020493 370533 Acitretin Oral Capsule NDF-RT: N0000148524 RxNORM: RXNORM/16818 DRON:00020504 370547 Allopurinol Oral Tablet NDF-RT: N0000146247 RxNORM: RXNORM/519 DRON:00020516 370559 Amantadine Oral Tablet NDF-RT: N0000147697 RxNORM: RXNORM/620 DRON:00020523 370568 Amiodarone Oral Tablet NDF-RT: N0000146406 NDF-RT: N0000147701 RxNORM: RXNORM/203114 RxNORM: RXNORM/703 DRON:00020525 370570 Amitriptyline Oral Tablet NDF-RT: N0000023131 RxNORM: RXNORM/203168 DRON:00020528 370573 Amlodipine Oral Tablet NDF-RT: N0000148333 RxNORM: RXNORM/17767 DRON:00020539 370588 anastrozole Oral Tablet NDF-RT: N0000148427 RxNORM: RXNORM/84857 DRON:00020557 370611 Aspirin Oral Tablet DRON:00020565 370621 atorvastatin Oral Tablet NDF-RT: N0000022046 RxNORM: RXNORM/83367 DRON:00020601 370657 hydroxyurea Oral Tablet NDF-RT: N0000146101 RxNORM: RXNORM/5552 DRON:00020620 370679 Imipramine Oral Tablet NDF-RT: N0000146215 NDF-RT: N0000147875 RxNORM: RXNORM/150816 RxNORM: RXNORM/5691 DRON:00020621 370680 Imipramine Oral Capsule NDF-RT: N0000146216 RxNORM: RXNORM/91118 DRON:00020625 370686 Indomethacin Oral Suspension NDF-RT: N0000146243 RxNORM: RXNORM/5781 DRON:00020635 370700 Iopamidol Injectable Solution NDF-RT: N0000146122 RxNORM: RXNORM/5966 DRON:00020645 370716 isoniazid Oral Tablet NDF-RT: N0000145890 RxNORM: RXNORM/6038 DRON:00020653 370725 Itraconazole Oral Capsule NDF-RT: N0000148264 RxNORM: RXNORM/28031 DRON:00020736 370819 Altretamine Oral Tablet NDF-RT: N0000147673 RxNORM: RXNORM/5296 DRON:00020868 370967 Auranofin Oral Tablet NDF-RT: N0000146358 RxNORM: RXNORM/1227 DRON:00020955 371065 Betaxolol Oral Tablet NDF-RT: N0000147726 RxNORM: RXNORM/1520 DRON:00020960 371070 bicalutamide Oral Tablet NDF-RT: N0000148428 RxNORM: RXNORM/83008 DRON:00021014 371127 Bromocriptine Oral Capsule DRON:00021046 371164 Buspirone Oral Tablet DRON:00021059 371181 Caffeine Oral Tablet DRON:00021113 371250 capecitabine Oral Tablet NDF-RT: N0000148555 RxNORM: RXNORM/996051 DRON:00021114 371251 Capsaicin Topical Solution NDF-RT: N0000147626 RxNORM: RXNORM/1992 DRON:00021345 371523 Ciprofloxacin Oral Capsule NDF-RT: N0000147503 RxNORM: RXNORM/2551 DRON:00021347 371525 Ciprofloxacin Oral Tablet NDF-RT: N0000147502 RxNORM: RXNORM/81981 DRON:00021386 371572 Clomipramine Oral Capsule NDF-RT: N0000147779 RxNORM: RXNORM/2597 DRON:00021423 371613 Codeine Oral Tablet DRON:00021462 371661 cyclobenzaprine Oral Tablet NDF-RT: N0000147791 RxNORM: RXNORM/21949 DRON:00021467 371666 Cyclosporine Oral Capsule NDF-RT: N0000147064 RxNORM: RXNORM/3008 DRON:00021489 371689 Dapsone Oral Tablet NDF-RT: N0000147467 RxNORM: RXNORM/3108 DRON:00021503 371709 Desipramine Oral Tablet NDF-RT: N0000147800 RxNORM: RXNORM/3247 DRON:00021599 371819 Didanosine Chewable Tablet NDF-RT: N0000148104 RxNORM: RXNORM/3364 DRON:00021629 371856 Diltiazem Oral Tablet NDF-RT: N0000147814 RxNORM: RXNORM/3443 DRON:00021698 371940 Disulfiram Oral Tablet NDF-RT: N0000146816 RxNORM: RXNORM/3554 DRON:00021749 372003 efavirenz Oral Capsule NDF-RT: N0000148587 RxNORM: RXNORM/195085 DRON:00021753 372007 Enalapril Oral Tablet DRON:00021832 372091 Ethambutol Oral Tablet NDF-RT: N0000146263 NDF-RT: N0000147838 RxNORM: RXNORM/142435 RxNORM: RXNORM/4110 DRON:00021860 372120 Etidronate Oral Tablet NDF-RT: N0000147844 RxNORM: RXNORM/42682 DRON:00021872 372132 Etoposide Oral Capsule NDF-RT: N0000146478 RxNORM: RXNORM/4179 DRON:00021897 372160 Fentanyl Injectable Solution NDF-RT: N0000147049 RxNORM: RXNORM/4337 DRON:00021934 372208 Fluconazole Oral Capsule NDF-RT: N0000147613 RxNORM: RXNORM/4450 DRON:00021937 372211 Flucytosine Oral Capsule NDF-RT: N0000146153 RxNORM: RXNORM/4451 DRON:00021951 372227 Fluorouracil Oral Capsule NDF-RT: N0000146166 RxNORM: RXNORM/4492 DRON:00021955 372231 Fluoxetine Oral Capsule DRON:00021976 372255 fluvastatin Oral Capsule NDF-RT: N0000021914 RxNORM: RXNORM/41127 DRON:00021977 372256 Fluvoxamine Oral Tablet NDF-RT: N0000148386 RxNORM: RXNORM/203143 DRON:00021999 372292 Ganciclovir Oral Capsule NDF-RT: N0000147855 RxNORM: RXNORM/4678 DRON:00022009 372302 Gentamicin Sulfate (USP) Injectable Solution DRON:00022073 372376 Haloperidol Oral Solution NDF-RT: N0000146461 RxNORM: RXNORM/5093 DRON:00022231 372563 Lamivudine Oral Tablet NDF-RT: N0000148418 RxNORM: RXNORM/68244 DRON:00022238 372570 leflunomide Oral Tablet NDF-RT: N0000148586 RxNORM: RXNORM/27169 DRON:00022244 372576 Leuprolide Injectable Solution DRON:00022253 372586 Levodopa Oral Tablet DRON:00022254 372588 Levofloxacin Oral Tablet NDF-RT: N0000148474 RxNORM: RXNORM/82122 DRON:00022275 372614 Lisinopril Oral Tablet NDF-RT: N0000147537 RxNORM: RXNORM/29046 DRON:00022291 372630 lomefloxacin Oral Tablet NDF-RT: N0000148144 NDF-RT: N0000148250 RxNORM: RXNORM/235762 RxNORM: RXNORM/28872 DRON:00022309 372651 Losartan Oral Tablet NDF-RT: N0000148401 NDF-RT: N0000148405 RxNORM: RXNORM/203160 RxNORM: RXNORM/52175 DRON:00022310 372652 Lovastatin Oral Tablet NDF-RT: N0000147602 RxNORM: RXNORM/6472 DRON:00022383 372745 Mefloquine Oral Tablet NDF-RT: N0000147900 RxNORM: RXNORM/6694 DRON:00022385 372747 Megestrol Oral Suspension NDF-RT: N0000020211 RxNORM: RXNORM/6703 DRON:00022395 372757 Memantine Oral Tablet DRON:00022419 372783 mesalamine Extended Release Capsule NDF-RT: N0000147614 RxNORM: RXNORM/52582 DRON:00022437 372803 Metformin Oral Tablet DRON:00022460 372827 Methimazole Oral Tablet NDF-RT: N0000145822 RxNORM: RXNORM/6835 DRON:00022468 372835 Methotrexate Injectable Solution NDF-RT: N0000147916 RxNORM: RXNORM/6851 DRON:00022495 372863 Methylprednisolone Topical Ointment NDF-RT: N0000146409 RxNORM: RXNORM/52582 DRON:00022497 372866 Methylprednisolone Injectable Suspension NDF-RT: N0000146411 RxNORM: RXNORM/155323 DRON:00022517 372888 Metolazone Oral Tablet NDF-RT: N0000146498 RxNORM: RXNORM/6916 DRON:00022521 372893 Metronidazole Oral Suspension NDF-RT: N0000146194 RxNORM: RXNORM/6922 DRON:00022568 372941 Misoprostol Oral Tablet NDF-RT: N0000147506 RxNORM: RXNORM/42331 DRON:00022663 373046 Nevirapine Oral Tablet NDF-RT: N0000148461 RxNORM: RXNORM/53654 DRON:00022714 373101 Nitrofurantoin Oral Tablet NDF-RT: N0000147151 RxNORM: RXNORM/7454 DRON:00022733 373120 Norfloxacin Oral Tablet NDF-RT: N0000147623 RxNORM: RXNORM/7517 DRON:00022739 373126 Nortriptyline Oral Tablet NDF-RT: N0000147946 RxNORM: RXNORM/7531 DRON:00022754 373141 Ofloxacin Oral Tablet NDF-RT: N0000147667 RxNORM: RXNORM/7623 DRON:00022757 373144 olsalazine Oral Tablet NDF-RT: N0000147671 RxNORM: RXNORM/104123 DRON:00022828 373222 pantoprazole Enteric Coated Tablet NDF-RT: N0000148654 RxNORM: RXNORM/40790 DRON:00022859 373258 Penicillamine Oral Tablet NDF-RT: N0000146290 RxNORM: RXNORM/7975 DRON:00022864 373263 Penicillin G Oral Solution DRON:00022867 373266 Penicillin V Oral Tablet NDF-RT: N0000145824 RxNORM: RXNORM/203195 DRON:00022889 373291 Pergolide Oral Tablet NDF-RT: N0000147968 RxNORM: RXNORM/8047 DRON:00022898 373303 Phenazopyridine Oral Tablet DRON:00023012 373432 Phenytoin Oral Tablet NDF-RT: N0000146211 RxNORM: RXNORM/8183 DRON:00023118 373560 Pravastatin Oral Tablet NDF-RT: N0000148255 RxNORM: RXNORM/42463 DRON:00023136 373578 prednisolone Oral Tablet DRON:00023158 373602 Procarbazine Oral Capsule DRON:00023184 373637 Propafenone Oral Tablet DRON:00023204 373658 Propylthiouracil Oral Tablet NDF-RT: N0000145820 RxNORM: RXNORM/8794 DRON:00023210 373665 Protriptyline Oral Tablet NDF-RT: N0000148003 RxNORM: RXNORM/8886 DRON:00023278 373749 Ramipril Oral Tablet NDF-RT: N0000147662 RxNORM: RXNORM/35296 DRON:00023302 373774 Ribavirin Oral Tablet DRON:00023323 373797 rivastigmine Oral Capsule NDF-RT: N0000148665 RxNORM: RXNORM/183379 DRON:00023325 373800 ropinirole Oral Tablet NDF-RT: N0000022086 RxNORM: RXNORM/72302 DRON:00023363 373842 Selegiline Oral Tablet NDF-RT: N0000148014 RxNORM: RXNORM/9639 DRON:00023379 373871 sildenafil Oral Tablet NDF-RT: N0000022115 RxNORM: RXNORM/136411 DRON:00023396 373888 Simvastatin Oral Tablet NDF-RT: N0000148200 RxNORM: RXNORM/36567 DRON:00023427 373937 Sotalol Oral Tablet NDF-RT: N0000148322 NDF-RT: N0000148334 RxNORM: RXNORM/7008 RxNORM: RXNORM/9947 DRON:00023447 373959 Stavudine Oral Capsule NDF-RT: N0000148369 RxNORM: RXNORM/59763 DRON:00023452 373964 Succimer Oral Capsule NDF-RT: N0000147417 RxNORM: RXNORM/3446 DRON:00023469 373981 Sulfamethizole Oral Tablet NDF-RT: N0000146815 DRON:00023479 373991 Sulfasalazine Oral Tablet NDF-RT: N0000146249 RxNORM: RXNORM/9524 DRON:00023497 374012 Sumatriptan Oral Tablet DRON:00023504 374020 Tamoxifen Oral Tablet NDF-RT: N0000148024 RxNORM: RXNORM/10324 DRON:00023599 374131 Ticlopidine Oral Tablet NDF-RT: N0000148235 RxNORM: RXNORM/10594 DRON:00023605 374138 Tinidazole Oral Tablet NDF-RT: N0000148851 RxNORM: RXNORM/10612 DRON:00023612 374146 tizanidine Oral Tablet NDF-RT: N0000148492 RxNORM: RXNORM/57258 DRON:00023613 374147 Tobramycin Injectable Solution DRON:00023619 374153 tolcapone Oral Tablet NDF-RT: N0000148551 RxNORM: RXNORM/72937 DRON:00023623 374157 Tolmetin Oral Tablet NDF-RT: N0000148037 RxNORM: RXNORM/10636 DRON:00023632 374166 topiramate Oral Tablet NDF-RT: N0000148493 RxNORM: RXNORM/38404 DRON:00023704 374239 Trimipramine Oral Tablet NDF-RT: N0000148047 RxNORM: RXNORM/10834 DRON:00023742 374285 venlafaxine Oral Tablet NDF-RT: N0000021906 RxNORM: RXNORM/39786 DRON:00023748 374291 Vigabatrin Oral Tablet NDF-RT: N0000171807 RxNORM: RXNORM/14851 DRON:00023781 374330 zafirlukast Oral Tablet NDF-RT: N0000148457 RxNORM: RXNORM/114970 DRON:00023783 374332 Zidovudine Oral Tablet NDF-RT: N0000147622 RxNORM: RXNORM/11413 DRON:00023808 374363 zolmitriptan Oral Tablet NDF-RT: N0000148550 RxNORM: RXNORM/135775 DRON:00023809 374364 zolpidem Oral Tablet NDF-RT: N0000021601 RxNORM: RXNORM/39993 DRON:00023989 374583 clopidogrel Oral Tablet DRON:00024008 374606 pioglitazone Oral Tablet DRON:00024010 374609 zaleplon Oral Capsule NDF-RT: N0000148625 RxNORM: RXNORM/74667 DRON:00024020 374619 moxifloxacin Oral Tablet NDF-RT: N0000148632 RxNORM: RXNORM/139462 DRON:00024022 374621 gatifloxacin Oral Tablet DRON:00024027 374626 linezolid Oral Tablet NDF-RT: N0000148664 RxNORM: RXNORM/190376 DRON:00024045 374649 ziprasidone Oral Capsule NDF-RT: N0000148690 RxNORM: RXNORM/115698 DRON:00024052 374656 valganciclovir Oral Tablet NDF-RT: N0000148704 RxNORM: RXNORM/275891 DRON:00024062 374667 mycophenolate mofetil Oral Tablet DRON:00024071 374678 peginterferon alfa-2b Injectable Solution NDF-RT: N0000148697 RxNORM: RXNORM/253453 DRON:00024356 375061 exemestane Oral Tablet NDF-RT: N0000148637 RxNORM: RXNORM/258494 DRON:00024436 375173 Mitoxantrone Injectable Solution NDF-RT: N0000147641 NDF-RT: N0000147929 RxNORM: RXNORM/203129 RxNORM: RXNORM/7005 DRON:00024462 375205 Pentamidine Injectable Solution NDF-RT: N0000147966 RxNORM: RXNORM/7994 DRON:00024497 375256 rabeprazole Enteric Coated Tablet DRON:00024567 375369 zonisamide Oral Tablet NDF-RT: N0000148668 RxNORM: RXNORM/39998 DRON:00024830 375794 cefepime Injectable Solution NDF-RT: N0000022054 RxNORM: RXNORM/20481 DRON:00025223 376337 Aurothiomalate Injectable Solution NDF-RT: N0000146340 RxNORM: RXNORM/4981 DRON:00025255 376374 Deferoxamine Injectable Solution NDF-RT: N0000147797 RxNORM: RXNORM/3131 DRON:00025297 376431 rofecoxib Oral Tablet NDF-RT: N0000148611 RxNORM: RXNORM/232158 DRON:00025299 376433 Cisplatin Injectable Solution NDF-RT: N0000146476 RxNORM: RXNORM/2555 DRON:00025587 376842 Foscarnet Injectable Solution NDF-RT: N0000148246 RxNORM: RXNORM/33562 DRON:00025622 376887 gemcitabine Injectable Solution NDF-RT: N0000022036 RxNORM: RXNORM/12574 DRON:00025623 376888 docetaxel Injectable Solution NDF-RT: N0000148441 RxNORM: RXNORM/72962 DRON:00025748 377091 Aldesleukin Injectable Solution NDF-RT: N0000148066 RxNORM: RXNORM/70223 DRON:00025763 377111 Paclitaxel Injectable Solution NDF-RT: N0000148314 RxNORM: RXNORM/56946 DRON:00025774 377125 vinorelbine Injectable Solution NDF-RT: N0000021986 RxNORM: RXNORM/39541 DRON:00025777 377128 Ifosfamide Injectable Solution NDF-RT: N0000147596 RxNORM: RXNORM/5657 DRON:00025779 377130 Teniposide Injectable Solution NDF-RT: N0000148273 RxNORM: RXNORM/10362 DRON:00025810 377175 Cladribine Injectable Solution NDF-RT: N0000148293 RxNORM: RXNORM/44157 DRON:00025837 377209 oxaliplatin Injectable Solution NDF-RT: N0000148774 RxNORM: RXNORM/32592 DRON:00025843 377216 trastuzumab Injectable Solution NDF-RT: N0000148593 RxNORM: RXNORM/224905 DRON:00025863 377259 rituximab Injectable Solution NDF-RT: N0000148560 RxNORM: RXNORM/121191 DRON:00026059 377483 Propofol Injectable Suspension NDF-RT: N0000147620 RxNORM: RXNORM/8782 DRON:00026584 378079 bexarotene Topical Gel NDF-RT: N0000148643 RxNORM: RXNORM/233272 DRON:00026599 378099 gabapentin Oral Tablet NDF-RT: N0000148345 RxNORM: RXNORM/25480 DRON:00026665 378233 Bupropion Oral Tablet NDF-RT: N0000147738 RxNORM: RXNORM/42347 DRON:00026688 378277 Sirolimus Oral Tablet DRON:00026716 378318 ropivacaine Injectable Solution NDF-RT: N0000022060 RxNORM: RXNORM/35780 DRON:00026729 378363 Carboplatin Injectable Solution NDF-RT: N0000147598 RxNORM: RXNORM/40048 DRON:00026857 378634 histrelin Injectable Solution NDF-RT: N0000176176 RxNORM: RXNORM/50975 DRON:00026889 378682 montelukast Oral Tablet NDF-RT: N0000022122 RxNORM: RXNORM/88249 DRON:00026893 378686 valdecoxib Oral Tablet NDF-RT: N0000148721 RxNORM: RXNORM/278567 DRON:00026894 378688 vardenafil Oral Tablet NDF-RT: N0000148820 RxNORM: RXNORM/306674 DRON:00026895 378691 voriconazole Oral Tablet NDF-RT: N0000148767 RxNORM: RXNORM/121243 DRON:00027059 378925 Paroxetine Oral Tablet NDF-RT: N0000148335 RxNORM: RXNORM/32937 DRON:00027119 379009 Insulin, Protamine Zinc, Human Injectable Suspension DRON:00027215 379127 Zalcitabine Oral Tablet NDF-RT: N0000021287 RxNORM: RXNORM/3363 DRON:00027279 379232 Triptorelin Injectable Suspension NDF-RT: N0000148818 RxNORM: RXNORM/38782 DRON:00027809 393413 fludarabine Oral Tablet NDF-RT: N0000148119 NDF-RT: N0000148244 RxNORM: RXNORM/24698 RxNORM: RXNORM/25102 DRON:00027818 393435 Omeprazole Oral Tablet NDF-RT: N0000147569 RxNORM: RXNORM/7646 DRON:00027823 393446 fluticasone Nasal Suspension NDF-RT: N0000148245 RxNORM: RXNORM/41126 DRON:00027865 402347 Miglustat Oral Capsule NDF-RT: N0000148822 RxNORM: RXNORM/402316 DRON:00027879 402394 bortezomib Injectable Solution NDF-RT: N0000148811 RxNORM: RXNORM/358258 DRON:00027893 402452 tadalafil Oral Tablet NDF-RT: N0000148829 RxNORM: RXNORM/358263 DRON:00027964 406050 imatinib Oral Tablet NDF-RT: N0000148698 RxNORM: RXNORM/282388 DRON:00027976 406178 pemetrexed Injectable Solution NDF-RT: N0000148831 RxNORM: RXNORM/68446 DRON:00028026 435471 butalbital Oral Tablet DRON:00029994 451875 Tacrolimus Oral Tablet NDF-RT: N0000148372 RxNORM: RXNORM/42316 DRON:00030017 451949 Streptomycin Oral Capsule NDF-RT: N0000148018 RxNORM: RXNORM/10109 DRON:00030051 452059 Thalidomide Oral Tablet NDF-RT: N0000148588 RxNORM: RXNORM/10432 DRON:00030338 483437 pregabalin Oral Capsule NDF-RT: N0000023107 RxNORM: RXNORM/187832 DRON:00030385 485467 Saquinavir Oral Tablet NDF-RT: N0000148419 RxNORM: RXNORM/83395 DRON:00030435 498897 Flecainide Oral Tablet NDF-RT: N0000147848 RxNORM: RXNORM/4441 DRON:00030440 498905 Nitrofurantoin Oral Capsule NDF-RT: N0000147151 NDF-RT: N0000163521 RxNORM: RXNORM/221129 RxNORM: RXNORM/7454 DRON:00030635 577211 tipranavir Oral Capsule NDF-RT: N0000023100 RxNORM: RXNORM/190548 DRON:00030779 596836 lansoprazole Oral Capsule NDF-RT: N0000148407 RxNORM: RXNORM/17128 DRON:00030794 597746 sorafenib Oral Tablet NDF-RT: N0000171742 RxNORM: RXNORM/495881 DRON:00030815 603565 nelarabine Injectable Solution NDF-RT: N0000171753 RxNORM: RXNORM/274771 DRON:00030845 608327 rasagiline Oral Tablet NDF-RT: N0000171790 RxNORM: RXNORM/134748 DRON:00030932 618427 Nalidixate Oral Tablet DRON:00031159 632025 tenofovir disoproxil Oral Tablet NDF-RT: N0000148716 RxNORM: RXNORM/117466 DRON:00031282 639882 emtricitabine Oral Tablet NDF-RT: N0000148813 RxNORM: RXNORM/276237 DRON:00031401 665018 posaconazole Oral Suspension DRON:00031408 665121 telbivudine Oral Tablet NDF-RT: N0000176071 RxNORM: RXNORM/474128 DRON:00031691 727885 Triamcinolone Prefilled Syringe DRON:00031753 745021 Pramipexole Oral Tablet NDF-RT: N0000022076 RxNORM: RXNORM/746741 DRON:00031780 746605 nilotinib Oral Capsule NDF-RT: N0000176124 RxNORM: RXNORM/662281 DRON:00031783 746765 fluticasone Dry Powder Inhaler DRON:00031788 747192 Topotecan Oral Capsule NDF-RT: N0000022037 RxNORM: RXNORM/57308 DRON:00032163 795080 certolizumab pegol Injectable Solution DRON:00032559 849596 certolizumab pegol Prefilled Syringe NDF-RT: N0000178499 RxNORM: RXNORM/709271 DRON:00033048 895759 tocilizumab Injectable Solution DRON:00033154 900574 Ritonavir Oral Tablet NDF-RT: N0000148436 RxNORM: RXNORM/85762 DRON:00033639 1044586 tesamorelin Injectable Solution NDF-RT: N0000182253 RxNORM: RXNORM/1044584 DRON:00033939 1147222 Vemurafenib Oral Tablet NDF-RT: N0000183250 RxNORM: RXNORM/1147220 DRON:00034152 1291305 avanafil Oral Tablet RxNORM: RXNORM/1291301 DRON:00034236 1302969 carfilzomib Injectable Solution NDF-RT: N0000185509 RxNORM: RXNORM/1302966 DRON:00034279 1310524 teriflunomide Oral Tablet NDF-RT: N0000185727 RxNORM: RXNORM/1310520 DRON:00034441 102692 penicillin G benzathine 115 MG/ML Oral Solution NDF-RT: N0000145827 RxNORM: RXNORM/7982 DRON:00046544 314167 Procarbazine 50 MG Oral Capsule DRON:00046801 317573 pioglitazone 15 MG Oral Tablet DRON:00053744 545835 Leuprolide Acetate 5 MG/ML Injectable Solution NDF-RT: N0000147256 RxNORM: RXNORM/203217 DRON:00057777 833449 0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe DRON:00059074 858804 Enalapril Maleate 2.5 MG Oral Tablet NDF-RT: N0000146304 RxNORM: RXNORM/203123 DRON:00061555 966903 Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension DRON:00072660 207588 Procarbazine 50 MG Oral Capsule [Matulane] NDF-RT: N0000147991 RxNORM: RXNORM/8702 DRON:00075444 261266 pioglitazone 15 MG Oral Tablet [Actos] DRON:00080145 835559 0.1 ML Triamcinolone Acetonide 80 MG/ML Prefilled Syringe [Trivaris] DRON:00082933 966907 Insulin, Protamine Zinc, Human 40 UNT/ML Injectable Suspension [ProZinc] NDF-RT: N0000147876 RxNORM: RXNORM/5856 Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter. GO:0010553 GO:0045816 down regulation of transcription from RNA polymerase II promoter down-regulation of transcription from RNA polymerase II promoter downregulation of transcription from RNA polymerase II promoter inhibition of transcription from RNA polymerase II promoter negative regulation of transcription from Pol II promoter biological_process down regulation of global transcription from RNA polymerase II promoter down-regulation of global transcription from RNA polymerase II promoter downregulation of global transcription from RNA polymerase II promoter inhibition of global transcription from RNA polymerase II promoter negative regulation of gene-specific transcription from RNA polymerase II promoter negative regulation of global transcription from Pol II promoter negative regulation of transcription from RNA polymerase II promoter, global GO:0000122 negative regulation of transcription from RNA polymerase II promoter GO:0000122 GO:0001838 embryonic epithelial tube formation GO:0001841 neural tube formation Any process that modulates the frequency, rate or extent of the cytokine mediated signaling pathway. regulation of cytokine and chemokine mediated signaling pathway regulation of cytokine mediated signaling pathway regulation of cytokine mediated signalling pathway biological_process GO:0001959 regulation of cytokine-mediated signaling pathway GO:0001959 Any process that stops, prevents, or reduces the frequency, rate or extent of the cytokine mediated signaling pathway. down regulation of cytokine mediated signaling pathway down-regulation of cytokine mediated signaling pathway downregulation of cytokine mediated signaling pathway negative regulation of cytokine and chemokine mediated signaling pathway negative regulation of cytokine mediated signaling pathway negative regulation of cytokine mediated signalling pathway inhibition of cytokine mediated signaling pathway biological_process GO:0001960 negative regulation of cytokine-mediated signaling pathway GO:0001960 GO:0002009 morphogenesis of an epithelium GO:0003008 system process GO:0005575 cellular_component GO:0005623 cell Any process that modulates the frequency, rate or extent of cellular DNA-templated transcription. GO:0032583 GO:0045449 GO:0061019 transcriptional control regulation of cellular transcription, DNA-dependent regulation of transcription, DNA-dependent biological_process regulation of gene-specific transcription GO:0006355 regulation of transcription, DNA-templated GO:0006355 Any process that modulates the frequency, rate or extent of transcription from an RNA polymerase II promoter. GO:0006358 GO:0010551 regulation of transcription from Pol II promoter biological_process global transcription regulation from Pol II promoter regulation of gene-specific transcription from RNA polymerase II promoter regulation of global transcription from Pol II promoter regulation of transcription from RNA polymerase II promoter, global GO:0006357 regulation of transcription from RNA polymerase II promoter GO:0006357 GO:0007275 multicellular organismal development GO:0007369 gastrulation GO:0007399 nervous system development GO:0007600 sensory perception GO:0007601 visual perception Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end. GO:0000004 GO:0007582 Wikipedia:Biological_process biological process physiological process biological_process GO:0008150 Note that, in addition to forming the root of the biological process ontology, this term is recommended for use for the annotation of gene products whose biological process is unknown. Note that when this term is used for annotation, it indicates that no information was available about the biological process of the gene product annotated as of the date the annotation was made; the evidence code ND, no data, is used to indicate this. biological_process GO:0008150 Any process that modulates the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity. regulation of G protein coupled receptor protein signaling pathway regulation of G protein coupled receptor protein signalling pathway regulation of G-protein coupled receptor protein signalling pathway regulation of G-protein-coupled receptor protein signaling pathway regulation of G-protein-coupled receptor protein signalling pathway regulation of GPCR protein signaling pathway regulation of GPCR protein signalling pathway biological_process GO:0008277 regulation of G-protein coupled receptor protein signaling pathway GO:0008277 GO:0009314 response to radiation GO:0009416 response to light stimulus GO:0009581 detection of external stimulus GO:0009582 detection of abiotic stimulus GO:0009583 detection of light stimulus GO:0009584 detection of visible light GO:0009605 response to external stimulus GO:0009628 response to abiotic stimulus GO:0009653 anatomical structure morphogenesis GO:0009790 embryo development GO:0009791 post-embryonic development GO:0009792 embryo development ending in birth or egg hatching GO:0009888 tissue development Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances. regulation of anabolism regulation of biosynthesis regulation of formation regulation of synthesis biological_process GO:0009889 regulation of biosynthetic process GO:0009889 Any process that stops, prevents, or reduces the rate of the chemical reactions and pathways resulting in the formation of substances. down regulation of biosynthetic process down-regulation of biosynthetic process downregulation of biosynthetic process negative regulation of anabolism negative regulation of biosynthesis negative regulation of formation negative regulation of synthesis inhibition of biosynthetic process biological_process GO:0009890 negative regulation of biosynthetic process GO:0009890 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. down regulation of metabolic process down-regulation of metabolic process downregulation of metabolic process negative regulation of metabolism inhibition of metabolic process biological_process GO:0009892 negative regulation of metabolic process GO:0009892 Any process that modulates the frequency, rate or extent of signal transduction. GO:0035466 biological_process regulation of signaling pathway regulation of signalling pathway GO:0009966 regulation of signal transduction GO:0009966 Any process that activates or increases the frequency, rate or extent of signal transduction. GO:0035468 Reactome:REACT_6227 up regulation of signal transduction up-regulation of signal transduction upregulation of signal transduction activation of signal transduction stimulation of signal transduction biological_process positive regulation of signaling pathway positive regulation of signalling pathway GO:0009967 positive regulation of signal transduction GO:0009967 Any process that stops, prevents, or reduces the frequency, rate or extent of signal transduction. GO:0035467 Reactome:REACT_6334 down regulation of signal transduction down-regulation of signal transduction downregulation of signal transduction inhibition of signal transduction biological_process negative regulation of signaling pathway negative regulation of signalling pathway GO:0009968 negative regulation of signal transduction GO:0009968 GO:0009987 cellular process Any process that modulates the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. Wikipedia:Regulation_of_gene_expression regulation of protein expression biological_process regulation of gene product expression GO:0010468 regulation of gene expression GO:0010468 Any process that modulates the frequency, rate or extent of receptor activity. Receptor activity is when a molecule combines with an extracellular or intracellular messenger to initiate a change in cell activity. biological_process GO:0010469 regulation of receptor activity GO:0010469 Any process that modulates the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. biological_process GO:0010556 regulation of macromolecule biosynthetic process GO:0010556 Any process that decreases the rate, frequency or extent of the chemical reactions and pathways resulting in the formation of a macromolecule, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. biological_process GO:0010558 negative regulation of macromolecule biosynthetic process GO:0010558 Any process that decreases the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. biological_process GO:0010605 negative regulation of macromolecule metabolic process GO:0010605 Any process that decreases the frequency, rate or extent of gene expression. Gene expression is the process in which a gene's coding sequence is converted into a mature gene product or products (proteins or RNA). This includes the production of an RNA transcript as well as any processing to produce a mature RNA product or an mRNA (for protein-coding genes) and the translation of that mRNA into protein. Some protein processing events may be included when they are required to form an active form of a product from an inactive precursor form. biological_process GO:0010629 negative regulation of gene expression GO:0010629 Any process that modulates the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. biological_process GO:0010646 regulation of cell communication GO:0010646 Any process that increases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. biological_process GO:0010647 positive regulation of cell communication GO:0010647 Any process that decreases the frequency, rate or extent of cell communication. Cell communication is the process that mediates interactions between a cell and its surroundings. Encompasses interactions such as signaling or attachment between one cell and another cell, between a cell and an extracellular matrix, or between a cell and any other aspect of its environment. biological_process GO:0010648 negative regulation of cell communication GO:0010648 Any process that decreases the rate or extent of the tumor necrosis factor-mediated signaling pathway. The tumor necrosis factor-mediated signaling pathway is the series of molecular signals generated as a consequence of tumor necrosis factor binding to a cell surface receptor. negative regulation of TNF signaling negative regulation of TNF-mediated signaling pathway negative regulation of tumor necrosis factor-mediated signalling pathway biological_process GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway GO:0010804 Any process that modulates the frequency, rate or extent of the regulated release of dopamine. biological_process GO:0014059 regulation of dopamine secretion GO:0014059 GO:0016265 death GO:0016331 morphogenesis of embryonic epithelium Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving lipids. regulation of lipid metabolism biological_process GO:0019216 regulation of lipid metabolic process GO:0019216 Any cellular process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids. regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism biological_process regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process GO:0019219 regulation of nucleobase-containing compound metabolic process GO:0019219 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism. regulation of metabolism biological_process GO:0019222 regulation of metabolic process GO:0019222 GO:0021915 neural tube development Any process that modulates the frequency, rate or extent of a signaling process. 2010-02-16T09:30:50Z biological_process regulation of signaling process regulation of signalling process GO:0023051 regulation of signaling GO:0023051 Any process that activates, maintains or increases the frequency, rate or extent of a signaling process. 2010-02-16T09:30:50Z positive regulation of signalling process biological_process positive regulation of signaling process GO:0023056 positive regulation of signaling GO:0023056 Any process that stops, prevents, or reduces the frequency, rate or extent of a signaling process. 2010-02-16T09:30:50Z biological_process negative regulation of signaling process negative regulation of signalling process GO:0023057 negative regulation of signaling GO:0023057 GO:0031012 extracellular matrix Any process that modulates the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances. regulation of cellular metabolism biological_process GO:0031323 regulation of cellular metabolic process GO:0031323 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways by which individual cells transform chemical substances. down regulation of cellular metabolic process down-regulation of cellular metabolic process downregulation of cellular metabolic process negative regulation of cellular metabolism inhibition of cellular metabolic process biological_process GO:0031324 negative regulation of cellular metabolic process GO:0031324 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells. regulation of cellular anabolism regulation of cellular biosynthesis regulation of cellular formation regulation of cellular synthesis biological_process GO:0031326 regulation of cellular biosynthetic process GO:0031326 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of substances, carried out by individual cells. down regulation of cellular biosynthetic process down-regulation of cellular biosynthetic process downregulation of cellular biosynthetic process negative regulation of cellular anabolism negative regulation of cellular biosynthesis negative regulation of cellular formation negative regulation of cellular synthesis inhibition of cellular biosynthetic process biological_process GO:0031327 negative regulation of cellular biosynthetic process GO:0031327 Any process that modulates the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine. biological_process GO:0032225 regulation of synaptic transmission, dopaminergic GO:0032225 Any process that stops, prevents, or reduces the frequency, rate or extent of dopaminergic synaptic transmission, the process of communication from a neuron to another neuron across a synapse using the neurotransmitter dopamine. down regulation of synaptic transmission, dopaminergic down-regulation of synaptic transmission, dopaminergic downregulation of synaptic transmission, dopaminergic inhibition of synaptic transmission, dopaminergic biological_process GO:0032227 negative regulation of synaptic transmission, dopaminergic GO:0032227 GO:0032501 multicellular organismal process GO:0032502 developmental process Any process that stops or reduces the rate of ATP hydrolysis by an ATPase. down regulation of ATPase activity down-regulation of ATPase activity downregulation of ATPase activity negative regulation of adenosinetriphosphatase activity inhibition of ATPase activity biological_process GO:0032780 negative regulation of ATPase activity GO:0032780 Any process that modulates the frequency, rate or extent of any process in which a cell, a substance, or a cellular entity is transported to, or maintained in, a specific location. regulation of localisation biological_process GO:0032879 regulation of localization GO:0032879 Any process that modulates the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway. regulation of steroid hormone receptor signaling pathway regulation of steroid hormone receptor signalling pathway biological_process GO:0033143 regulation of intracellular steroid hormone receptor signaling pathway GO:0033143 Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of any intracellular steroid hormone receptor signaling pathway. negative regulation of steroid hormone receptor signaling pathway negative regulation of steroid hormone receptor signalling pathway biological_process GO:0033144 negative regulation of intracellular steroid hormone receptor signaling pathway GO:0033144 Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of dopamine. down regulation of dopamine secretion down-regulation of dopamine secretion downregulation of dopamine secretion inhibition of dopamine secretion biological_process GO:0033602 negative regulation of dopamine secretion GO:0033602 Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of a catecholamine. down regulation of catecholamine secretion down-regulation of catecholamine secretion downregulation of catecholamine secretion inhibition of catecholamine secretion biological_process GO:0033604 negative regulation of catecholamine secretion GO:0033604 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving amides. regulation of amide metabolism biological_process GO:0034248 regulation of cellular amide metabolic process GO:0034248 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving amides. negative regulation of amide metabolism biological_process GO:0034249 negative regulation of cellular amide metabolic process GO:0034249 GO:0035148 tube formation GO:0035239 tube morphogenesis GO:0035295 tube development GO:0040016 embryonic cleavage GO:0043009 chordate embryonic development Any process that stops or reduces the activity of an enzyme. down regulation of enzyme activity down-regulation of enzyme activity downregulation of enzyme activity negative regulation of enzyme activity inhibition of enzyme activity biological_process GO:0043086 negative regulation of catalytic activity GO:0043086 Any process that modulates the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0043269 regulation of ion transport GO:0043269 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of charged atoms or small charged molecules into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. down regulation of ion transport down-regulation of ion transport downregulation of ion transport inhibition of ion transport biological_process GO:0043271 negative regulation of ion transport GO:0043271 Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. negative regulation of transcription factor activity down regulation of transcription factor activity down-regulation of transcription factor activity downregulation of transcription factor activity inhibition of transcription factor activity biological_process GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043433 Any process that modulates the rate of ATP hydrolysis by an ATPase. regulation of adenosinetriphosphatase activity biological_process GO:0043462 regulation of ATPase activity GO:0043462 Any process that modulates the frequency, rate or extent of the directed movement of anions, atoms or small molecules with a net negative charge into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0044070 regulation of anion transport GO:0044070 Any process that stops or reduces the rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding. jane 2009-04-21T04:07:27Z biological_process GO:0044092 negative regulation of molecular function GO:0044092 GO:0044699 single-organism process GO:0044707 single-multicellular organism process GO:0044763 single-organism cellular process GO:0044767 single-organism developmental process Any process that activates or increases the frequency, rate or extent of G-protein coupled receptor protein signaling pathway activity. positive regulation of G protein coupled receptor protein signaling pathway positive regulation of G protein coupled receptor protein signalling pathway positive regulation of G-protein coupled receptor protein signalling pathway positive regulation of G-protein-coupled receptor protein signaling pathway positive regulation of G-protein-coupled receptor protein signalling pathway positive regulation of GPCR protein signaling pathway positive regulation of GPCR protein signalling pathway up regulation of G-protein coupled receptor protein signaling pathway up-regulation of G-protein coupled receptor protein signaling pathway upregulation of G-protein coupled receptor protein signaling pathway activation of G-protein coupled receptor protein signaling pathway stimulation of G-protein coupled receptor protein signaling pathway biological_process GO:0045745 positive regulation of G-protein coupled receptor protein signaling pathway GO:0045745 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving lipids. down regulation of lipid metabolic process down-regulation of lipid metabolic process downregulation of lipid metabolic process negative regulation of lipid metabolism inhibition of lipid metabolic process biological_process GO:0045833 negative regulation of lipid metabolic process GO:0045833 Any process that stops, prevents, or reduces the frequency, rate or extent of cellular DNA-templated transcription. GO:0016481 GO:0032582 GO:0061021 down regulation of transcription, DNA-dependent down-regulation of transcription, DNA-dependent downregulation of transcription, DNA-dependent negative regulation of cellular transcription, DNA-dependent negative regulation of transcription, DNA-dependent inhibition of transcription, DNA-dependent biological_process down regulation of gene-specific transcription down-regulation of gene-specific transcription downregulation of gene-specific transcription inhibition of gene-specific transcription negative regulation of gene-specific transcription transcription repressor activity GO:0045892 negative regulation of transcription, DNA-templated GO:0045892 Any cellular process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nucleobases, nucleosides, nucleotides and nucleic acids. down regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process down-regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process downregulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism inhibition of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process biological_process negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process GO:0045934 negative regulation of nucleobase-containing compound metabolic process GO:0045934 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of glucosylceramide. down regulation of glucosylceramide biosynthetic process down-regulation of glucosylceramide biosynthetic process downregulation of glucosylceramide biosynthetic process negative regulation of glucosylceramide anabolism negative regulation of glucosylceramide biosynthesis negative regulation of glucosylceramide formation negative regulation of glucosylceramide synthesis inhibition of glucosylceramide biosynthetic process biological_process GO:0046318 negative regulation of glucosylceramide biosynthetic process GO:0046318 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. regulation of lipid anabolism regulation of lipid biosynthesis regulation of lipid formation regulation of lipid synthesis regulation of lipogenesis biological_process GO:0046890 regulation of lipid biosynthetic process GO:0046890 GO:0048513 organ development Any process that activates or increases the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0043119 positive regulation of physiological process up regulation of biological process up-regulation of biological process upregulation of biological process activation of biological process stimulation of biological process biological_process GO:0048518 positive regulation of biological process GO:0048518 Any process that stops, prevents, or reduces the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0043118 down regulation of biological process down-regulation of biological process downregulation of biological process negative regulation of physiological process inhibition of biological process biological_process GO:0048519 negative regulation of biological process GO:0048519 Any process that activates or increases the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0051242 positive regulation of cellular physiological process up regulation of cellular process up-regulation of cellular process upregulation of cellular process activation of cellular process stimulation of cellular process biological_process GO:0048522 positive regulation of cellular process GO:0048522 Any process that stops, prevents, or reduces the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0051243 down regulation of cellular process down-regulation of cellular process downregulation of cellular process negative regulation of cellular physiological process inhibition of cellular process biological_process GO:0048523 negative regulation of cellular process GO:0048523 Any process that modulates the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. biological_process GO:0048583 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. regulation of response to stimulus GO:0048583 Any process that activates, maintains or increases the rate of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. up regulation of response to stimulus up-regulation of response to stimulus upregulation of response to stimulus activation of response to stimulus stimulation of response to stimulus biological_process GO:0048584 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. positive regulation of response to stimulus GO:0048584 Any process that stops, prevents, or reduces the frequency, rate or extent of a response to a stimulus. Response to stimulus is a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. down regulation of response to stimulus down-regulation of response to stimulus downregulation of response to stimulus inhibition of response to stimulus biological_process GO:0048585 Note that this term is in the subset of terms that should not be used for direct gene product annotation. Instead, select a child term or, if no appropriate child term exists, please request a new term. Direct annotations to this term may be amended during annotation QC. negative regulation of response to stimulus GO:0048585 GO:0048598 embryonic morphogenesis GO:0048646 anatomical structure formation involved in morphogenesis GO:0048729 tissue morphogenesis GO:0048731 system development GO:0048856 anatomical structure development Any process that modulates the frequency, rate or extent of the regulated release of catecholamines. biological_process GO:0050433 regulation of catecholamine secretion GO:0050433 Any process that modulates the frequency, rate or extent of a biological process. Biological processes are regulated by many means; examples include the control of gene expression, protein modification or interaction with a protein or substrate molecule. GO:0050791 regulation of physiological process biological_process GO:0050789 regulation of biological process GO:0050789 Any process that modulates the activity of an enzyme. regulation of enzyme activity biological_process GO:0050790 regulation of catalytic activity GO:0050790 Any process that modulates the frequency, rate or extent of a cellular process, any of those that are carried out at the cellular level, but are not necessarily restricted to a single cell. For example, cell communication occurs among more than one cell, but occurs at the cellular level. GO:0051244 regulation of cellular physiological process biological_process GO:0050794 regulation of cellular process GO:0050794 Any process that modulates the frequency or rate of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. biological_process GO:0050804 regulation of synaptic transmission GO:0050804 Any process that stops, prevents, or reduces the frequency, rate or extent of synaptic transmission, the process of communication from a neuron to a target (neuron, muscle, or secretory cell) across a synapse. down regulation of synaptic transmission down-regulation of synaptic transmission downregulation of synaptic transmission inhibition of synaptic transmission biological_process GO:0050805 negative regulation of synaptic transmission GO:0050805 GO:0050877 neurological system process GO:0050896 response to stimulus GO:0050906 detection of stimulus involved in sensory perception GO:0050953 sensory perception of light stimulus Any process that modulates the frequency, rate or extent of the controlled release of a substance from a cell or a tissue. biological_process GO:0051046 regulation of secretion GO:0051046 Any process that stops, prevents, or reduces the frequency, rate or extent of the controlled release of a substance from a cell or a tissue. down regulation of secretion down-regulation of secretion downregulation of secretion inhibition of secretion biological_process GO:0051048 negative regulation of secretion GO:0051048 Any process that modulates the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0051049 regulation of transport GO:0051049 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. down regulation of transport down-regulation of transport downregulation of transport inhibition of transport biological_process GO:0051051 negative regulation of transport GO:0051051 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of lipids. down regulation of lipid biosynthetic process down-regulation of lipid biosynthetic process downregulation of lipid biosynthetic process negative regulation of lipid anabolism negative regulation of lipid biosynthesis negative regulation of lipid formation negative regulation of lipid synthesis negative regulation of lipogenesis inhibition of lipid biosynthetic process biological_process GO:0051055 negative regulation of lipid biosynthetic process GO:0051055 Any process that modulates the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. regulation of transcription factor activity Reactome:REACT_104536 Reactome:REACT_107559 Reactome:REACT_109535 Reactome:REACT_110257 Reactome:REACT_110693 Reactome:REACT_21326 Reactome:REACT_82719 Reactome:REACT_83365 Reactome:REACT_90659 Reactome:REACT_92725 Reactome:REACT_96476 Reactome:REACT_99415 biological_process GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051090 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds. regulation of nitrogen metabolic process regulation of nitrogen metabolism biological_process GO:0051171 regulation of nitrogen compound metabolic process GO:0051171 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving nitrogen or nitrogenous compounds. down regulation of nitrogen metabolic process down-regulation of nitrogen metabolic process downregulation of nitrogen metabolic process negative regulation of nitrogen metabolic process negative regulation of nitrogen metabolism inhibition of nitrogen metabolic process biological_process GO:0051172 negative regulation of nitrogen compound metabolic process GO:0051172 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving RNA. regulation of RNA metabolism biological_process GO:0051252 regulation of RNA metabolic process GO:0051252 Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways involving RNA. down regulation of RNA metabolic process down-regulation of RNA metabolic process downregulation of RNA metabolic process negative regulation of RNA metabolism inhibition of RNA metabolic process biological_process GO:0051253 negative regulation of RNA metabolic process GO:0051253 GO:0051301 cell division Any process that modulates the frequency, rate or extent of hydrolase activity, the catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3. hydrolase regulator biological_process GO:0051336 regulation of hydrolase activity GO:0051336 Any process that modulates the frequency, rate or extent of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. oxidoreductase regulator biological_process GO:0051341 regulation of oxidoreductase activity GO:0051341 Any process that stops or reduces the rate of cyclic nucleotide phosphodiesterase activity, the catalysis of the reaction: nucleotide 3',5'-cyclic phosphate + H2O = nucleotide 5'-phosphate. 3',5' cyclic nucleotide phosphodiesterase inhibitor down regulation of cyclic nucleotide phosphodiesterase activity down-regulation of cyclic nucleotide phosphodiesterase activity downregulation of cyclic nucleotide phosphodiesterase activity negative regulation of 3',5' cyclic nucleotide phosphodiesterase activity negative regulation of cyclic nucleotide phosphodiesterase activity 3',5'-cyclic-AMP phosphodiesterase inhibitor cAMP phosphodiesterase inhibitor inhibition of cyclic nucleotide phosphodiesterase activity negative regulation of 3',5'-cyclic-AMP phosphodiesterase activity negative regulation of cAMP phosphodiesterase activity negative regulation of cGMP phosphodiesterase activity biological_process phosphodiesterase inhibitor GO:0051344 negative regulation of cyclic-nucleotide phosphodiesterase activity GO:0051344 Any process that stops or reduces the rate of hydrolase activity, the catalysis of the hydrolysis of various bonds. down regulation of hydrolase activity down-regulation of hydrolase activity downregulation of hydrolase activity hydrolase inhibitor inhibition of hydrolase activity biological_process GO:0051346 negative regulation of hydrolase activity GO:0051346 Any process that stops or reduces the rate of oxidoreductase activity, the catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. down regulation of oxidoreductase activity down-regulation of oxidoreductase activity downregulation of oxidoreductase activity oxidoreductase inhibitor inhibition of oxidoreductase activity biological_process GO:0051354 negative regulation of oxidoreductase activity GO:0051354 Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell. regulation of neurotransmitter import regulation of neurotransmitter reuptake biological_process GO:0051580 regulation of neurotransmitter uptake GO:0051580 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into a neuron or glial cell. down regulation of neurotransmitter uptake down-regulation of neurotransmitter uptake downregulation of neurotransmitter uptake negative regulation of neurotransmitter import biological_process GO:0051581 negative regulation of neurotransmitter uptake GO:0051581 Any process that modulates the frequency, rate or extent of the directed movement of the catecholamine neurotransmitter dopamine into a cell. regulation of dopamine import involved in synaptic transmission biological_process GO:0051584 regulation of dopamine uptake involved in synaptic transmission GO:0051584 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of dopamine into a presynaptic neuron or glial cell. down regulation of dopamine uptake involved in synaptic transmission down-regulation of dopamine uptake involved in synaptic transmission downregulation of dopamine uptake involved in synaptic transmission negative regulation of dopamine import involved in synaptic transmission biological_process GO:0051585 negative regulation of dopamine uptake involved in synaptic transmission GO:0051585 Any process that modulates the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0051588 regulation of neurotransmitter transport GO:0051588 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of a neurotransmitter into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. down regulation of neurotransmitter transport down-regulation of neurotransmitter transport downregulation of neurotransmitter transport inhibition of neurotransmitter transport biological_process GO:0051589 negative regulation of neurotransmitter transport GO:0051589 GO:0051606 detection of stimulus Any process that modulates the frequency, rate or extent of the directed movement of the monoamine neurotransmitter serotonin into a cell. regulation of 5-HT uptake regulation of 5-hydroxytryptamine uptake regulation of 5HT uptake regulation of serotonin import biological_process GO:0051611 regulation of serotonin uptake GO:0051611 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of serotonin into a cell. down regulation of serotonin uptake down-regulation of serotonin uptake downregulation of serotonin uptake negative regulation of 5-HT uptake negative regulation of 5-hydroxytryptamine uptake negative regulation of 5HT uptake negative regulation of serotonin import biological_process GO:0051612 negative regulation of serotonin uptake GO:0051612 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of norepinephrine into a cell. down regulation of norepinephrine uptake down-regulation of norepinephrine uptake downregulation of norepinephrine uptake negative regulation of levarterenol uptake negative regulation of noradrenaline uptake negative regulation of norepinephrine import biological_process GO:0051622 negative regulation of norepinephrine uptake GO:0051622 Any process that prevents the activation of the directed movement of norepinephrine into a cell. inhibition of levarterenol uptake inhibition of noradrenaline uptake inhibition of norepinephrine import biological_process GO:0051624 inhibition of norepinephrine uptake GO:0051624 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. down regulation of calcium ion transport down-regulation of calcium ion transport downregulation of calcium ion transport negative regulation of calcium transport inhibition of calcium ion transport biological_process GO:0051926 negative regulation of calcium ion transport GO:0051926 Any process that modulates the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell. regulation of catecholamine uptake during transmission of nerve impulse regulation of catecholamine neurotransmitter reuptake regulation of catecholamine neurotransmitter uptake biological_process GO:0051940 regulation of catecholamine uptake involved in synaptic transmission GO:0051940 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of catecholamine neurotransmitters into a neuron or glial cell. negative regulation of catecholamine uptake during transmission of nerve impulse down regulation of catecholamine uptake during transmission of nerve impulse down-regulation of catecholamine uptake during transmission of nerve impulse downregulation of catecholamine uptake during transmission of nerve impulse negative regulation of catecholamine neurotransmitter reuptake negative regulation of catecholamine neurotransmitter uptake inhibition of catecholamine uptake during transmission of nerve impulse biological_process GO:0051945 negative regulation of catecholamine uptake involved in synaptic transmission GO:0051945 Any process that modulates the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. biological_process GO:0051952 regulation of amine transport GO:0051952 Any process that stops, prevents, or reduces the frequency, rate or extent of the directed movement of amines into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. down regulation of amine transport down-regulation of amine transport downregulation of amine transport inhibition of amine transport biological_process GO:0051953 negative regulation of amine transport GO:0051953 Any process that modulates the frequency, rate or extent of the chemical reactions and pathways involving macromolecules, any molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. biological_process GO:0060255 regulation of macromolecule metabolic process GO:0060255 Any process that modulates the frequency, rate or extent of a process in which a cell, a substance, or a cellular entity is transported to, or maintained in a specific location within or in the membrane of a cell. regulation of cellular localisation biological_process GO:0060341 regulation of cellular localization GO:0060341 GO:0060429 epithelium development GO:0060562 epithelial tube morphogenesis Any process that modulates the rate, frequency, or extent of a response to cytokine stimulus. dph 2009-06-22T02:56:12Z biological_process GO:0060759 regulation of response to cytokine stimulus GO:0060759 Any process that decreases the rate, frequency, or extent of a response to cytokine stimulus. dph 2009-06-22T02:59:57Z biological_process GO:0060761 negative regulation of response to cytokine stimulus GO:0060761 Any process that modulates the rate, frequency, or extent of the androgen receptor signaling pathway. dph 2009-07-06T11:07:38Z regulation of androgen receptor signalling pathway biological_process GO:0060765 regulation of androgen receptor signaling pathway GO:0060765 Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway. dph 2009-07-06T11:09:36Z negative regulation of androgen receptor signalling pathway biological_process GO:0060766 negative regulation of androgen receptor signaling pathway GO:0060766 Any process that modulates a measurable attribute of any biological process, quality or function. regulation biological_process GO:0065007 biological regulation GO:0065007 Any process that modulates the frequency, rate or extent of a molecular function, an elemental biological activity occurring at the molecular level, such as catalysis or binding. regulation of a molecular function biological_process GO:0065009 regulation of molecular function GO:0065009 GO:0072175 epithelial tube formation Any process that modulates the frequency, rate or extent of the chemical reactions and pathways within a cell or an organism involving those compounds formed as a part of the normal anabolic and catabolic processes. These processes take place in most, if not all, cells of the organism. donghui 2009-04-22T04:30:52Z biological_process GO:0080090 regulation of primary metabolic process GO:0080090 Any process that modulates the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). tanyaberardini 2009-12-08T03:25:49Z biological_process GO:0090153 regulation of sphingolipid biosynthetic process GO:0090153 Any process that decreases the rate, frequency or extent of sphingolipid biosynthesis. Sphingolipid biosynthesis is the chemical reactions and pathways resulting in the formation of sphingolipids, any of a class of lipids containing the long-chain amine diol sphingosine or a closely related base (a sphingoid). tanyaberardini 2009-12-08T03:33:39Z biological_process GO:0090155 negative regulation of sphingolipid biosynthetic process GO:0090155 Any process that stops, prevents or reduces the frequency, rate or extent of a ceramide biosynthetic process. dph 2012-01-25T03:18:07Z down regulation of ceramide anabolism down regulation of ceramide biosynthesis down regulation of ceramide formation down regulation of ceramide synthesis down-regulation of ceramide anabolism down-regulation of ceramide biosynthesis down-regulation of ceramide formation down-regulation of ceramide synthesis downregulation of ceramide anabolism downregulation of ceramide biosynthesis downregulation of ceramide formation downregulation of ceramide synthesis inhibition of ceramide anabolism inhibition of ceramide biosynthesis inhibition of ceramide formation inhibition of ceramide synthesis negative regulation of ceramide anabolism negative regulation of ceramide biosynthesis negative regulation of ceramide formation negative regulation of ceramide synthesis biological_process down regulation of ceramide biosynthetic process down-regulation of ceramide biosynthetic process downregulation of ceramide biosynthetic process inhibition of ceramide biosynthetic process GO:1900060 negative regulation of ceramide biosynthetic process GO:1900060 Any process that modulates the frequency, rate or extent of cellular response to insulin stimulus. yaf 2012-01-31T11:22:22Z biological_process GO:1900076 regulation of cellular response to insulin stimulus GO:1900076 Any process that activates or increases the frequency, rate or extent of cellular response to insulin stimulus. yaf 2012-01-31T11:24:30Z up regulation of cellular response to insulin stimulus up-regulation of cellular response to insulin stimulus upregulation of cellular response to insulin stimulus activation of cellular response to insulin stimulus biological_process GO:1900078 positive regulation of cellular response to insulin stimulus GO:1900078 Any process that stops, prevents or reduces the frequency, rate or extent of RNA biosynthetic process. jl 2014-02-05T16:32:01Z down regulation of RNA anabolism down regulation of RNA biosynthesis down regulation of RNA biosynthetic process down regulation of RNA formation down regulation of RNA synthesis down-regulation of RNA anabolism down-regulation of RNA biosynthesis down-regulation of RNA biosynthetic process down-regulation of RNA formation down-regulation of RNA synthesis downregulation of RNA anabolism downregulation of RNA biosynthesis downregulation of RNA biosynthetic process downregulation of RNA formation downregulation of RNA synthesis negative regulation of RNA anabolism negative regulation of RNA biosynthesis negative regulation of RNA formation negative regulation of RNA synthesis inhibition of RNA anabolism inhibition of RNA biosynthesis inhibition of RNA biosynthetic process inhibition of RNA formation inhibition of RNA synthesis biological_process GO:1902679 negative regulation of RNA biosynthetic process GO:1902679 Any process that modulates the frequency, rate or extent of nucleic acid-templated transcription. pr 2014-10-01T14:44:47Z biological_process GO:1903506 regulation of nucleic acid-templated transcription GO:1903506 Any process that stops, prevents or reduces the frequency, rate or extent of nucleic acid-templated transcription. pr 2014-10-01T14:44:56Z down regulation of nucleic acid-templated transcription down-regulation of nucleic acid-templated transcription downregulation of nucleic acid-templated transcription inhibition of nucleic acid-templated transcription biological_process GO:1903507 negative regulation of nucleic acid-templated transcription GO:1903507 Any process that modulates the frequency, rate or extent of secretion by cell. pm 2014-10-08T13:24:59Z regulation of cellular secretion biological_process GO:1903530 regulation of secretion by cell GO:1903530 Any process that stops, prevents or reduces the frequency, rate or extent of secretion by cell. pm 2014-10-08T13:25:08Z down regulation of cellular secretion down regulation of secretion by cell down-regulation of cellular secretion down-regulation of secretion by cell downregulation of cellular secretion downregulation of secretion by cell negative regulation of cellular secretion inhibition of cellular secretion inhibition of secretion by cell biological_process GO:1903531 negative regulation of secretion by cell GO:1903531 Any process that stops, prevents or reduces the frequency, rate or extent of anion transport. sl 2015-01-12T21:50:20Z down regulation of anion transport down-regulation of anion transport downregulation of anion transport inhibition of anion transport biological_process GO:1903792 negative regulation of anion transport GO:1903792 Any process that modulates the frequency, rate or extent of cellular macromolecule biosynthetic process. tanyaberardini 2010-09-15T08:55:45Z regulation of cellular biopolymer biosynthetic process regulation of cellular macromolecule anabolism regulation of cellular macromolecule biosynthesis regulation of cellular macromolecule formation regulation of cellular macromolecule synthesis biological_process GO:2000112 regulation of cellular macromolecule biosynthetic process GO:2000112 Any process that stops, prevents, or reduces the frequency, rate or extent of cellular macromolecule biosynthetic process. tanyaberardini 2010-09-15T08:55:48Z negative regulation of cellular biopolymer biosynthetic process negative regulation of cellular macromolecule anabolism negative regulation of cellular macromolecule biosynthesis negative regulation of cellular macromolecule formation negative regulation of cellular macromolecule synthesis biological_process GO:2000113 negative regulation of cellular macromolecule biosynthetic process GO:2000113 Any process that stops, prevents or reduces the frequency, rate or extent of receptor activity. rfoulger 2010-12-02T09:28:47Z biological_process GO:2000272 negative regulation of receptor activity GO:2000272 Any process that modulates the frequency, rate or extent of a ceramide biosynthetic process. dph 2011-01-04T02:37:12Z regulation of ceramide anabolism regulation of ceramide biosynthesis regulation of ceramide formation regulation of ceramide synthesis biological_process GO:2000303 regulation of ceramide biosynthetic process GO:2000303 Any process that modulates the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity. midori 2011-02-09T02:35:27Z regulation of DNA gyrase activity regulation of DNA topoisomerase IV activity regulation of DNA topoisomerase type II activity regulation of DNA-gyrase activity regulation of deoxyribonucleic topoisomerase activity regulation of topoisomerase II regulation of type II DNA topoisomerase activity biological_process regulation of DNA topoisomerase (ATP-hydrolysing) regulation of DNA topoisomerase II regulation of deoxyribonucleate topoisomerase regulation of topoisomerase GO:2000371 regulation of DNA topoisomerase (ATP-hydrolyzing) activity GO:2000371 Any process that stops, prevents or reduces the frequency, rate or extent of DNA topoisomerase (ATP-hydrolyzing) activity. midori 2011-02-09T02:35:36Z negative regulation of DNA gyrase activity negative regulation of DNA topoisomerase IV activity negative regulation of DNA topoisomerase type II activity negative regulation of DNA-gyrase activity negative regulation of deoxyribonucleic topoisomerase activity negative regulation of topoisomerase II negative regulation of type II DNA topoisomerase activity biological_process negative regulation of DNA topoisomerase (ATP-hydrolysing) negative regulation of DNA topoisomerase II negative regulation of deoxyribonucleate topoisomerase negative regulation of topoisomerase GO:2000372 negative regulation of DNA topoisomerase (ATP-hydrolyzing) activity GO:2000372 Any process that activates or increases the frequency, rate or extent of opioid receptor signaling pathway. rfoulger 2011-03-09T09:41:35Z positive regulation of opioid receptor signalling pathway biological_process GO:2000476 positive regulation of opioid receptor signaling pathway GO:2000476 Any process that modulates the frequency, rate or extent of androgen receptor activity. yaf 2011-07-15T10:56:08Z biological_process GO:2000823 regulation of androgen receptor activity GO:2000823 Any process that stops, prevents or reduces the frequency, rate or extent of androgen receptor activity. yaf 2011-07-15T10:56:12Z biological_process GO:2000824 negative regulation of androgen receptor activity GO:2000824 Any process that modulates the frequency, rate or extent of RNA biosynthetic process. dph 2011-10-17T11:36:25Z regulation of RNA anabolism regulation of RNA biosynthesis regulation of RNA formation regulation of RNA synthesis biological_process GO:2001141 regulation of RNA biosynthetic process GO:2001141 Any process that stops, prevents or reduces the frequency, rate or extent of hydroxymethylglutaryl-CoA reductase (NADPH) activity. rfoulger 2011-11-16T11:34:17Z biological_process negative regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity negative regulation of HMG-CoA reductase activity GO:2001216 negative regulation of hydroxymethylglutaryl-CoA reductase (NADPH) activity GO:2001216 IAO:0000027 data item IAO:0000030 information content entity IAO:0000078 curation status specification The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) PERSON:Bill Bug GROUP:OBI:<http://purl.obolibrary.org/obo/obi> OBI_0000266 curation status specification IAO:0000102 data about an ontology part is a data item about a part of an ontology, for example a term Person:Alan Ruttenberg data about an ontology part NCBITaxon:2759 Eukaryota NCBITaxon:33154 Opisthokonta NCBITaxon:33208 Metazoa NCBITaxon:33213 Bilateria NCBITaxon:6072 Eumetazoa OAE:0000001 a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. Yongqun He AE adverse reaction WEB: http://en.wikipedia.org/wiki/Adverse_event WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 The OAE official website is: http://www.oae-ontology.org/. adverse event OAE:0000002 medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury. YH WEB: http://wiki.answers.com/Q/What_is_medical_intervention medical intervention OAE:0000011 a medical intervention where a patient is administered with a drug YH drug administration OAE:0000162 a peripheral neuropathy AE which has an outcome of sensory neuropathy that involves damage to nerves of the peripheral nervous system. YH, AG sensory neuropathy AE sensory neuropathy AE OAE:0000168 a peripheral neuropathy AE which is caused by a damage to motor neurons AG, YH motor neuropathy AE OAE:0000169 A peripheral neuropathy AE which is characterized by damage to more than one nerve AG, YH, RR WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html polyneuropathy AE HPO: HP_0001271 MedDRA ID: 10036105 SIDER: C0152025 OAE:0000337 an neuropathy AE that results in a damage to the peripheral nervous system (PNS, outside the brain and spinal cord), the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body. SS, YH neuropathy peripheral AE WEB: http://en.wikipedia.org/wiki/Peripheral_neuropathy WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm peripheral neuropathy AE MedDRA: 10029331 OAE:0000392 a sensory neuropathy AE that shows a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect. YH WEB: http://en.wikipedia.org/wiki/Paraesthesia Paresthesia is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic. paresthesia AE MedDRA: 10033775 OAE:0000418 a nervous system AE that shows a damage to or disease affecting the nerves. YH, RR WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm WEB: http://www.medicalnewstoday.com/articles/147963.php WEB: http://www.neuropathy.org/ neuropathy AE HPO: HP_0007141 SIDER: C0442874 OAE:0000570 an AE that occurs in nervous system. YH nervous system AE MP: MP_0003633 OAE:0000625 a peripheral neuropathy AE which has an outcome of neuritis, the local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord neuritis AE MP: MP_0006082 MedDRA ID: 10029240 OAE:0001215 a nervous system AE that alters the normal activity of the nervous system due to exposure to neurotoxins, causes damage to nervous tissue SZ, SS, YH WEB: http://en.wikipedia.org/wiki/Neurotoxicity neurotoxicity AE MedDRA: 10029350 OAE:0001287 a peripheral sensory neuropathy AE that results in the patient losing the ability to move or feel. SZ, SS, YH WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000750.htm Neuropathy can affect nerves that provide feeling (sensory neuropathy) or cause movement (motor neuropathy). It can also affect both, in which case it is called a sensorimotor neuropathy. peripheral sensorimotor neuropathy AE MedDRA: 10056673 OAE:0001288 a sensory neuropathy AE that has an outcome of damaged nerves outside the brain and spinal cord SZ, SS, YH WEB: http://medical-dictionary.thefreedictionary.com/Peripheral+sensory+neuropathy peripheral sensory neuropathy AE HPO: HP_0000763 MedDRA: 10034620 SIDER: C0151313 OAE:0002005 Carpal tunnel syndrome AE is a peripheral neuropathy AE that is a median entrapment neuropathy that causes paresthesia, pain, numbness, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel. JX, LW, YH median nerve neuropathy AE WEB: http://emedicine.medscape.com/article/1141168-clinical#showall WEB: http://en.wikipedia.org/wiki/Carpal_tunnel_syndrome 腕管综合征 carpal tunnel syndrome AE MedDRA: 10007697 OAE:0002056 an optic neuropahty AE which shows an infarction of the optic disk which presents as painless vision loss RR optic ischemic neuropathy AE WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ WEB: http://www.merckmanuals.com/professional/eye_disorders/optic_nerve_disorders/ischemic_optic_neuropathy.html ischemic optic neuropathy AE MedDRA: 10030924 OAE:0002553 a peripheral neuropathy AE which shows an damage or abnormality to the nerves in the eyes. RR, YH WEB: http://www.allaboutvision.com/conditions/optic-neuritis.htm optic neuropathy AE MedDRA: 10061323 OAE:0002554 an optic neuropathy AE characterized by optic disc swelling, peripapillary and macular hard exudates, and vitreous cells. RR, YH WEB: http://www.ncbi.nlm.nih.gov/pubmed/6466175 neuroretinitis AE MedDRA: 10060701 OAE:0002555 an optic neuropathy AE characterized by vision loss, optic disc swelling, flame hemorrhages, and cotton-wool exudates. It occurs when blood flow is interrupted to the front (anterior) part of the optic nerve (also called optic nerve head). RR, YH AION WEB: http://emedicine.medscape.com/article/1216891-overview WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ anterior ischemic optic neuropathy AE MedDRA: 10068250 OAE:0002556 a type of anterior ischemic optic neuropathy AE that presents primarily with vision loss, especially upon wakening, and sectorial disc edema. RR, YH WEB: http://emedicine.medscape.com/article/1216891-clinical#a0217 non-arteritic anterior ischemic optic neuropathy AE MedDRA: 10068249 OAE:0002557 a peripheral neuropathy AE that shows a combination of axonal and demyelinating neuropathy. RR, YH WEB: http://www.aafp.org/afp/2010/0401/p887.html mixed neuropathy AE OAE:0002558 a peripheral sensory neuropathy AE that shows neuropathy in many sensory nerves at one time RR, YH WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html sensory peripheral polyneuropathy AE OAE:0002559 a peripheral neuropathy AE that results from the loss of the myelin sheath on peripheral nerves roughly evenly distributed on both sides of the body RR, YH peripheral demyelinating polyneuropathy AE OAE:0002560 a neuropathy AE that shows nerve damage and occurs in a patient with diabetes RR, YH WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/definition/con-20033336 diabetic neuropathy AE MedDRA: 10012680 OAE:0002561 a nervous system AE that is an umbrella term referring to conditions relating to the nervous system, including loss of sensation and paralysis RR, YH WEB: http://en.wikipedia.org/wiki/Functional_neurological_deficit neurological deficit AE OBI:0000011 A processual entity that realizes a plan which is the concretization of a plan specification. planned process OBI:0000047 processed material Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples Is a material entity that is created or changed during material processing. PERSON: Alan Ruttenberg http://purl.obolibrary.org/obo/obi.owl processed material OBI:0000576 scattered molecular aggregate scattered molecular aggregate the sodium and chloride ions in a glass of salt water A scattered molecular aggregate is a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates PERSON: Alan Ruttenberg Collective Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349 scattered molecular aggregate OBI:0100026 organism animal fungus plant virus A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') GROUP: OBI Biomaterial Branch WEB: http://en.wikipedia.org/wiki/Organism organism ODNAE:0000001 a neuropathy adverse event that is associated with a drug. YH, RR drug-associated neuropathy AE ODNAE:0000002 RR, YH role in cellular and molecular interactions ODNAE:0000003 RR, YH drug-associated mixed neuropathy AE ODNAE:0000004 RR, YH drug-associated peripheral neuropathy adverse event ODNAE:0000005 RR, YH drug-associated motor neuropathy AE ODNAE:0000006 RR, YH drug-associated neuritis neuropathy AE ODNAE:0000007 RR, YH drug-associated optic neuropathy AE ODNAE:0000008 RR, YH drug-associated diabetic neuropathy AE ODNAE:0000009 RR, YH drug-associated neuroretinitis neuropathy AE ODNAE:0000010 RR, YH drug-associated polyneuropathy AE ODNAE:0000011 RR, YH drug-associated sensory neuropathy AE ODNAE:0000012 RR, YH drug-associated neurotoxicity neuropathy AE ODNAE:0000013 RR, YH drug-associated peripheral sensory neuropathy AE ODNAE:0000014 RR, YH drug-associated sensory peripheral polyneuropathy AE ODNAE:0000015 RR, YH drug-associated peripheral sensorimotor neuropathy AE ODNAE:0000016 RR, YH drug-associated peripheral demyelinating polyneuropathy AE ODNAE:0000017 RR, YH drug-associated anterior ischemic optic neuropathy AE ODNAE:0000018 RR, YH drug-associated non-arteritic anterior ischemic optic neuropathy AE ODNAE:0000019 RR, YH drug-associated carpal tunnel syndrome AE ODNAE:0000020 RR, YH drug-associated neurological deficit AE ODNAE:0000022 RR, YH drug-associated paresthesia AE ODNAE:0000023 RR, AG, YH WEB: http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/UCM130802.pdf ciprofloxacin hydrochloride (Ciloxan, Cipro, Cetraxal)-associated peripheral neuropathy AE ODNAE:0000024 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050679s036lbl.pdf cefepime (Maxipime)-associated neurotoxicity AE ODNAE:0000025 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050141s231lbl.pdf penicillin G benzathine (Bicillin L-A)-associated neuropathy AE ODNAE:0000026 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021549s021lbl.pdf fosaprepitant dimeglumine (Emend)-associated sensory neuropathy AE ODNAE:0000027 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf emtricitabine (Emtriva)-associated neuropathy AE ODNAE:0000028 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021500s019lbl.pdf emtricitabine (Emtriva)-associated peripheral neuritis AE ODNAE:0000029 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020533s028lbl.pdf ropivacaine (Naropin)-associated neuropathy AE ODNAE:0000030 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019810s095,022056s011lbl.pdf omeprazole (Prilosec)-associated anterior ischemic optic neuropathy AE ODNAE:0000031 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/016295s041s042lbl.pdf hydroxyurea (Droxia, Hydrea)-associated peripheral neuropathy AE ODNAE:0000032 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202429s000lbl.pdf vemurafenib (Zelboraf)-associated peripheral neuropathy AE ODNAE:0000033 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf ipilimumab (Yervoy)-associated neuropathy AE ODNAE:0000034 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125289s0038lbl.pdf golimumab (Simponi)-associated peripheral demylinating polyneuropathy AE ODNAE:0000035 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103949s5217s5222lbl.pdf peginterferon alfa-2b (Peg Intron, Sylatron)-associated peripheral neuropathy AE ODNAE:0000036 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5301lbl.pdf infliximab (Remicade)-associated neuropathy AE ODNAE:0000037 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neuropathy AE ODNAE:0000038 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050708s036s037,050709s028s030lbl.pdf tacrolimus (Astagraf XL, Hecoria, Prograf, Protopic)-associated neurotoxicity AE ODNAE:0000039 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022505s001s003lbl.pdf tesamorelin (Egrifta)-associated peripheral neuropathy AE ODNAE:0000040 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022234s000lbl.pdf docetaxel (Taxotere, Docefrez)-associated neuropathy AE ODNAE:0000041 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022187s008lbl.pdf etravirine (Intelence)-associated peripheral neuropathy AE ODNAE:0000042 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022128s007lbl.pdf maraviroc (Selzentry)-associated peripheral neuropathy AE ODNAE:0000043 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022108s005s006lbl.pdf bupropion (Aplezin, Wellbutrin, Zyban, Budeprion SR, Buproban, Forfivo XL)-associated neuropathy AE ODNAE:0000044 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022068s008s009lbl.pdf nilotinib (Tasigna)-associated peripheral neuropathy AE ODNAE:0000045 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022065s006lbl.pdf ixabepilone (Ixempra)-associated peripheral neuropathy AE ODNAE:0000046 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022011S012,022154S009lbl.pdf telbivudine (Tyzeka)-associated peripheral neuropathy AE ODNAE:0000047 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021986s009s010lbl.pdf dasatinib (Sprycel)-associated neuropathy AE ODNAE:0000048 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021923s012lbl.pdf sorafenib (NexAVAR)-associated sensory neuropathy AE ODNAE:0000049 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021880s023lbl.pdf lenalidomide (Revlimid)-associated neuropathy AE ODNAE:0000050 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021814s011lbl.pdf tipranavir (Aptivus)-associated peripheral neuropathy AE ODNAE:0000051 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021806s003lbl.pdf metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated peripheral neuropathy AE ODNAE:0000052 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021732s007s010s012lbl.pdf histrelin (Vantas, Supprelin LA)-associated neuropathy AE ODNAE:0000053 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021602s029s030lbl.pdf bortezomib (Velcade)-associated peripheral neuropathy AE ODNAE:0000054 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021588s030s031lbl.pdf imatinib (Gleevec)-associated peripheral neuropathy AE ODNAE:0000055 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021572s038lbl.pdf daptomycin (Cubicin)-associated peripheral neuropathy AE ODNAE:0000056 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021567s026lbl.pdf atazanavir (Reyataz)-associated peripheral neurologic symptoms AE ODNAE:0000057 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021481s020lbl.pdf enfuvirtide (Fuzeon)-associated peripheral neuropathy AE ODNAE:0000058 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf pemetrexed (Alimta)-associated motor neuropathy AE ODNAE:0000059 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021462s029s030s032lbl.pdf pemetrexed (Alimta)-associated sensory neuropathy AE ODNAE:0000060 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021400s013lbl.pdf vardenafil (Levitra, Staxyn)-associated non-arteritic anterior ischemic optic neuropathy AE ODNAE:0000061 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021356s041lbl.pdf tenofovir (Viread)-associated peripheral neuropathy AE ODNAE:0000062 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021266s035,021267s040,021630s026lbl.pdf voriconazole (Vfend)-associated neuropathy AE ODNAE:0000063 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021158s021lbl.pdf gemifloxacin (Factive)-associated peripheral neuropathy AE ODNAE:0000064 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021085s050s053,021277s046s050lbl.pdf moxifloxacin (Avelox, Vigamox, Moxeza)-associated peripheral neuropathy AE ODNAE:0000065 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021055s006lbl.pdf bexarotene (Targretin)-associated neuropathy AE ODNAE:0000066 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021041s023lbl.pdf cytarabine (Cytosar-U, Tarabine PFS)-associated peripheral neuropathy AE ODNAE:0000067 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021016s018lbl.pdf eletriptan (Relpax)-associated neuropathy AE ODNAE:0000068 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020972s040lbl.pdf efavirenz (Sustiva)-associated neuropathy AE ODNAE:0000069 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020905s022lbl.pdf leflunomide (Arava)-associated peripheral neuropathy AE ODNAE:0000070 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020896s026lbl.pdf capecitabine (Xeloda)-associated peripheral sensory neuropathy AE ODNAE:0000071 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020895s036lbl.pdf sildenafil (Revatio, Viagra)-associated neuropathy AE ODNAE:0000072 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020829s060,020830s062,021409s037lbl.pdf montelukast (Singulair)-associated neuropathy AE ODNAE:0000073 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020753s009s011s012lbl.pdf exemestane (Aromasin)-associated neuropathy AE ODNAE:0000074 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020715s025,021288s022,022437s003lbl.pdf triptorelin (Trelstar)-associated neuropathy AE ODNAE:0000075 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020667s025lbl.pdf pramipexole (Mirapex)-associated neuropathy AE ODNAE:0000076 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020659s055,022417s006lbl.pdf ritonavir (Norvir)-associated neuropathy AE ODNAE:0000077 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020636s039_020933s030lbl.pdf nevirapine (Viramune)-associated paresthesia AE ODNAE:0000078 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020634s062s064,020635s068s070,021721s029s031lbl.pdf levofloxacin (Levaquin, Quixin, Iquix)-associated peripheral neuropathy AE ODNAE:0000079 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020564s031,020596s030lbl.pdf lamivudine (Epivir)-associated neuropathy AE ODNAE:0000080 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020547s031lbl.pdf zafirlukast (Accolate)-associated neuropathy AE ODNAE:0000081 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020509s069lbl.pdf gemcitabine (Gemzar)-associated neuropathy AE ODNAE:0000082 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020505s042,020844s036lbl.pdf topiramate (Topamax, Topiragen, Trokendi XR, Qudexy XR)-associated neuropathy AE ODNAE:0000083 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020427s002lbl.pdf vigabatrin (Sabril)-associated peripheral neuropathy AE ODNAE:0000084 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020412s038,020413s030lbl.pdf stavudine (Zerit)-associated peripheral neuropathy AE ODNAE:0000085 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020386s056lbl.pdf losartan (Cozaar)-associated peripheral neuropathy AE ODNAE:0000086 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020261s042,021192s016lbl.pdf fluvastatin (Lescol)-associated peripheral neuropathy AE ODNAE:0000087 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020156s048lbl.pdf desipramine (Norpramin)-associated peripheral neuropathy AE ODNAE:0000088 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020140s002lbl.pdf levoleucovorin (Fusilev)-associated neuropathy AE ODNAE:0000089 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020092s017lbl.pdf diltiazem (Dilacor, Cardizem, Cartia XT, Tiazac, Dilt-CD, Dilt-XR, Diltia XT)-associated neuropathy AE ODNAE:0000090 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020031s058s066,020710s022s030lbl.pdf paroxetine (Paxil, Pexeva, Brisdelle)-associated neuropathy AE ODNAE:0000091 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019943s032,020011s039lbl.pdf leuprolide acetate (Lupron, Eligard, Viadur)-associated peripheral neuropathy AE ODNAE:0000092 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019901s058lbl.pdf ramipril (Altace)-associated neuropathy AE ODNAE:0000093 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019898s061lbl.pdf pravastatin (Pravachol)-associated neuropathy AE ODNAE:0000094 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s020lbl.pdf sotalol (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE ODNAE:0000095 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019821s018lbl.pdf acitretin (Soriatane)-associated peripheral neuropathy AE ODNAE:0000096 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019787s052lbl.pdf amlodipine (Norvasc)-associated neuropathy peripheral AE ODNAE:0000097 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019766s083lbl.pdf simvastatin (Zocor)-associated peripheral neuropathy AE ODNAE:0000098 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019763s016lbl.pdf ifosfamide (Ifex)-associated polyneuropathy AE ODNAE:0000099 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019735s061lbl.pdf ofloxacin (Floxin, Ocuflox)-associated peripheral neuropathy AE ODNAE:0000100 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019655s052,019910s039,020518s022lbl.pdf zidovudine (Retrovir)-associated neuropathy AE ODNAE:0000101 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019558s054lbl.pdf lisinopril (Prinivil, Zestril)-associated peripheral neuropathy AE ODNAE:0000102 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019537s074,020780s032lbl.pdf ciprofloxacin (Cipro, Ciloxan, Cetraxal)-associated peripheral neuropathy AE ODNAE:0000103 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019507s008lbl.pdf betaxolol (Kerlone, Betoptic S)-associated neuropathy AE ODNAE:0000104 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019384s060lbl.pdf norfloxacin (Noroxin)-associated peripheral neuropathy AE ODNAE:0000105 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018972s044lbl.pdf amiodarone (Cordarone, Pacerone)-associated peripheral neuropathy AE ODNAE:0000106 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018057s081lbl.pdf cisplatin (Platinol)-associated peripheral neuropathy AE ODNAE:0000107 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017422s042lbl.pdf carmustine (Bicnu, Gliadel)-associated neuroretinitis AE ODNAE:0000108 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016267s050lbl.pdf deferoxamine (Desferal)-associated mixed neuropathy AE ODNAE:0000109 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/010669s032lbl.pdf chlorambucil (Leukeran)-associated peripheral neuropathy AE ODNAE:0000110 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/006188s021s022lbl.pdf propylthiouracil-associated neuropathy AE ODNAE:0000111 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf eribulin (Halaven)-associated peripheral neuropathy AE ODNAE:0000112 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf cabazitaxel (Jevtana)-associated peripheral neuropathy AE ODNAE:0000113 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125160s111lbl.pdf certolizumab pegol (Cimzia)-associated peripheral neuropathy AE ODNAE:0000114 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf erlotinib (Tarceva)-associated neuropathy AE ODNAE:0000115 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021549s017lbl.pdf aprepitant (Emend)-associated sensory neuropathy AE ODNAE:0000116 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021348s008lbl.pdf miglustat (Zavesca)-associated peripheral neuropathy AE ODNAE:0000117 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021304s008,022257s003lbl.pdf valganciclovir (Valcyte)-associated peripheral neuropathy AE ODNAE:0000118 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021130s022lbl.pdf linezolid (Zyvox)-associated optic neuropathy AE ODNAE:0000119 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020825s038,020919s025,021483s005lbl.pdf ziprasidone (Geodon)-associated neuropathy AE ODNAE:0000120 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020671s016s017lbl.pdf topotecan (Hycamtin)-associated neuropathy AE ODNAE:0000121 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020498s022lbl.pdf bicalutamide (Casodex)-associated neuropathy AE ODNAE:0000122 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020151s056s057lbl.pdf venlafaxine (Effexor)-associated neuropathy AE ODNAE:0000123 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020083s046lbl.pdf itraconazole (Onmel, Sporanox)-associated neuropathy AE ODNAE:0000124 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020038s033lbl.pdf fludarabine (Fludara)-associated peripheral neuropathy AE ODNAE:0000125 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/019908s029lbl.pdf zolpidem (Zolpimist, Ambien, Edluar, Intermezzo)-associated neuropathy AE ODNAE:0000126 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012802s031lbl.pdf triamcinolone (Aristocort, Azmacort, Cinolar, Kenalog, Nasacort, Clinacort, Triam-Forte, Triamcot, Aristospan)-associated neuropathy AE ODNAE:0000127 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf metronidazole (Flagyl, Metrocream, Metrogel, Metrolotion, Noritate)-associated optic neuropathy AE ODNAE:0000128 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/078810s000lbl.pdf oxaliplatin (Eloxatin)-associated neuropathy AE ODNAE:0000129 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/050715s028,050716s029lbl.pdf cyclosporine (Gengraf, Neoral, Sandimmune, Restasis)-associated neuropathy AE ODNAE:0000130 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022395lbl.pdf capsaicin (Zostrix, Capsagel, Capsagesic HP, Capsin, Trixaicin, Pain Enz, Rid-A-Pain, Sportsmed)-associated peripheral sensory neuropathy AE ODNAE:0000131 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021877s001lbl.pdf nelarabine (Arranon)-associated peripheral neuropathy AE ODNAE:0000132 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021794s006lbl.pdf dapsone (Aczone)-associated peripheral neuropathy AE ODNAE:0000133 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021641s002s003s004s005s007s008s010lbl.pdf rasagiline (Azilect)-associated neuropathy AE ODNAE:0000134 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021476s012lbl.pdf eszopiclone (Lunesta)-associated neuropathy AE ODNAE:0000135 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021001s010s011lbl.pdf almotriptan (Axert)-associated neuropathy AE ODNAE:0000136 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020702s056lbl.pdf atorvastatin (Lipitor)-associated peripheral neuropathy AE ODNAE:0000137 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020697s013s015lbl.pdf tolcapone (Tasmar)-associated neuropathy AE ODNAE:0000138 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020064s019lbl.pdf nitrofurantoin (Furadantin)-associated peripheral neuropathy AE ODNAE:0000139 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019715s027lbl.pdf olsalazine sodium (Dipentum)-associated peripheral neuropathy AE ODNAE:0000140 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf mefloquine (Lariam)-associated sensory neuropathy AE ODNAE:0000141 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019591s026s028lbl.pdf mefloquine (Lariam)-associated motor neuropathy AE ODNAE:0000142 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019268s041lbl.pdf misoprostol (Cytotec)-associated neuropathy AE ODNAE:0000143 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/018332s032lbl.pdf indomethacin (Indocin, Tivorbex)-associated peripheral neuropathy AE ODNAE:0000144 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf etidronate (Didronel)-associated peripheral neuropathy AE ODNAE:0000145 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf sulfasalazine (Azulfidine, Sulfazine)-associated peripheral neuropathy AE ODNAE:0000146 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf doxorubicin (Doxil, Adriamycin)-associated peripheral neuropathy AE ODNAE:0000147 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022301lbl.pdf mesalamine (Canasa, Pentasa, Rowasa, Lialda, Apriso, Asacol HD, sfRowasa, Delzicol)-associated peripheral neuropathy AE ODNAE:0000148 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021479s003s004lbl.pdf selegiline (Emsam, Eldepryl, Zelapar)-associated neuropathy AE ODNAE:0000149 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020658s018s020s021lbl.pdf ropinirole (Requip)-associated peripheral neuropathy AE ODNAE:0000150 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/018998s071lbl.pdf enalapril maleate (Vasotec, Epaned)-associated peripheral neuropathy AE ODNAE:0000151 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021777lbl.pdf cyclobenzaprine (Flexeril, Amrix, Fexmid, FusePaq Tabradol)-associated peripheral neuropathy AE ODNAE:0000152 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021618s003lbl.pdf tinidazole (Tindamax)-associated neuropathy AE ODNAE:0000153 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020859s011lbl.pdf zaleplon (Sonata)-associated neuropathy AE ODNAE:0000154 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020068s017lbl.pdf foscarnet (Foscavir)-associated neuropathy AE ODNAE:0000155 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019998s013lbl.pdf succimer (Chemet)-associated sensorimotor neuropathy AE ODNAE:0000156 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019906s34lbl.pdf clomipramine (Anafranil)-associated neuropathy AE ODNAE:0000157 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018013s58lbl.pdf nortriptyline (Aventyl, Pamelor)-associated peripheral neuropathy AE ODNAE:0000158 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/016792s025lbl.pdf trimipramine (Surmontil)-associated peripheral neuropathy AE ODNAE:0000159 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021430s000,020785s031lbl.pdf thalidomide (Thalomid)-associated peripheral neuropathy AE ODNAE:0000160 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020989s008lbl.pdf cevimeline (Evoxac)-associated neuropathy AE ODNAE:0000161 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020397s021,021447s002lbl.pdf tizanidine (Zanaflex)-associated neuropathy AE ODNAE:0000162 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020154s50,20155s39,20156s40,21183s16lbl.pdf didanosine (Videx)-associated peripheral neuropathy AE ODNAE:0000163 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019661s030lbl.pdf ganciclovir (Cytovene, Vitrasert, Zirgan)-associated neuropathy AE ODNAE:0000164 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/017001s027lbl.pdf flucytosine (Ancobon)-associated peripheral neuropathy AE ODNAE:0000165 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20013s015lbl.pdf lomefloxacin (Maxaquin)-associated peripheral neuropathy AE ODNAE:0000166 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021785s001,002,020828s019,020,020628s022,023lbl.pdf saquinavir (Invirase)-associated peripheral neuropathy AE ODNAE:0000167 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21341lbl.pdf valdecoxib (Bextra)-associated neuropathy AE ODNAE:0000168 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21316s010lbl.pdf lovastatin (Altoprev, Mevacor)-associated peripheral neuropathy AE ODNAE:0000169 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/20549slr016,20548slr020,20121slr030_flonase_lbl.pdf fluticasone (Flonase, Cutivate, Flovent)-associated neuropathy AE ODNAE:0000170 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/19853s012,014lbl.pdf penicillamine (Cuprimine, Depen)-associated peripheral neuropathy AE ODNAE:0000171 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11664slr062_decadron_lbl.pdf dexamethasone (Decadron, DexPak, Maxidex, Dekpak 13 day Taperpak, Baycadron Elixer, Ozurdex)-associated neuropathy AE ODNAE:0000172 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/021052s026_021042s019lbl.pdf This drug has been withdrawn from the US market. rofecoxib-associated median nerve neuropathy AE ODNAE:0000173 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/basnov010203LB.htm basiliximab (Simulect)-associated neuropathy AE ODNAE:0000174 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2003/19385slr030,031,035_permax_lbl.pdf This drug has been withdrawn from the US market. pergolide (Permax)-associated neuropathy AE ODNAE:0000175 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20388S014lbl.pdf vinorelbine (Navelbine)-associated neuropathy AE ODNAE:0000176 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/20199s16lbl.pdf This drug has been discontinued from the US market. zalcitabine-associated peripheral neuropathy AE ODNAE:0000177 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20740S19lbl.pdf This drug has been withdrawn from the US market. cerivastatin (Baycol)-associated peripheral neuropathy AE ODNAE:0000178 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20705S8lbl.pdf delavirdine (Rescriptor)-associated neuropathy AE ODNAE:0000179 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/98/74-739_Amiodarone_prntlbl.pdf amiodarone hydrochloride (Cordarone, Pacerone)-associated optic neuropathy AE ODNAE:0000180 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2002/75184_Paclitaxel_Prntlbl.pdf paclitaxel (Taxol, Onxol, Nov-Onxol, Paclitaxel Novaplus)-associated peripheral neuropathy AE ODNAE:0000181 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ff61b237-be8e-461b-8114-78c52a8ad0ae#nlm34084-4 tadalafil (Cialis, Adcirca)-associated non-arteritic anterior ischemic optic neuropathy AE ODNAE:0000182 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fead084a-a376-4d57-bdf0-aa7ed3655505#nlm34084-4 rivastigmine (Exelon)-associated peripheral neuropathy AE ODNAE:0000183 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fcb8ef8a-f770-4416-8fc5-fa01d98c8eee#nlm34084-4 mitoxantrone hydrochloride (Novantrone)-associated neurological deficit AE ODNAE:0000184 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f94b2ba4-024f-4068-8759-da6c8d31c546#nlm34084-4 zonisamide (Zonegran)-associated neuropathy AE ODNAE:0000185 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f16f9ae6-d29f-4b31-a240-c7ebb0d7d36a#nlm34084-4 sotalol hydrochloride (Betapace, Sorine, Sotylize)-associated peripheral neuropathy AE ODNAE:0000186 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e3105799-a4b6-f3f4-e6e2-b2b29bbdb538#nlm34084-4 propofol (Diprivan, Fresenious Propoven)-associated neuropathy AE ODNAE:0000187 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2ad9d3c-b6c3-4f70-87e0-722a8ff94ccb#nlm34084-4 pentamidine (Nebupent, Pentam)-associated neuropathy AE ODNAE:0000188 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=de1c8271-64d8-4ea5-85e8-871faa4d7632#nlm34084-4 procarbazine 50 MG oral capsule [Matulane]-associated neuropathy AE ODNAE:0000189 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d6918541-6285-48ea-8255-23212f9a3ad7#nlm34084-4 penicillin V potassium (Veetids, Truxcillin VK)-associated neuropathy AE ODNAE:0000190 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d1dde497-1889-4424-af18-da7ca6459cf3#nlm34084-4 Imipramine pamoate (Tofranil-PM)-associated peripheral neuropathy AE ODNAE:0000191 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ccb4d123-7b12-4aef-8ef0-f8d68c1a6547#nlm34084-4 methylprednisolone acetate (Depo-Medrol)-associated neuropathy AE ODNAE:0000192 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=be27854a-a805-4300-9729-accd1b7f226f#nlm34084-4 This drug has been discontinued from the US market. sulfamethizole-associated neuropathy AE ODNAE:0000193 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bac91e37-91ce-4bbf-77bc-ef5f242589f8#nlm34084-4 zolmitriptan (Zomig)-associated neuropathy AE ODNAE:0000194 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4 ethambutol (Myambutol)-associated peripheral neuritis AE ODNAE:0000195 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b2f95b0b-9de3-4c0b-a46e-a7eee6428b4b#nlm34084-4 ethambutol hydrochloride (Myambutol)-associated optic neuropathy AE ODNAE:0000196 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563#nlm34084-4 rituximab (Rituxan)-associated peripheral sensory neuropathy AE ODNAE:0000197 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=acd53964-52dc-4534-b20f-14a7561b8a6c#nlm34084-4 amitriptyline hydrochloride (Elavil, Vanatrip)-associated peripheral neuropathy AE ODNAE:0000198 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aa2e353f-860b-4d10-9a62-aad1c533b8aa#nlm34084-4 gabapentin (Gabarone, Neurontin, Gralise, FusePaq Fanatrex)-associated neuropathy AE ODNAE:0000199 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a6c72634-4613-4d21-bc9a-09dad17eb137#nlm34084-4 tolmetin (Tolectin)-associated optic neuropathy AE ODNAE:0000200 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=65b28775-ee59-88cf-e4d8-372c6c79ad14#nlm34084-4 megestrol (Megace)-associated neuropathy AE ODNAE:0000201 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=60185c88-ecfd-46f9-adb9-b97c6b00a553#nlm34084-4 pregabalin (Lyrica)-associated neuropathy AE ODNAE:0000202 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=55311747-710c-43c4-821d-76323ff2520e#nlm34084-4 imipramine (Tofranil, Tofranil-PM)-associated peripheral neuropathy AE ODNAE:0000203 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=532f0c6c-cd76-44d1-27b7-581cee86bc34#nlm34084-4 methylprednisolone (Medrol, Methylpred-DP)-associated neuropathy AE ODNAE:0000204 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d80812c-dfc1-456c-9368-697267630c2c#nlm34084-4 fluvoxamine maleate (Luvox)-associated neuropathy AE ODNAE:0000205 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4d0f0f1a-31af-40fa-9c64-e90891fa6ce4#nlm34084-4 mitoxantrone (Novantrone)-associated neuropathy AE ODNAE:0000206 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4b4edc09-bbfd-471f-ac16-6118937a6e7e#nlm34084-4 pantoprazole (Protonix)-associated neuropathy AE ODNAE:0000207 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4a4c577d-9267-40eb-9ed9-09ceb6377026#nlm34084-4 phenytoin (Dilantin, Phenytek)-associated sensory peripheral polyneuropathy AE ODNAE:0000208 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4 trastuzumab (Herceptin)-associated motor neuropathy AE ODNAE:0000209 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=492dbdb2-077e-4064-bff3-372d6af0a7a2#nlm34084-4 trastuzumab (Herceptin)-associated sensory neuropathy AE ODNAE:0000210 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3f60ac2e-031a-48fa-ab47-4e3aec49cb83#nlm34084-4 losartan potassium (Cozaar)-associated peripheral neuropathy AE ODNAE:0000211 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=34868f95-78d0-4089-8cbd-bec1cb730eda#nlm34084-4 metolazone (Mykrox, Zaroxolyn)-associated neuropathy AE ODNAE:0000212 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=27cfe684-7d11-4f37-9c8b-b2bdd6b5348e#nlm34084-4 haloperidol (Haldol)-associated neurotoxicity AE ODNAE:0000213 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=173018f5-fd76-4480-90f8-4b7efe328444#nlm34084-4 lomefloxacin hydrochloride (Maxaquin)-associated peripheral neuropathy AE ODNAE:0000214 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=13d85420-75e2-46e7-93eb-dcd10675cd03#nlm34084-4 ticlopidine (Ticlid)-associated peripheral neuropathy AE ODNAE:0000215 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=12850de3-c97c-42c1-b8d3-55dc6fd05750#nlm34084-4 disulfiram (Antabuse)-associated peripheral neuropathy AE ODNAE:0000216 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4 nitrofurantoin macrocrystals (Macrodantin)-associated peripheral neuropathy AE ODNAE:0000217 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=013433a1-c27c-4712-a03b-0949b2969fbb#nlm34084-4 nitrofurantoin, monohydrate (Macrobid)-associated peripheral neuropathy AE ODNAE:0000218 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f694c617-3383-416c-91b6-b94fda371204&type=display fluconazole (Diflucan)-associated paresthesia AE ODNAE:0000219 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f1ffd18c-9f6b-4479-94b9-6890bc730ecc&type=display fludarabine phosphate-associated peripheral neuropathy AE ODNAE:0000220 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=90b94524-f913-48b3-3771-7b2fcffd888a&type=display fentanyl (Actiq, Duragesic, Subsys, Fentora, Abstral)-associated neuropathy AE ODNAE:0000221 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8dbc0e47-8df9-4484-903b-70fdd26f7998&type=display insulin, protamine zinc, human 40 UNT/ML injectable suspension [ProZinc]-associated diabetic neuropathy AE ODNAE:0000222 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8379f1db-4255-4285-abd3-8ecdcaf03372&type=display fluorouracil (Carac, Efudex, Fluoroplex, Adrucil)-associated neurotoxicity AE ODNAE:0000223 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=806736d3-215a-4df5-8187-97f2161e5a53&type=display carboplatin (Paraplatin)-associated peripheral neuropathy AE ODNAE:0000224 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=77795c31-1cdf-4a20-b4a1-cd15f5b310f1&type=display isoniazid (Nydrazid)-associated peripheral neuropathy AE ODNAE:0000225 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6cf2e15a-6286-41f7-aa7d-3968d735c864&type=display methotrexate (Rheumatrex, Trexall, Otrexup, Rasuvo)-associated neurotoxicity AE ODNAE:0000226 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=2f7d5e7f-79aa-4f3a-b9a6-758d9f3ce74d&type=display imipramine hydrochloride (Tofranil)-associated peripheral neuropathy AE ODNAE:0000227 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=063fa789-4570-4715-c3bd-1bad0449fb26&type=display tamoxifen (Nolvadex, Soltamox)-associated neurotoxicity AE ODNAE:0000228 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026#section-6 colchicine (Colcrys, Mitigare)-associated sensory motor neuropathy AE ODNAE:0000229 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202570s003lbl.pdf crizotinib (Xalkori)-associated neuropathy AE ODNAE:0000230 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=73cd79c1-6bab-4d7b-ae8b-0176efbaf5b9#nlm34084-4 allopurinol (Zyloprim, Aloprim)-associated peripheral neuropathy AE ODNAE:0000231 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103293s5130lbl.pdf aldesleukin (Proleukin)-associated neuropathy AE ODNAE:0000232 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=8456a8db-a7f6-4bc0-86be-e9c8c374140b&type=display altretamine (Hexalen)-associated peripheral neuropathy AE ODNAE:0000233 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fc78c074-3ca8-4e29-9c18-8fab97558fc2&type=display amantadine (Symmetrel)-associated paresthesia AE ODNAE:0000234 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=03586c40-eb32-45c5-beb7-6762a6b78790&type=display anastrozole (Arimidex)-associated paresthesia AE ODNAE:0000235 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=05c34ddf-a0f7-4267-83f5-d02be3defc37&type=display auranofin (Ridaura)-associated peripheral neuropathy AE ODNAE:0000236 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202276s001lbl.pdf avanafil (Stendra)-associated non-arteritic anterior ischemic optic neuropathy AE ODNAE:0000237 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202714lbl.pdf carfilzomib (Kyprolis)-associated peripheral neuropathy AE ODNAE:0000238 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display cladribine (Leustatin)-associated peripheral sensory neuropathy AE ODNAE:0000239 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display cladribine (Leustatin)-associated motor neuropathy AE ODNAE:0000240 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a2592a9b-bca6-4a5a-89c2-855a0634d5fe&type=display cladribine (Leustatin)-associated polyneuropathy AE ODNAE:0000241 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=e28c05f0-081f-406d-8bfb-9160a6908307&type=display etoposide (Vepesid, Etopophos)-associated peripheral neurotoxicity AE ODNAE:0000242 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=fa68b35e-9f50-408b-9e70-e84cecf3fd6e&type=display flecainide (Tambocor)-associated neuropathy AE ODNAE:0000243 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a29045b5-ba4f-407a-a0fd-3ef7e1ce64ee&type=display gold sodium thiomalate (Myochrysine)-associated peripheral neuropathy AE ODNAE:0000244 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=416ab996-a2e8-4fe1-a9c9-f10b86df3bb5&type=display iopamidol (Isovue)-associated paresthesia AE ODNAE:0000245 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=924c5a35-4804-4e14-a2fc-2b84d186d257&type=display lansoprazole (Prevacid)-associated paresthesia AE ODNAE:0000246 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=dc92f45f-8d27-4dcb-b72d-6b8b04c6f0ce&type=display methimazole (Tapazole)-associated paresthesia AE ODNAE:0000247 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=700abc58-9362-4ef5-9d7a-dd3c4d364d0a&type=display protriptyline (Vivactil)-associated peripheral neuropathy AE ODNAE:0000248 RR, AG, YH WEB: http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e&type=display streptomycin-associated paresthesia AE ODNAE:0000249 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf teniposide (Vumon)-associated neurotoxicity AE ODNAE:0000250 RR, AG, YH WEB: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202992s000lbl.pdf teriflunomide (Aubagio)-associated peripheral neuropathy AE OGMS:0000060 Albert Goldfain creation date: 2009-06-23T11:53:49Z bodily process OGMS:0000061 A bodily process that is clinically abnormal. Albert Goldfain http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf creation date: 2009-06-23T11:54:29Z pathological bodily process A time quality inhering in a bearer by virtue of how long the bearer has existed. PATO:0000011 age PATO:0000011 A quality in which events occur in sequence. PATO:0000165 time PATO:0000165 A quality of a physical entity that exists through action of continuants at the physical level of organisation in relation to other entities. PATO:0002079 Wikipedia:Physical_property relational physical quality PATO:0001018 physical quality PATO:0001018 A quality which inheres in a continuant. PATO:0001237 PATO:0001238 snap:Quality monadic quality of a continuant multiply inhering quality of a physical entity quality of a continuant quality of a single physical entity quality of an object quality of continuant monadic quality of an object monadic quality of continuant PATO:0001241 Relational qualities are qualities that hold between multiple entities. Normal (monadic) qualities such as the shape of a eyeball exist purely as a quality of that eyeball. A relational quality such as sensitivity to light is a quality of that eyeball (and connecting nervous system) as it relates to incoming light waves/particles. physical object quality PATO:0001241 PATO:0001992 cellularity PATO:0001993 multicellular PATO:0001995 organismal quality A major division of the nervous system that contains nerves which connect the central nervous system (CNS) with sensory organs, other organs, muscles, blood vessels and glands. Nervous structures including ganglia outside of the central nervous system. Kimmel et al, 1995.[TAO] Part of nervous system in which nerves extend throughout the body outside of the brain and spinal cord.[AAO] The peripheral nervous system (PNS) is the part of the nervous system connected to the CNS which contains cranial nerves III - XII, spinal, peripheral and autonomic nerves. (CUMBO) (...) specific vertebrate traits within the chordate phylum such as skeletal tissues, PNS, and spectacular head and brain development, are linked to the NC (neural crest) and its derivatives.[well established][VHOG] AAO:0000429 BAMS:PNS BILA:0000081 BTO:0001028 CALOHA:TS-0808 EFO:0000891 EHDAA2:0001445 EHDAA:2893 EMAPA:16665 EMAPA:18370 EV:0100335 FBbt:00005098 FMA:9903 GAID:715 MA:0000218 MAT:0000338 MESH:A08.800 MIAA:0000338 TAO:0000142 UMLS:C0206417 UMLS:C1305921 VHOG:0000399 XAO:0000178 ZFA:0000142 http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=247 uberon PNS lateral part of the basal amygdalar nucleus lateral part of the basolateral nucleus nucleus amygdalae basalis, pars lateralis nucleus amygdaloideus basalis, pars lateralis magnocellularis nucleus basalis lateralis amygdalae pars peripherica; systema nervosum periphericum UBERON:0000010 peripheral nervous system UBERON:0000010 An organ that is capable of detection of chemical stimulus involved in sensory perception of smell. AEO:0000094 BSA:0000121 BTO:0000202 CALOHA:TS-2043 EHDAA2:0001824 EHDAA:500 EMAPA:16192 EMAPA:35955 FBbt:00005155 GAID:63 HAO:0000930 MA:0000017 MESH:A09 UMLS:C0935626 VHOG:0001407 WBbt:0006929 organ of sense organ system organ of sensory organ system organ of sensory system sense organ system organ sensory organ sensory organ system organ sensory system organ sensillum uberon Sinnesorgan sensor UBERON:0000020 sense organ UBERON:0000020 Material anatomical entity that has inherent 3D shape and is generated by coordinated expression of the organism's own genome. AAO:0010825 AEO:0000003 BILA:0000003 CARO:0000003 EHDAA2:0003003 EMAPA:0 FBbt:00007001 FMA:67135 GAID:781 HAO:0000003 MA:0003000 MESH:A13 TAO:0000037 TGMA:0001823 VHOG:0001759 WBbt:0000100 XAO:0003000 ZFA:0000037 biological structure uberon UBERON:0000061 anatomical structure UBERON:0000061 Anatomical structure that performs a specific function or group of functions [WP]. Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. CARO does not include a generic 'organ' class, only simple and compound organ EFO:0000634 EMAPA:35949 ENVO:01000162 FMA:67498 MA:0003001 OpenCyc:Mx4rv5XMb5wpEbGdrcN5Y29ycA OpenCyc:Mx4rwP3iWpwpEbGdrcN5Y29ycA UMLS:C0178784 WBbt:0003760 uberon anatomical unit body organ element UBERON:0000062 organ UBERON:0000062 The stage of development at which the animal is fully formed, including immaturity and maturity. Includes both sexually immature stage, and adult stage. adult stage BTO:0001043 BilaDO:0000004 EFO:0001272 FBdv:00005369 WBls:0000041 XtroDO:0000084 fully formed animal stage juvenile-adult stage uberon UBERON:0000066 fully formed stage UBERON:0000066 A stage that is part of the embryo stage. embryonic stage part uberon UBERON:0000067 embryo stage part UBERON:0000067 A life cycle stage that starts with fertilization and ends with the fully formed embryo. BilaDO:0000002 EV:0300001 FBdv:00005289 HsapDv:0000002 MmusDv:0000002 OGES:000000 OGES:000022 WBls:0000003 WBls:0000092 WBls:0000102 XAO:1000012 embryonic stage uberon embryogenesis UBERON:0000068 embryo stage UBERON:0000068 End of the life of an organism. ncit:Death is an outcome XAO:0000437 XtroDO:0000085 uberon death UBERON:0000071 death stage UBERON:0000071 stage succeeding embryo, including mature structure In birds, the postnatal stage begins when the beak penetrates the shell (i.e., external pipping) (Brown et al. 1997) BilaDO:0000003 OGES:000010 OGES:000014 OGES:000024 WBls:0000022 WBls:0000093 WBls:0000103 postembryonic stage post-hatching stage uberon postembryonic UBERON:0000092 post-embryonic stage UBERON:0000092 An entire span of an organism's life, commencing with the zygote stage and ending in the death of the organism. FBdv:00000000 HsapDv:0000001 MmusDv:0000001 OGES:000011 life lifespan uberon UBERON:0000104 life cycle UBERON:0000104 A spatiotemporal region encompassing some part of the life cycle of an organism. we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage BILS:0000105 EFO:0000399 FBdv:00007012 HsapDv:0000000 MmusDv:0000000 OlatDv:0000010 PdumDv:0000090 WBls:0000002 XAO:1000000 ZFS:0000000 ZFS:0100000 developmental stage stage uberon UBERON:0000105 life cycle stage UBERON:0000105 A stage at which the organism is a single cell produced by means of sexual reproduction. As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG] BILS:0000106 BilaDO:0000005 EFO:0001322 EHDAA:27 EMAPA:16033 FBdv:00005288 PdumDv:0000100 VHOG:0000745 XAO:1000001 ZFS:0000001 1-cell stage fertilized egg stage one cell stage uberon fertilized egg stage one-cell stage zygote zygotum UBERON:0000106 zygote stage UBERON:0000106 The first few specialized divisions of an activated animal egg; Stage consisting of division of cells in the early embryo. The zygotes of many species undergo rapid cell cycles with no significant growth, producing a cluster of cells the same size as the original zygote. The different cells derived from cleavage are called blastomeres and form a compact mass called the morula. Cleavage ends with the formation of the blastula. BILS:0000107 BilaDO:0000006 EFO:0001290 FBdv:00000054 MESH:A16.254.270 MmusDv:0000004 OGES:000015 OGES:000020 PdumDv:0000200 XAO:1000004 ZFS:0000046 uberon UBERON:0000107 cleavage stage UBERON:0000107 An early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. consider adding a preceding stage 'morula stage' as part of cleavage BILS:0000108 BilaDO:0000007 EFO:0001282 HsapDv:0000006 MmusDv:0000007 OGES:000003 OGES:000016 OGES:000021 OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg WBls:0000005 XAO:1000003 ZFS:0000045 uberon UBERON:0000108 blastula stage UBERON:0000108 A stage defined by complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm. BILS:0000109 BilaDO:0000008 EFO:0001296 FBdv:00005317 HsapDv:0000010 MmusDv:0000013 OGES:000004 OGES:000019 WBls:0000010 XAO:1000005 ZFS:0000047 uberon blastocystis trilaminaris stage trilaminar blastocyst stage trilaminar blastoderm stage trilaminar disk stage trilaminar germ stage trilaminar stage UBERON:0000109 gastrula stage UBERON:0000109 Staged defined by the formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system. BILS:0000110 BilaDO:0000009 HsapDv:0000012 MmusDv:0000017 XAO:1000006 uberon UBERON:0000110 neurula stage UBERON:0000110 A stage at which the ectoderm, endoderm, and mesoderm develop into the internal organs of the organism. BILS:0000111 BilaDO:0000010 HsapDv:0000015 MmusDv:0000018 OGES:000005 OGES:000032 uberon segmentation stage UBERON:0000111 organogenesis stage UBERON:0000111 Organism at the blastula stage - an early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. TODO - check relationship with epiblast. Note in FMA this is not a subclass of embryo, but in uberon embryo is the whole organism from zygote onwards and thus includes the blastula UBERON:0007011 BILA:0000059 BTO:0000128 GAID:1294 MESH:A16.254.270.274 OGEM:000006 OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg blastula embryo uberon blastosphere UBERON:0000307 blastula UBERON:0000307 Anatomical entity that has mass. AAO:0010264 AEO:0000006 BILA:0000006 CARO:0000006 EHDAA2:0003006 FBbt:00007016 FMA:67165 HAO:0000006 TAO:0001836 TGMA:0001826 VHOG:0001721 uberon UBERON:0000465 material anatomical entity UBERON:0000465 Anatomical entity that has no mass. AAO:0010265 AEO:0000007 BILA:0000007 CARO:0000007 EHDAA2:0003007 FBbt:00007015 FMA:67112 HAO:0000007 TAO:0001835 TGMA:0001827 VHOG:0001727 immaterial physical anatomical entity uberon UBERON:0000466 immaterial anatomical entity UBERON:0000466 Anatomical group that is has as its parts distinct anatomical structures interconnected by anatomical structures at a lower level of granularity[CARO]. A group of organs that work together to perform a certain task [Wikipedia]. system AAO:0000007 AEO:0000011 BILA:0000011 BSA:0000049 CALOHA:TS-2088 CARO:0000011 EHDAA2:0003011 EHDAA:392 EMAPA:16103 EV:0100000 FBbt:00004856 FMA:7149 HAO:0000011 MA:0000003 OpenCyc:Mx4rCWM0QCtDEdyAAADggVbxzQ TAO:0001439 TGMA:0001831 UMLS:C0460002 VHOG:0001725 WBbt:0005746 WBbt:0005763 XAO:0003002 ZFA:0001439 galen:AnatomicalSystem body system organ system uberon UBERON:0000467 anatomical system UBERON:0000467 Anatomical structure that is an individual member of a species and consists of more than one cell. TODO - split body and mc organism? body continues after death stage organismal AAO:0010026 AEO:0000191 BILA:0000012 BSA:0000038 BTO:0000042 CARO:0000012 EFO:0002906 EHDAA2:0003103 EHDAA2:0003191 EHDAA:1 EHDAA:9178 EMAPA:25765 EV:0100016 FBbt:00000001 FMA:256135 HAO:0000012 TADS:0000001 TAO:0001094 TGMA:0001832 VHOG:0000671 WBbt:0007833 XAO:0003004 ZFA:0001094 galen:Organism organism whole organism animal uberon Koerper body whole body UBERON:0000468 multi-cellular organism UBERON:0000468 Anatomical group that has its parts adjacent to one another. AAO:0010009 AEO:0000041 BILA:0000041 CARO:0000041 EHDAA2:0003041 FBbt:00007277 FMA:49443 HAO:0000041 TADS:0000605 TAO:0001478 TGMA:0001842 VHOG:0001737 XAO:0003160 ZFA:0001478 uberon UBERON:0000477 anatomical cluster UBERON:0000477 Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. changed label and definition to reflect CARO2 AAO:0000607 AAO:0010054 AEO:0000043 BILA:0000043 CALOHA:TS-2090 CARO:0000043 EHDAA2:0003043 EMAPA:35868 FBbt:00007003 FMA:9637 HAO:0000043 MA:0003002 MESH:A10 TAO:0001477 TGMA:0001844 UMLS:C0040300 VHOG:0001757 WBbt:0005729 XAO:0003040 ZFA:0001477 galen:Tissue portion of tissue tissue portion simple tissue uberon UBERON:0000479 tissue UBERON:0000479 Anatomical structure consisting of at least two non-overlapping organs, multi-tissue aggregates or portion of tissues or cells of different types that does not constitute an organism, organ, multi-tissue aggregate, or portion of tissue. AAO:0010008 AEO:0000054 BILA:0000054 CARO:0000054 EHDAA2:0003054 HAO:0000054 TAO:0001512 TGMA:0001846 VHOG:0001724 XAO:0003001 ZFA:0001512 uberon UBERON:0000480 anatomical group UBERON:0000480 Anatomical entity that comprises the organism in the early stages of growth and differentiation that are characterized by cleavage, the laying down of fundamental tissues, and the formation of primitive organs and organ systems. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant. embryonic AAO:0011035 AEO:0000169 BILA:0000056 BSA:0000039 BTO:0000379 CALOHA:TS-0229 EFO:0001367 EHDAA2:0000002 EHDAA2_RETIRED:0003236 EHDAA:38 EMAPA:16039 FBbt:00000052 FMA:69068 GAID:963 MAT:0000226 MESH:A16.254 MIAA:0000019 OGEM:000001 OpenCyc:Mx4rwP1ceZwpEbGdrcN5Y29ycA UMLS:C0013935 VHOG:0001766 XAO:0000113 ZFA:0000103 embryonic organism uberon developing organism developmental tissue UBERON:0000922 Obsoleted in ZFA. Note that embryo is not classified as an embryonic structure - an embryonic structure is only the parts of an embryo embryo UBERON:0000922 A layer of cells produced during the process of gastrulation during the early development of the animal embryo, which is distinct from other such layers of cells, as an early step of cell differentiation. The three types of germ layers are the endoderm, ectoderm, and mesoderm. The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] embryonic tissue AAO:0000480 BILA:0000035 BTO:0000556 FBbt:00000110 FMA:69069 GAID:1303 MESH:A16.254.425 TAO:0001122 UMLS:C0920502 UMLS:C1708239 VHOG:0001223 XAO:0003011 ZFA:0001122 germinal layer primary germ layer uberon embryonic germ layer embryonic germ layers UBERON:0000923 Classically the germ layers are ectoderm, mesoderm and endoderm. Alternatively: primary = ectoderm, endoderm; secondary=mesoderm; tertiary=dorsal mesoderm, NC[UBERONREF:0000002] germ layer UBERON:0000923 Primary germ layer that is the outer of the embryo's three germ layers and gives rise to epidermis and neural tissue. Primary germ layer that is the outer of the embryonic germ layers and gives rise to epidermis and neural tissue.[AAO] The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] ectodermal AAO:0000137 BILA:0000036 BTO:0000315 CALOHA:TS-0216 EFO:0000414 EHDAA2:0000428 EMAPA:16069 EV:0100003 FBbt:00000111 FMA:69070 GAID:1304 MAT:0000155 MAT:0000173 MESH:A16.254.425.273 MIAA:0000173 TAO:0000016 UMLS:C0013574 VHOG:0000153 XAO:0000001 ZFA:0000016 embryonic ectoderm uberon UBERON:0000924 ectoderm UBERON:0000924 An organ that detects light. This class encompasses a variety of light-detecting structures from different phyla with no implication of homology, from the compound insect eye to the vertebrate camera-type eye (distinct classes are provided for each) ocular optic Note that whilst this is classified as an organ, it is in fact more of a unit composed of different structures: in Drosophila, it includes the interommatidial bristle as a part; we consider here the vertebrate eye to include the eyeball/eye proper as a part, with the eye having as parts (when present): eyelids, conjuctiva, BILA:0000017 BTO:0000439 CALOHA:TS-0309 EFO:0000827 EV:0100336 FBbt:00005162 GAID:69 MAT:0000140 MESH:A01.456.505.420 MIAA:0000140 OpenCyc:Mx4rvViTvpwpEbGdrcN5Y29ycA uberon light-detecting organ visual apparatus UBERON:0000970 eye UBERON:0000970 The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO]. A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO] Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO] relationship type change: differentiates_from ectoderm (AAO:0000137) CHANGED TO: develops_from ectoderm (UBERON:0000924)[AAO] Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG] nervous neural AAO:0000324 BILA:0000079 BTO:0001484 CALOHA:TS-1313 EFO:0000802 EHDAA2:0001246 EHDAA:826 EMAPA:16469 EV:0100162 FBbt:00005093 FMA:7157 GAID:466 MA:0000016 MAT:0000026 MESH:A08 MIAA:0000026 OpenCyc:Mx4rvViT_pwpEbGdrcN5Y29ycA TAO:0000396 UMLS:C0027763 VHOG:0000402 WBbt:0005735 XAO:0000177 ZFA:0000396 nerve net uberon Nervensystem systema nervosum UBERON:0001016 nervous system UBERON:0001016 The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the brain, spinal cord and spinal nerves. In those invertebrates with a central nervous system it typically consists of a brain, cerebral ganglia and a nerve cord[GO]. Part of the nervous system which includes the brain and spinal cord.[AAO] The brain and spinal cord. Kimmel et al, 1995.[TAO] The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina (CUMBO). (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2); Taken together, our data make a very strong case that the complex molecular mediolateral architecture of the developing trunk CNS (central nervous system), as shared between Platynereis and vertebrates, was already present in their last common ancestor, Urbilateria. The concept of bilaterian nervous system centralization implies that neuron types concentrate on one side of the trunk, as is the case in vertebrates and many invertebrates including Platynereis, where they segregate and become spatially organized (as opposed to a diffuse nerve net). Our data reveal that a large part of the spatial organization of the annelid and vertebrate CNS was already present in their last common ancestor, which implies that Urbilateria had already possessed a CNS (reference 3).[well established][VHOG] AAO:0000090 BAMS:CNS BILA:0000080 BTO:0000227 CALOHA:TS-0150 EFO:0000908 EHDAA2:0000225 EHDAA:828 EMAPA:16470 EMAPA:16754 EV:0100163 FBbt:00005094 FMA:55675 GAID:570 MA:0000167 MAT:0000457 MESH:A08.186 OpenCyc:Mx4rvzYt3pwpEbGdrcN5Y29ycA TAO:0000012 UMLS:C0927232 VHOG:0000293 XAO:0000215 ZFA:0000012 http://braininfo.rprc.washington.edu/centraldirectory.aspx?ID=246 CNS neuraxis systema nervosum centrale cerebrospinal axis uberon basal nucleus of the amygdala basolateral nucleus of amygdala basolateral nucleus of the amygdala nucleus amygdalae basalis nucleus amygdaloideus basalis nucleus amygdaloideus basolateralis nucleus basalis amygdalae UBERON:0001017 central nervous system UBERON:0001017 Anatomical system that overlaps the nervous system and is responsible for receiving and processing sensory information. An early step in the evolution of neural crest, therefore, may have been the origin of a specific dorsal neural cell population contributing to sensory processing; this would predate the divergence of the amphioxus and vertebrate lineages.[well established][VHOG] note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs AAO:0000555 BAMS:SEN BILA:0000099 EFO:0000805 EHDAA2:0003094 EMAPA:16192 FBbt:00005827 FMA:75259 MA:0002442 MAT:0000031 MIAA:0000031 TAO:0000282 VHOG:0001674 XAO:0003194 ZFA:0000282 organa sensuum sense organ subsystem sense organs sense organs set sensory subsystem sensory systems uberon organa sensuum sensory organ system set of sense organs UBERON:0001032 sensory system UBERON:0001032 Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. AAO:0010841 AEO:0000000 BILA:0000000 CARO:0000000 EHDAA2:0002229 FBbt:10000000 FBbt_root:00000000 FMA:62955 HAO:0000000 MA:0000001 TAO:0100000 TGMA:0001822 UMLS:C1515976 XAO:0000000 ZFA:0100000 uberon UBERON:0001062 anatomical entity UBERON:0001062 Anatomical structure that is part of an embryo. Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[AAO] Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[TAO] Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[VSAO] in FMA embryo is_a embryonic structure AAO:0000138 BILA:0000034 BTO:0000174 CALOHA:TS-2110 EFO:0000461 FBbt:00004208 FMA:69067 GAID:407 MESH:A16 RETIRED_EHDAA2:0003169 TAO:0001105 UMLS:C0013948 VSAO:0000178 XAO:0003042 ZFA:0001105 developing embryonic structure embryonic anatomical structure uberon developing structure embryonale Struktur UBERON:0002050 embryonic structure UBERON:0002050 The sensory system subserving the sense of vision. This class was created automatically from a combination of ontologies The sensory system used for sight.[AAO] UBERON:0007036 AAO:0000632 BILA:0000140 FMA:7191 MA:0002444 OpenCyc:Mx4rvViCtpwpEbGdrcN5Y29ycA TAO:0001127 UMLS:C0587900 XAO:0003198 ZFA:0001127 photosensory system visual organ system uberon UBERON:0002104 visual system UBERON:0002104 Sensory system responsible for the perception of spatial orientation and auditory stimuli. The sensory system used for balance and hearing.[AAO] AAO:0000631 FMA:78500 TAO:0001138 XAO:0003195 ZFA:0001138 auditory organ system vestibuloauditory system uberon auditory system auditory/vestibular system vestibuloauditory system UBERON:0002105 vestibulo-auditory system UBERON:0002105 In amniote animal embryology, the epiblast is a tissue type derived either from the inner cell mass in mammals or the blastodisc in birds and reptiles. It lies above the hypoblast. In mammalian embryogenesis, the columnar cells of the epiblast are adjacent to the trophoblast, while the cuboidal cells of the hypoblast are closer to the blastocoele. The epiblast, whilst referred to as the primary ectoderm, differentiates to form all three layers of the trilaminar germ disc in a process called gastrulation[WP]. The outer of the two layers of the blastoderm that form during gastrulation, corresponding to primitive ectoderm during gastrulation and to the definitive ectoderm after gastrulation[ZFA] MP says - tissue that gives rise to the ectoderm, endoderm and mesoderm of the embryo proper. In HOG, epiblast is part of primitive streak/blastpore, which is inconsistent with the MP definition of primitive streak as a ridge of the epiblast. Note that these terms, epiblast and hypoblast, are also used to describe layers of the avian embryonic blastoderm, but the layers so-named seem to be altogether different in these two kinds of vertebrate embryos(CVS). Consider obsoleting this as a grouping class In pregastrula zebrafish embryos, the epiblast is an inverted cup of cells that sits on top of a large yolk cell. (...) In amniote embryos (mammals and birds), gastrulation initiates in an epithelial layer called the epiblast. Cells in the epiblast undergo an epithelial to mesenchymal transition (EMT), migrate through the primitive streak (PS), and incorporate in the middle (mesoderm) or outer (endoderm) layer. The presumptive definitive endoderm (DE) cells invade and displace an outer layer of extraembryonic tissue cells, the hypoblast in chick and the visceral endoderm (VE) in mouse, which form supporting structures such as the yolk sac.[uncertain][VHOG] BTO:0004593 MAT:0000067 MIAA:0000067 VHOG:0000243 epiblast uberon blastocyst ectoblast epiblastus primitive ectoderm UBERON:0002532 epiblast (generic) UBERON:0002532 An anatomical structure that develops (entirely or partially) from the ectoderm. uberon UBERON:0004121 Grouping term for query purposes ectoderm-derived structure UBERON:0004121 Sum of all sensory systems in an organism. note the distinct between entire sensory system and individual system. this reconciles is_a and part_of distinctions between ssAOs FMA:78499 sense organ system uberon UBERON:0004456 entire sense organ system UBERON:0004456 A portion of tissue that is part of an embryo. CALOHA:TS-2100 portion of embryonic tissue uberon developing tissue UBERON:0005291 embryonic tissue UBERON:0005291 AEO:0000125 CALOHA:TS-2122 EHDAA2:0003125 FBbt:00007006 MIAA:0000019 uberon developing structure developmental structure developmental tissue UBERON:0005423 developing anatomical structure UBERON:0005423 AAO:0000479 TAO:0001116 ZFA:0001116 presumptive structures uberon UBERON:0006598 presumptive structure UBERON:0006598 Presumptive structure of the blastula that will develop into ectoderm. AAO:0000470 EFO:0003466 TAO:0001376 XAO:0004132 ZFA:0001376 uberon presumptive epidermis UBERON:0006601 presumptive ectoderm UBERON:0006601 Non-material anatomical entity of two dimensions, that is demarcated by anatomical lines or points on the external or internal surfaces of anatomical structures. AAO:0010270 BILA:0000010 CARO:0000010 EHDAA2:0003192 FMA:24137 ID:0000000 UMLS:C1515977 ZFA:0005594 uberon UBERON:0006984 anatomical surface UBERON:0006984 Organism at the cleavage stage. BILA:0000058 uberon UBERON:0007010 cleaving embryo UBERON:0007010 An anatomical structure that has more than one cell as a part. CARO:0010000 FBbt:00100313 multicellular structure uberon UBERON:0010000 multicellular anatomical structure UBERON:0010000 uberon UBERON:0010316 germ layer / neural crest UBERON:0010316 Anatomical structure, which consists of a specific set of the members of (predominantly) one organ or organ part subclass interconnected by zones of continuity or body substances; is demarcated from other subdivisions of the same organ system by one or more zones of continuity or anatomical lines; together with other subdivisions of the same organ system, it constitutes an organ system. Examples: rib cage, facial skeleton, portal system, central nervous system, upper respiratory tract, muscle group of back. FBbt:00007330 FMA:67509 uberon UBERON:0011216 organ system subdivision UBERON:0011216 Primordium that develops into the central nervous system UBERON:3000469 future CNS presumptive central nervous system uberon UBERON:0016879 future central nervous system UBERON:0016879 Primordium that develops into the nervous system UBERON:3000477 AAO:0000477 presumptive nervous system uberon UBERON:0016880 future nervous system UBERON:0016880 example to be eventually removed Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. metadata complete term created to ease viewing/sort terms for development purpose, and will not be included in a release organizational term Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." ready for release Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. metadata incomplete Nothing done yet beyond assigning a unique class ID and proposing a preferred term. uncurated All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the definition editor. pending final vetting Terms with this status should eventually replaced with a term from another ontology. Alan Ruttenberg group:OBI to be replaced with external ontology term A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. Alan Ruttenberg group:OBI requires discussion axiom holds for all times Vision Release; 1.0.13 C264 Display_Name C134 MeSH_DUI C287 MeSH_Name C10490107818172 NUI C818 RxNorm_CUI C136 Synonym C140 UMLS_CUI AHC0 1 BFO:0000051 uberon has_part has_part has part has_part bearer-of_st bearerOfAt b bearer_of c at t =Def. c s-depends_on b at t & b is an independent continuant that is not a spatial region. (axiom label in BFO2 Reference: [053-004]) Alan Ruttenberg: This is a binary version of a ternary time-indexed, instance level, relation. The BFO reading of the binary relation 'bearer of at some time@en' is: exists t, exists_at(x,t) & exists_at(y,t) & 'bearer of@en'(x,y,t) BFO2 Reference: independent continuant that is not a spatial region BFO2 Reference: specifically dependent continuant bearer of bearer_of http://purl.obolibrary.org/obo/omrse.owl (iff (bearerOfAt a b t) (and (specificallyDependsOnAt b a t) (IndependentContinuant a) (not (SpatialRegion a)) (existsAt b t))) // axiom label in BFO2 CLIF: [053-004] bearer of at some time is bearer of is_bearer_of realized-in realizedIn [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) if a realizable entity b is realized in a process p, then p stands in the has_participant relation to the bearer of b. (axiom label in BFO2 Reference: [106-002]) (forall (x y z t) (if (and (RealizableEntity x) (Process y) (realizesAt y x t) (bearerOfAt z x t)) (hasParticipantAt y z t))) // axiom label in BFO2 CLIF: [106-002] realized in has participant has_participant has participant X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) preceded by preceded_by proceeds starts_after BFO:0000062 is preceded by takes place after uberon preceded_by preceded_by X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) is preceded by preceded by preceded_by BFO:0000063 uberon precedes precedes precedes precedes occurs-in occursIn b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t [XXX-001 BFO:0000066 occurs_in occurs in occurs in has-q_st has quality at some time a 'occurs in' relation that is applied at the adverse event setting and indicates where an adverse event occurs in. Yongqun He adverse event occurs in RO:0000086 uberon has_quality has_quality has quality has quality this person has role this investigator role (more colloquially: this person has this role of investigator) a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. has_role has role The relationship between a material entity and the boundary (2D immaterial entity) that delimits it. RO:0002002 uberon has_boundary has_boundary has boundary has boundary Relation between occurrents, shares start and end boundaries. RO:0002082 coincides_with is_equal_to uberon simultaneous_with simultaneous_with simultaneous_with simultaneous_with X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. RO:0002087 directly preceded by is directly preceded by is immediately preceded by starts_at_end_of uberon immediately_preceded_by immediately_preceded_by immediately_preceded_by immediately_preceded_by S only_in_taxon T iff: S SubClassOf in_taxon only T x only in taxon y if and only if x is in taxon y, and there is no other organism z such that y!=z a and x is in taxon z. RO:0002160 uberon only_in_taxon only_in_taxon only in taxon only_in_taxon x is in taxon y if an only if y is an organism, and the relationship between x and y is one of: part of (reflexive), developmentally preceded by, derives from, secreted by, expressed. RO:0002162 uberon in_taxon in_taxon in taxon A relation between a material entity (such as a cell) and a process, in which the material entity has the ability to carry out the process. RO:0002215 uberon capable_of capable_of capable of capable_of c stands in this relationship to p if and only if there exists some p' such that c is capable_of p', and p' is part_of p. RO:0002216 uberon capable_of_part_of capable_of_part_of capable of part of capable_of_part_of Relation between occurrents, shares a start boundary with. inverse of starts with RO:0002223 uberon starts starts starts starts Relation between occurrents, shares an end boundary with. inverse of ends with RO:0002229 finishes uberon ends ends ends ends x has the potential to develop into y iff x develops into y or if x is capable of developing into y x has the potential to develop into y iff x develops into y or if x is capable of developing into y RO:0002387 uberon has_potential_to_develop_into has_potential_to_develop_into has potential to develop into has potential to develop into x composed_primarily_of y if and only if more than half of the mass of x is made from y or units of the same type as y. x composed_primarily_of y iff: more than half of the mass of x is made from parts of y UBREL:0000002 RO:0002473 uberon composed_primarily_of composed_primarily_of composed primarily of composed_primarily_of Relation between continuant and occurrent, such that c comes into existence at the start of p. c existence starts during s iff start_of(c) = start_of(s) RO:0002489 uberon existence_starts_with existence_starts_with existence starts with Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. BFO:0000069 RO:0002492 ceases_to_exist_during uberon existence_ends_during existence_ends_during existence ends during Relation between continuant and occurrent, such that c ceases to exist at the end of p. RO:0002493 uberon existence_ends_with existence_ends_with existence ends with x immediate transformation of y iff x immediately succeeds y temporally at a time boundary t, and all of the matter present in x at t is present in y at t, and all the matter in y at t is present in x at t RO:0002495 direct_transformation_of immediately transforms from uberon immediate_transformation_of immediate_transformation_of immediate transformation of RO:0002496 uberon existence_starts_during_or_after existence_starts_during_or_after existence starts during or after RO:0002497 uberon existence_ends_during_or_before existence_ends_during_or_before existence ends during or before Product version Guoqian Jiang Jane Bane Junguk Hur Yu Lin Abra Guo Rebecca Racz Yongqun "Oliver" He (YH) 2016-05-16 ODNAE is an extension of OAE with a focus on drug-associated neuropathy adverse events. OWL-DL An ontology for the annotation of the adverse event domain. ODNAE: Ontology of Drug Neuropathy Adverse Events Vision Release; 1.0.13 uberon existence_starts_and_ends_during existence starts and ends during http://purl.org/obo/owl/relationship OBO_REL:0000007 relationship has_proper_part has_proper_part